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ABSTRACT
 A crucial component of the cellular response to stress is the attenuation of 
protein synthesis to allow the cell to dedicate resources for the restoration of 
homeostasis or towards the induction of apoptotic cell death in case the stressors 
overwhelm the cell. This process is itself regulated by one of the four eIF2α kinases of 
which PKR (Protein Kinase R) is responsible for inhibiting general translation during viral 
infection, oxidative stress, ER stress, heat shock or serum withdrawal.  
 During viral infection, PKR is transcriptionally induced by interferon but remains 
latent until it interacts with dsRNA. This interaction induces a conformational change 
that activates PKR’s catalytic activity, resulting in the phosphorylation of the eukaryotic 
initiation factor eIF2α and the cessation of both general and viral protein synthesis. This 
inhibition of viral protein synthesis is however short-lived, as several viral and host 
cellular factors are coopted by viruses to neutralize PKR’s catalytic activity against viral 
replication. One such cellular factor is PACT (Protein Activator of PKR), PKR’s protein 
activator during non-viral stress, which interacts strongly with PKR during HIV infection 
but does not activate its catalytic activity. We investigated the mechanisms behind 
PACT’s inability to activate PKR robustly during HIV infection. Our results show that 
PACT acts synergistically with the HIV trans-activator, Tat, dsRNA-containing mRNAs, as 
well as the adenosine deaminase, ADAR1 to form a PKR inhibitory complex to facilitate 
the translation of viral mRNAs during HIV infection. Most importantly, these results 
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elucidate a pathway that could be a target of antiviral therapy to promote PKR 
activation and reduce viral load in infected cells. 
 During non-viral stress, PKR’s activity is regulated negatively by the TAR RNA 
Binding Protein, TRBP. TRBP regulates PKR activity by interacting with PKR as well as 
PACT. Stress-induced phosphorylation of PACT at Serine 287 weakens its interaction 
with TRBP, while increasing PACT’s homomeric interactions and heteromeric 
interactions with PKR. The role, if any, of similar stress-induced post-translational 
modifications on TRBP’s ability to form homomeric interactions and heteromeric 
interactions with PKR as well as to inhibit PKR have remained unclear. In this light, we 
investigated whether TRBP is subject to stress-induced phosphorylation and how that 
might alter TRBP-TRBP and TRBP-PKR interactions as well as TRBP’s ability to inhibit PKR. 
Our results demonstrate that TRBP is phosphorylated by the Mitogen Activated Protein 
Kinases JNK and ERK in response to oxidative stress, and consequently forms strong 
homomeric interactions with PKR, resulting in increased inhibition of PKR and better cell 
recovery during oxidative stress. 
 PKR, PACT, and TRBP ‘s homomeric and heteromeric interactions are primarily 
mediated by the evolutionarily conserved dsRNA binding motif (dsRBM) present in all 
three proteins as well as in several other dsRNA binding proteins. We investigated the 
contributions of the two copies of dsRBMs in PACT to PACT’s interactions with dsRNA, 
PACT, TRBP, and PKR. Our results establish that each motif contributes to a varying 
extent towards PACT’s interaction with its known binding partners, and highlight the 
importance of PACT homodimerization for PKR activation.
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CHAPTER 1 
 
INTRODUCTION1
                                                          
1 To be adapted into a comprehensive review titled: ‘The double-stranded RNA binding proteins 
PACT, PKR, and TRBP – diverse roles in cellular stress, innate immunity, and RNA interference’ 
Chukwurah, E., and Patel RC. Manuscript in preparation. 
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1.1 THE EIF2A KINASES: MASTER REGULATORS OF PROTEIN SYNTHESIS 
DURING CELLULAR STRESS
 Eukaryotic cells encounter a diverse array of stressful conditions and must 
respond in each situation such that the cells ensure their survival while limiting the 
deleterious effects of the stressor. These stressful conditions, which range from viral 
infection to the accumulation of misfolded proteins in the cell’s endoplasmic reticulum 
(ER), elicit a coordinated response in eukaryotic cells termed the Integrated Stress 
Response (ISR)1.  
 The focal point of the ISR, which is an evolutionarily conserved signaling pathway 
induced in response to various stress signals, rests on the attenuation of general protein 
synthesis and the preferential translation of mRNA transcripts encoding proteins 
essential for ameliorating the stressful conditions 2,3. The ISR is also responsible for 
inducing apoptosis if the stressful conditions overwhelm the cell. The entire stress 
response pathway is initiated by the phosphorylation of the α-subunit of the eukaryotic 
initiation factor (eIF2) by one of four dedicated eIF2α kinases 4–8.  
 During the initiation of protein synthesis, eIF2 forms a ternary complex with GTP 
and the methionyl charged initiator tRNA (Met-tRNAi). The ternary complex 
subsequently associates with the 40S small ribosomal subunit and other initiation 
factors to form the 43S pre-initiation complex (PIC). The 5’m7-G-cap binding initiation 
factor complex eIF4F facilitates the interaction of the mRNA transcript with the newly 
formed PIC, and the PIC scans the 5’UTR of the mRNA transcript until it encounters the 
AUG start codon. At this point, the 60S large ribosomal subunit associates with the 
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mRNA transcript and the PIC to initiate the translation of the mRNA transcript. This 
results in the hydrolysis of the eIF2-bound GTP to GDP, and the release of eIF2-GDP 
from the ribosome so another round of protein translation can commence 1. 
 The eIF2α kinases effectively inhibit protein synthesis by phosphorylating eIF2’s 
α subunit (eIF2α). The eIF2 protein consists of three subunits, eIF2α, -β, and -γ. Active 
eIF2 has a non-phosphorylated eIF2α and low affinity to the guanine nucleotide 
exchange factor eIF2B. In that state, eIF2B exchanges GDP to GTP from the eIF2γ 
subunit, ensuring its active state. Non-phosphorylated eIF2α, eIF2β, GTP-loaded eIF2γ, 
methionyl tRNA (Met-tRNAi), and eIF5 form the ternary complex. Upon start site 
recognition, eIF2 and eIF5 dissociate from the complex and translation initiation and 
elongation ensue. eIF2α phosphorylation at Serine 51 increases its affinity for eIF2B and 
eIF59, thereby reducing the guanine nucleotide exchange factor that slows down the 
formation of the ternary complex, resulting in the attenuation of protein translation 
initiation (Figure 1.1.) The decreased abundance of the ternary complex consisting of 
eIF2, GTP, and the methionyl-charged initiator tRNA leads to the preferential translation 
of mRNAs encoding stress-responsive proteins i.e. the transcription factors ATF4 10 and 
CHOP11,12, and protein phosphatase regulatory subunit GADD34 13 due to alterations in 
translation initiation at multiple upstream open reading frames (uORFs) in the 5’ 
untranslated region (5’ UTR) of these mRNAs. 
 These transcription factors stimulate the expression of proteins which include 
chaperones, antioxidant proteins, or proapoptotic proteins among others to ensure 
cellular recovery or induce apoptosis if stress signals are sustained14–17. The GADD34 
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protein interacts with the catalytic subunit of protein phosphatase 1 (PP1) to trigger 
eIF2α dephosphorylation and promote ISR termination 13. The duration and extent of 
the stress response is regulated by several feedback mechanisms. For instance, ATF4 
regulates the transcription of GADD34, which is essential for translational recovery 
towards survival, and of CHOP 18, whose accumulation plays a pivotal role in converting 
the stress response from an adaptive phase to apoptosis when the ISR is overwhelmed. 
Many laboratories over several years have characterized each of the four eIF2α kinases 
and the specific stress signals that lead to their activation and consequent inhibition of 
general protein synthesis3. The specificity of activation of each kinase in response to 
stress signals is conferred by the presence of varied regulatory domains flanking a 
common homologous kinase domains. These regulatory domains mediate the kinases’ 
homodimerization, autophosphorylation, activation and eventual phosphorylation of 
eIF2α (Figure 1.2.)  
 General control nonderepressible 2 (GCN2), which has the distinction of being 
the only eIF2α kinase conserved in almost all eukaryotes, is activated during amino acid 
deprivation, and contains, in addition to its kinase domain, regulatory domains 
consisting of RING finger and WD repeat (RWD), pseudokinase, histidyl tRNA 
synthetase-like (HisRS-like), and dimerization/ribosome binding domains. These 
domains together mediate the interaction between GCN2 and uncharged tRNAs, 
resulting in GCN2 homodimerization, trans-autophosphorylation and eIF2α 
phosphorylation19,7,20,21. 
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 The PKR-like ER resident kinase (PERK) is activated in response to the 
accumulation of misfolded proteins in the endoplasmic reticulum (ER) and is essential 
component of the Unfolded Protein Response (UPR)22,23. In line with this function as a 
sensor of ER stress, PERK contains an ER luminal domain that associates with the ER-
resident chaperone Bip/Grp7824. Increased association of misfolded proteins with Bip 
during ER stress causes its dissociation from PERK’s luminal domain and results in the 
dimerization and activation of PERK’s C-terminal cytoplasmic kinase domain, and 
inhibition of protein synthesis. 
 The Heme Regulated Inhibitor (HRI) kinase is responsive to the presence of 
heme, which is essential to globin synthesis in erythroid cells. HRI possesses two heme-
binding sites; the first of which is in HRI’s N-terminus, and the second inserted within 
HRI’s kinase domain. This second heme binding is essential to ensure HRI’s activation in 
response to heme deficiency, as the reversible binding of heme to this site when heme 
is abundant within the cell prevents HRI activation, resulting in eIF2α phosphorylation 
and the cessation of globin synthesis6,25,26. 
Protein Kinase R (PKR) is the primary eIf2α kinase activated in response to viral 
infection in the cell. To that effect, PKR contains evolutionarily conserved double-
stranded RNA binding motifs (dsRBMs) which mediate its interactions, not only with 
dsRNA generated during viral infection, but also with other dsRBM containing proteins. 
PKR is also activated in response to non-viral cellular stress which includes stress 
resulting from the accumulation of misfolded proteins in the ER, reactive oxygen species 
(oxidative stress), heat shock, and serum deprivation. Additionally, various studies have 
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shown that PKR is also important for the optimal activation of transcription factors in 
key cellular signaling pathways such as ATF327, IRF128, NF-κB29,30, and p5331 among 
others32. 
As such, PKR and PKR-mediated signaling pathways have been implicated in 
several cellular processes such as mitotic regulation and inflammation through NF-κB 
signaling and in human pathological conditions ranging from diabetes to several 
neurological and neurodegenerative diseases33,34. 
In this chapter, we describe PKR’s structure and the mechanisms by which it is 
activated during viral and non-viral stress through its interaction with dsRNA and the 
stress-regulated protein, PACT. We also describe the importance of protein-protein 
interactions and stress-induced post-translational modifications of PACT as well as the 
dsRNA binding protein, TRBP, in activating or inhibiting PKR’s activity during cellular 
stress.  
 
1.2 THE INTERFERON INDUCED EIF2A KINASE, PKR 
 Cells employ both cytoplasmic and cell-surface pathogen-recognition receptors 
to recognize a wide range of pathogens and their molecular products. The association of 
these Pathogen associated molecular patterns (PAMPs)35,36 with their cognate receptors 
induces the secretion of cytokines known as interferons (IFNs)37,38 which bind to 
receptors on the target cell to induce the expression of genes termed Interferon 
Stimulated Genes (ISGs). These ISGs encode proteins with potent antiviral activity 
targeting several aspects of viral replication in host cells39,40. 
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 Separate groups of researchers independently observed that synthesis of both 
host and viral proteins in IFN-treated reovirus41, or encephalomyocarditis virus42 
infected cells as well as in IFN and dsRNA-treated cells were significantly diminished.  
These observations added inhibition of protein synthesis to the growing list of IFN-
induced antiviral activities, and raised questions about the identity of the specific IFN 
induced translational inhibitor. Previous studies performed with HRI, then a recently 
characterized eIF2α kinase in rabbit reticulocytes, led researchers to believe that this 
IFN-induced factor was an eIF2α kinase particularly sensitive to the presence of 
dsRNA19. 
 Autoradiographs of γ-32P ATP labelled proteins from dsRNA and IFN treated cells 
showed bands at ~67 kDa and ~35 kDa respectively that increased in intensity with 
increasing dsRNA concentrations indicative of protein phosphorylation. Further 
experiments confirmed that the increased intensities of the 67 kDa (PKR) and 35 kDa 
(eIF2α) bands were due to increased PKR autophosphorylation and subsequent eIF2α 
phosphorylation, while northern and western blot analyses showed steady increases in 
PKR mRNA transcript and protein levels with IFN-α exposure43. These findings 
demonstrated that PKR is the IFN-induced eIF2α kinase responsible for the inhibition of 
viral mRNA translation. 
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1.2.1 PKR’s DOMAIN STRUCTURE: DSRNA BINDING MOTIFS AND EIF2 ALPHA KINASE 
DOMAIN 
 PKR, like the other eIF2α kinases, is a serine-threonine kinase responsible for 
phosphorylating eIF2α on Serine 51. A direct comparison of PKR’s 551 amino acid 
sequence with those of other eIF2α kinases as seen in Figure 1.2 places PKR’s kinase 
catalytic domain at its C-terminus (residues 165 – 551). This was confirmed by 
experiments using a mutant PKR protein in which the C-terminus had been deleted; 
while the expression of full length PKR in Saccharomyces cerevisiae induced an 
inhibitory growth phenotype, the mutant protein was unable to produce a similar effect 
on the yeast cells’ growth. This mutant protein also retained its dsRNA binding 
properties, indicating that PKR’s regulatory dsRNA binding domain was located at its N 
terminus (residues 1-64).  
 Further characterization of PKR’s N-terminal dsRNAs binding domain (dsRBD) 
indicated that this domain was comprised of two tandem dsRNA binding motifs; 
dsRBM1 (residues 10 -72) and dsRBM2 (residues 100 -165), separated by a flexible 20-
amino acid long linker sequence44. Like dsRBMs in other dsRNA binding proteins, PKR’s 
dsRBMs have been shown to possess an α-β-β-β-α fold with the α-helices lying on one 
face of a three-stranded antiparallel β-sheet. 
 These α-helices are amphipathic in nature as they are primarily made up of basic and 
hydrophobic residues on opposite sides of the helices. Some of the basic amino acids in 
these helices were shown to be important for dsRNA binding, as targeted mutations of 
several of those residues (K60, K61, K64, and K69) were shown to disrupt PKR binding to 
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dsRNA through a poly I:C agarose binding assay, with some mutations directly affecting 
PKR activation45–47. Together with the random coiled 20-amino acid linker, these basic 
amino acid residues have been proposed to wrap around the target dsRNA and establish 
essential electrostatic interactions with the 2’-OH groups and negatively charged 
phosphate backbone of the dsRNA to ensure optimal PKR-dsRNA binding, resulting in 
efficient PKR activation48.  
 The amphipathic α-helical structures in PKR and other proteins have been shown 
to play key roles in the proteins’ dimerization, and accordingly mediate PKR’s 
dimerization through mutational analysis. Mutations of hydrophobic residues in PACT’s 
α-helices necessary for PKR dimerization destroyed PKR’s ability to phosphorylate eIF2α 
and inhibit yeast growth, demonstrating that PKR dimerization is important for PKR’s full 
enzymatic activity49.  
 On the other hand, structural analysis of PKR’s C-terminal kinase domain showed 
that it consisted of an ATP binding pocket flanked on either side by an N-terminal and C-
terminal lobe. Mechanistic studies of dsRNA-PKR binding show that dsRNA binding to 
PKR induces a conformational change in PKR that exposes the ATP binding pocket such 
that PKR can trans-autophosphorylate itself50,51, become activated and then 
phosphorylate eIF2α on Serine 51. 
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1.3 REGULATION OF PKR ACTIVITY DURING VIRAL AND NON-VIRAL CELLULAR 
STRESS: DSRNA, HEPARIN, PACT AND TRBP 
1.3.1 PKR ACTIVATION BY DSRNA AND HEPARIN 
 dsRNA remained the most well-characterized and recognized PKR activator until 
studies demonstrating PKR activation in response to other cellular conditions without 
dsRNA spurred the search for other cellular PKR activators. Due to the nature of PKR’s 
interaction with polyanionic dsRNA, researchers used in vitro kinase activity assays to 
test the ability of other polyanionic molecules such as dextran sulfate and chondroitin 
sulfate to activate PKR in the absence of dsRNA52. All the compounds that were tested 
induced PKR activation, but the highest PKR activity was observed when the assay was 
performed using the polyanionic glycosaminoglycan, heparin46,52,53. Heparin is a 
polysaccharide synthesized and secreted by mast cells and basophils and made up of 
alternating sulfated glucosamine with glucuronic or sulfated iduronic acid units.  
 Based on previous findings that showed strong PKR activation by heparin in vitro, 
researchers investigated heparin’s ability to activate PKR in vivo and the effects of this 
event on VSMC proliferation54. They found a significant increase in PKR activation in 
heparin-treated VSMCs correlative with increased PKR-heparin interaction, and noted 
that the absence of PKR, observed with cell cycle analysis of PKR null (PKR -/-) and wild 
type (PKR +/+) MEFs, was sufficient to negate the anti-proliferative effects of heparin 
treatment54. These results were recapitulated in rat primary aortic vascular smooth 
muscle cells (RASMCs) transfected with the dominant negative PKR mutant, K296R PKR, 
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where inhibition of PKR partially rescued the G1-to-S transition block55. Taken together, 
these results established PKR as a key effector of heparin’s anti-proliferative activity. 
 Based on the comparable properties of heparin and dsRNA, it was expected that 
the mechanism by which heparin induced PKR activation would also involve interaction 
with PKR’s N-terminal dsRBMs. Intriguingly, researchers observed that in vitro kinase 
assays performed with N-terminal PKR deletion mutants and wt PKR showed 
comparable levels of PKR autophosphorylation and eIF2α phosphorylation with 
heparin56. Later work also demonstrated that pre-incubation of PKR with heparin 
blocked subsequent PKR activation by dsRNA and heparin did not out-compete the 
adenovirus VAI dsRNA for binding to PKR57. All these findings suggested that heparin 
associated with PKR at a different site than the expected dsRBD, and conformational 
changes induced by heparin precluded the activation of PKR’s kinase activity by dsRNA 
interaction with PKR’s dsRBD. More importantly, these findings clearly indicated that 
heparin induces PKR activation by an alternative mechanism involving heparin’s 
interaction with PKR’s C-terminal kinase domain. 
 Deletion mapping of PKR’s heparin interaction domains showed that two regions 
designated ATD (residues 279 - 318) and CTD (412 - 479) within PKR’s C-terminal kinase 
domain were crucial to heparin-PKR interaction and heparin-induced PKR activation56. 
Further characterization of the heparin interacting domains revealed the presence of a 
positively charged binding cleft conducive to heparin binding57, and provided evidence 
for a mechanism of PKR activation in which heparin associates with PKR monomers and 
induces a conformational change to facilitate dimerization and PKR activation.  
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1.3.2 PKR ACTIVATION BY PACT 
 The specific circumstances required for PKR’s activation by heparin led 
researchers to continue to search for other cellular activators that could account for PKR 
activation in other non-viral cellular contexts. 
 PACT (Protein Activator of PKR), a 313-amino acid long protein, was identified as 
a PKR interacting protein in a yeast two-hybrid screen of a human cDNA library using the 
trans-dominant negative PKR mutant K296R as bait58. A murine PACT homolog, RAX 
(PKR-associated protein X), was also similarly identified in a mouse cDNA library screen 
using the catalytically inactive murine PKR homolog (K271R mPKR) as bait59.  
A comparison of PACT/RAX’s amino acid sequence to that of PKR and other dsRNA 
binding proteins showed that PACT also contained three evolutionarily conserved 
dsRBMs (Figure 1.3)  
 PACT’s first two dsRBMs showed the strongest sequence conservation to PKR’s 
N-terminal dsRBD and the first two dsRBMs found in TRBP (TAR RNA Binding Protein), 
TRBP’s murine homolog Prbp (Protamine RNA-binding Protein) and the Xenopus dsRBP 
Xlrbpa (Xenopus laevis RNA-binding Protein A). PACT/RAX’s ability to recognize and bind 
dsRNA were independently confirmed through dsRNA binding assays that showed their 
preferential binding to synthetic dsRNA (poly I:C) over dsDNA or ssDNA58,59. 
 To determine the functional importance of PACT’s interaction with PKR for PKR’s 
catalytic activity, investigators performed in vitro PKR activity assays using purified 
recombinant PACT and immunoprecipitated PKR. Similar to results obtained with 
previously characterized PKR activators, the addition of increasing amounts of PACT 
13 
resulted in a corresponding increase in PKR’s kinase activity, after which higher PACT 
concentrations resulted in PKR inhibition58. 
Further evidence that PACT could efficiently activate PKR in the absence of dsRNA was 
provided by in vitro kinase assays performed with recombinant PACT purified to remove 
associated dsRNA and in vivo yeast growth inhibition assays58. In the former set of 
experiments, the results demonstrated that PACT strongly activated PKR in the absence 
of dsRNA and could even activate PKR point mutants defective in activation by dsRNA 
(K150A PKR, and A158D PKR), indicating that PKR association with dsRNA was 
inconsequential to PACT-mediated PKR activation. 
 The latter set of experiments supported results from the first set of experiments, 
as investigators observed a marked reduction of yeast growth in cells co-expressing 
PACT and wt PKR. Like the previous results, PACT was still able to enhance PKR-
mediated yeast growth inhibition in yeast cells expressing the dsRNA-binding defective 
PKR point mutants, showing that this activation was independent of dsRNA binding. 
The results from these experiments showed that PACT retained its ability to strongly 
activate PKR in the absence of dsRNA or PKR’s dsRNA binding ability, establishing PACT 
as a PKR-interacting protein that could activate PKR in response to non-viral cell stress. 
Considering the evidence pointing towards PACT as a potential cellular activator of PKR, 
it became necessary to identify the specific cellular conditions that required PACT for 
efficient PKR activation in vivo, as well as the domains of PACT necessary for mediating 
its interaction with PKR and PKR’s consequent activation. 
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PACT ACTIVATION OF PKR DURING NON-VIRAL CELLULAR STRESS: DSRBM-MEDIATED 
INTERACTIONS AND REQUIREMENT OF STRESS-INDUCED PACT PHOSPHORYLATION FOR 
EFFICIENT PKR ACTIVATION. 
 To investigate PACT’s role in enhancing PKR activation in vivo, mammalian cells 
were transiently transfected with PACT and subsequently assessed for changes in 
translation, PKR autophosphorylation, and eIF2α phosphorylation. Results indicated that 
PACT overexpression significantly enhanced PKR activation and consequently eIF2α 
phosphorylation, resulting in a ~2-fold increase in protein translation inhibition 
compared to cells expressing an empty vector58. Cells overexpressing PACT/RAX also 
demonstrated an increased sensitivity to cellular stress and apoptosis59,60 resulting from 
serum starvation, exposure to hydrogen peroxide, sodium arsenite and inflammatory 
cytokines59–61. In contrast, PACT overexpression in PKR -/- MEFs had a marginal effect on 
stress-induced apoptosis60, indicating that PACT primarily exerted its effects on PKR in 
response to stressful cellular conditions. 
 These results were recapitulated in PACT -/- and PKR -/- MEFs treated with 
tunicamycin, a reagent which induces the unfolded protein response and ER stress in 
cells by inhibiting N-linked glycosylation of nascent proteins62. Reconstitution of PACT or 
PKR restored tunicamycin-induced apoptosis, eIF2α phosphorylation, as well as 
downstream induction of CHOP expression, implicating PACT in PKR’s response to ER 
stress62. Taken together, these findings provided conclusive evidence that PACT is 
responsible for the efficient activation of PKR in response to a diverse range of non-viral 
cellular stressors. 
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PACT INTERACTION WITH PKR – DSRNA BINDING MOTIF MEDIATED INTERACTIONS 
 Co-immunoprecipitation assays with in vitro synthesized PACT and PKR or PKR’s 
N-terminal dsRNA binding domain showed that PACT directly interacted with PKR, and 
specifically with PKR’s dsRBD, as no direct interaction was observed between PKR’s C-
terminal kinase domain and PACT58.  
 With noted similarities between two of PACT’s dsRBMs and PKR’s own dsRBMs, 
experiments were performed to determine which of PACT’s three dsRBMs were 
absolute requirements for PKR interaction and activation were by successively deleting 
each PACT dsRNA binding motif. Co-immunoprecipitation assays with full length PKR 
and the various PACT deletion mutants demonstrated that while each individual motif 
was unable to co-immunoprecipitate PKR, the PACT mutant lacking the M3 motif 
retained PACT’s ability to interact with PKR63,64, demonstrating that PACT’s M1 and M2 
cooperated with each other to ensure PACT’s interaction with PKR. 
 Having determined that PACT’s interaction with PKR is primarily mediated by the 
M1 and M2 motifs, in vitro translation inhibition assays and apoptosis assays in cells 
transfected with the PACT deletion mutants were subsequently performed to 
characterize the contribution of each motif to PKR activation. While the PACT deletion 
mutants lacking the M1 and M2 motifs showed similar levels of enhanced PKR-mediated 
translation inhibition of a luciferase reporter and induction of apoptosis, removal of 
PACT’s M3 motif completed abolished both effects. In vitro kinase assays performed 
with these mutants showed also that the M3 motif alone induced PKR activation 
strongly, which the other two motifs were unable to do. However, when cells were 
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transfected with a PACT M3 deletion expression construct, this PACT mutant was unable 
to activate PKR in vivo, suggesting that while the M3 motif is essential for PACT’s 
activation, the M1 and M2 motifs contribute in vivo to PACT’s ability to activate PKR63. 
 This suggestion was borne out by independent experiments performed with 
chimeric proteins consisting of PACT’s M3 motif and PKR’s dsRBD or TRBP’s two dsRNA 
binding motifs65. While both proteins’ dsRBDs had previously been shown to inhibit PKR 
activity, the addition of PACT’s M3 motif to each domain led to PKR activation, 
indicating that the M3 motif confers PKR activation abilities to PACT and PACT-PKR 
heterodimerization conferred by PACT’s first two dsRBMs is important to ensure PACT’s 
activation of PKR in vivo. 
Interestingly, while in vivo co-immunoprecipitation assays showed strong interaction 
between PACT/RAX and PKR in stressed cells, the interaction between PACT and PKR is 
markedly reduced although not completely absent. This indicated that specific stress-
induced changes such as posttranslational modifications may be responsible for the 
stronger in vivo interactions. 
 
ROLE OF STRESS-INDUCED PACT PHOSPHORYLATION IN EFFICIENT PKR ACTIVATION 
DURING NON-VIRAL CELLULAR STRESS 
 Initial insights into the regulation of PKR activity via stress-induced PACT 
phosphorylation were provided by two different studies; in the first study, the authors 
observed a stress-dependent rapid enhancement of RAX-PKR interaction that correlated 
with an increase in eIF2α phosphorylation in IL-3 dependent cells deprived of IL-3 or 
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treated with thapsigargin, sodium arsenite, or hydrogen peroxide59. Anti-RAX 
immunoblotting performed after isoelectric focusing of protein extracts from the 
examined cells revealed the presence of a banding pattern consistent with stress-
induced RAX phosphorylation59. In the second study, investigators exposed cells to 
sodium arsenite or hydrogen peroxide to activate PKR, and observed a similar stress-
dependent increase in PACT-PKR association over the course of treatment60. In vivo 32P-
orthophosphate labeling of PACT in the treated cells also showed that the observed 
increase in PACT-PKR interaction coincided with increased PACT phosphorylation60.  
Interestingly, both studies demonstrated that PACT/RAX phosphorylation preceded 
eIF2α phosphorylation in response to cellular stress induced by IL-3 deprivation or 
treatment with hydrogen peroxide, sodium arsenite or thapsigargin.  
These results led both sets of investigators to conclude that stress-induced PACT/RAX 
phosphorylation increased the interaction between PACT and PKR to enhance PKR 
activation and consequently PKR-mediated eIF2α phosphorylation in response to non-
viral cellular stress. 
 Given that PACT’s M3 motif had been demonstrated to be crucial for PKR 
activation and increased PACT-PKR heterodimerization and PKR activation is always 
accompanied by stress-induced phosphorylation of PACT, Li and colleagues set about 
identifying candidate serine residues in PACT’s M3 motif that could be phosphorylated 
in response to stress66. Alanine-scanning mutagenesis identified four of these residues 
(S246, S265, S279, S287) of which two (S246, S287) were unable to induce PKR 
activation and consequently apoptosis. Substitution of threonine or aspartic acid for 
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alanine in the S246A and S287A mutants restored their ability to induce apoptosis in 
transfected cells and activate as well as bind PKR.  
 Results from further biochemical analysis of purified PACT from stress and 
unstressed cells revealed the presence of three differentially phosphorylated PACT 
isoforms. Researchers observed that PACT was either unphosphorylated or partially 
phosphorylated when purified from unstressed cells, and exposure of these cells to 
stress resulted in a significant increase in a fully phosphorylated PACT isoform. 
Intriguingly, the researchers also observed that the S246A PACT mutant exhibited only 
the unphosphorylated PACT isoform while the S287A PACT mutant exhibited both the 
unphosphorylated and partially phosphorylated PACT isoforms before and after stress. 
These results established that PACT is constitutively phosphorylated at S246 in the 
absence of stress, and becomes phosphorylated at S287 in response to stress signals 
leading to the observed increased interaction between PACT and PKR and subsequent 
PKR activation. 
 
ROLE OF PACT HOMODIMERISATION IN EFFICIENT PKR ACTIVATION DURING NON-VIRAL 
CELLULAR STRESS 
 Since PKR dimerization had already been shown to be important to PKR 
activation, it was unclear as to whether PACT’s ability to activate PKR was equally 
dependent on its ability to dimerize, and if stress-induced PACT phosphorylation had 
any role in inducing this dimerization. Yeast two-hybrid assays were subsequently 
performed to identify the PACT motifs required for PACT-PACT dimerization, and results 
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showed that while PACT’s M1 and M2 motifs could interact with each other (M1-M1, 
M1-M2, M2-M2), PACT’s M3 motif was only able to interact with itself (M3-M3). As 
PACT’s M3 motif had already been shown to contain two phosphorylation sites (S246, 
S287) crucial to PACT’s activation of PKR, the specificity of the M3-M3 motif interaction 
strongly suggested that M3-M3 motif interaction could be enhanced during stress to 
enhance PACT-PACT interaction and consequently, PACT-PKR interaction and PKR 
activation. Increased homomeric PACT-PACT interactions in response to stress signals 
were supported by yeast two-hybrid experiments with phosphorylation-mimetic (PACT 
S246 S287D) and phosphorylation-defective (S246A S287D) PACT point mutants67.  
 The importance of the observed PACT homodimer formation in PACT-mediated 
PKR activation in response to stress was clearly demonstrated in experiments with a 
dimerization-deficient PACT mutant (L99E PACT) which retained its ability to interact 
with PKR. While wt PACT, dsRNA, and heparin robustly activated PKR, L99E PACT was 
unable to activate PKR efficiently, indicating that PACT dimerization was necessary for 
efficient PACT-mediated PKR activation68.  
While the studies with PACT phosphorylation-defective and mimetic mutants 
underscored the importance of stress induced PACT-PACT and PACT-PKR interaction and 
reduced PACT-TRBP mediated through residues in PACT’s M3 motif, the individual 
contributions of PACT’s M1 and M2 motifs to PACT’s ability to interact with dsRNA as 
well as with itself, PKR and TRBP have remained unclear and have been elucidated in 
Chapter 4 of my dissertation. 
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PACT AND PKR DURING VIRAL INFECTION 
 In addition to its established role in the PKR-mediated stress response pathway, 
PACT has also been shown to be involved in a steadily increasing number of key cellular 
pathways, such as small RNA biogenesis69–72 during RNA interference via interaction 
with the Dicer protein and the cellular innate immune response to viral infection via 
interaction with pattern recognition receptors RIG-I and MDA-573,74.  
 A possible antiviral function for PACT was first presented in a study in which 
siRNA PACT/RAX-depleted MEFs were infected with vesicular stomatitis virus (VSV). 
These VSV-infected cells exhibited significantly increased viral titers and viral protein 
synthesis as well as decreased eIF2α phosphorylation levels compared to the wildtype 
cells61. These results suggested then that in addition to its role as a PKR activator during 
non-viral stress, PACT could also enhance PKR’s antiviral activity or possess an inherent 
antiviral function independent of PKR activation.  A subsequent study involving L929 
cells infected with the Newcastle disease virus (NDV) demonstrated that PACT 
expression could in fact stimulate IRF3 and IRF7 activity in these cells in a PKR 
independent manner, resulting in IFN-β expression and increased IFN-β enhancer 
reporter activity75. PACT was also shown to be directly involved in enhancing the RLR-
mediated response to viral infection by interacting directly with the cytoplasmic RNA 
sensor, RIG-I, during Sendai virus infection73. PACT’s interaction with RIG-I’s CTD 
stimulated RIG-I’s ATPase activity and facilitated the production of IFN in the Sendai-
virus infected cells as indicated by decreased viral plaque formation with PACT and RIG-I 
co-expression73.  
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 As a well-characterized activator of PKR in response to cellular stress, it was 
interesting to study PACT’s ability to activate PKR during HIV infection. A 2013 study of 
PACT’s role during HIV infection revealed a significant increase in PACT-PKR interaction 
as well as between PACT, PKR, and another dsRNA binding protein, ADAR1, coincidental 
with a decrease in PKR activity over the course of viral infection76. An ISG product, 
ADAR1 (Adenosine Deaminase Acting on RNA 1) is an RNA-editing enzyme that catalyzes 
the deamination of adenosine to inosine in dsRNA substrates, which in turn leads to the 
destabilization of RNA secondary structure or the erroneous incorporation of amino 
acids detrimental to viral protein structure and function77. Thus, ADAR1 can work in an 
anti-viral manner, but HIV specifically seemed to target ADAR1 to inactivate its anti-viral 
functions and replicate efficiently78. siRNA mediated knockdown of either PACT or 
ADAR1 in HIV infected cells was sufficient to restore PKR-mediated viral replication 
inhibition, suggesting that both proteins act synergistically to enhance viral replication, 
and more importantly, it was suggested that PACT could in fact inhibit PKR’s activity in 
HIV-infected cells76. Questions however remained from this study about the 
mechanisms underlying this dramatic change in PACT’s ability to activate PKR. Chapter 2 
of my dissertation aims to fill this gap and elucidates the mechanism of ADAR1 –
mediated inactivation of PACT-induced PKR activation during HIV replication79. 
 
1.3.2 PKR INHIBITION BY TRBP 
 As a key effector of IFN’s antiviral activities, PKR is the target of several viral 
strategies to limit its inhibition of viral protein synthesis in infected cells. While many of 
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these strategies rely on viral factors that may sequester potentially PKR-activating 
dsRNAs80,81, act as decoy substrates80,82, or directly interact with PKR83, some strategies 
involve the recruitment of cellular host proteins to enhance viral replication, 
transcription, and translation by inhibiting PKR84–86. 
 One such protein is the TAR RNA Binding Protein (TRBP) which was initially 
identified as a HIV TAR RNA binding protein in a HeLa cDNA expression library screen 
with a TAR RNA probe87. TRBP was subsequently shown to enhance the expression of 
reporter genes driven by the HIV-1 LTR, as well as the translation of TAR RNA containing 
mRNAs by destabilizing the secondary structure of the dsRNA to allow for greater 
translation efficiency. These findings, together with the observation that knockdown of 
TRBP expression resulted in dramatically decreased HIV-1 LTR driven gene expression 
and viral protein production during active HIV-1 replication88 and viral replication in 
astrocytes which express low levels of TRBP was markedly limited89, confirmed that 
TRBP is indeed a cellular protein co-opted by the HIV-1 virus to ensure its replication.  
 TRBP has also been shown to be involved in miRNA biogenesis and RNA induced 
silencing through its interaction with Dicer and the RNA induced silencing complex 
(RISC)90,91. Mass spectrometric analysis of proteins coimmunoprecipitated with human 
Dicer showed an interaction with TRBP, which was also independent of the presence of 
dsRNA90. While the initial studies characterizing TRBP’s interaction with Dicer and 
functional importance to miRNA processing showed that TRBP depletion had 
deleterious effects on miRNA silencing efficiency, subsequent studies have raised 
skepticism about the role, if any, that TRBP plays in RNA induced silencing, and if that 
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role is simply non-essential92. Questions have also been raised about PACT, which is 40% 
similar to TRBP, and whether it serves a redundant function to TRBP and similarly 
interacts with Dicer92. Some reports indicate that PACT associates with Dicer to facilitate 
miRNA production93,70, while a more recent study shows that TALEN-mediated knockout 
of PACT expression has no functional effect on Dicer’s activity or miRNA biogenesis, and 
any interaction between PACT and Dicer that was previously observed was attributable 
to the fact that the studies were conducted under conditions where PACT was 
excessively overexpressed92.  
 Sequence alignment of TRBP with the amino acid sequences of members of the 
double-stranded RNA binding protein family (of which PKR is a member) showed that 
TRBP contained three conserved dsRNA binding motifs like PKR’s cellular activator, PACT 
(Figure 1.3). Since TRBP and PACT had been shown to interact with the TAR RNA to 
different effects on TAR mRNA translation94 and both proteins have similar interacting 
partners (i.e. PKR, Dicer), several laboratories sought to uncover the potential regulation 
of PKR’s activities during viral replication and cellular stress by TRBP. 
 
TRBP INHIBITION OF PKR DURING HIV-1 INFECTION 
 During viral infection, IFNs transcriptionally induce the expression of PKR which 
remains latent within the cell until it is activated by dsRNA binding. This results in the 
inhibition of viral protein synthesis, and consequently, the abrogation of viral 
replication. To determine if TRBP could prevent the translational inhibition imposed by 
IFN-induced PKR during HIV infection, Benkirane et al infected cells with a chimeric HIV-
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1 virus expressing TRBP, and assayed for changes in viral replication compared to the 
cells infected with wild type HIV-1 virus after IFNα treatment95. While the cells infected 
with the wild-type HIV-1 virus demonstrated a dose-dependent reduction in viral 
replication with IFNα treatment, the cells infected with the HIV-1 virus expressing TRBP 
were completely resistant to IFNα, suggesting that TRBP was involved in limiting IFN’s 
anti-viral activities in infected cells. 
 Comparative analysis of HIV protein synthesis in HeLa cells expressing the HIV 
genome and transfected with PKR or PKR and TRBP showed that while PKR evidently 
reduced the expression of HIV encoded proteins, TRBP significantly blunted PKR’s 
inhibition of HIV protein synthesis.  Direct detection of viral replication by HIV reverse 
transcriptase activity in infected cells transfected with PKR, or co-transfected with PKR 
and TRBP showed that TRBP expression boosted viral replication as compared to the 
cells infected only with the HIV virus, demonstrating that TRBP directly inhibited PKR 
activity to enhance viral replication and protein synthesis. Researchers also observed 
that a TRBP mutant devoid of dsRNA-binding inhibited PKR’s activity at similar levels 
with wt TRBP, indicating that this inhibitory activity was independent of TRBP’s dsRNA 
binding. The interaction of PKR and TRBP was also shown to be independent of dsRNA 
interaction, as cellular extracts completely depleted of dsRNA still demonstrated strong 
PKR-TRBP interaction, even when the interaction between a dsRNA binding defective 
PKR mutant and TRBP was tested. This inhibition of PKR by TRBP in the absence of 
dsRNA strongly indicated that TRBP could potentially regulate PKR’s activity during non-
viral cellular conditions. 
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TRBP INHIBITS PKR’S CATALYTIC ACTIVITY BY INTERACTION WITH PACT 
 Since PACT had been shown to be primarily responsible for activating PKR in 
response to cellular stress, investigators sought to uncover if TRBP could regulate PKR’s 
activity through its interaction with its cellular activator, PACT. Co-immunoprecipitation 
assays with PACT and TRBP in the complete absence of RNA showed that both proteins 
could heterodimerize independently of dsRNA96,58, and subsequent yeast two-hybrid 
experiments demonstrated that each protein’s M1, M2 and M3 motifs could interact 
with the corresponding protein’s motifs. The effect of such a strong PACT-TRBP 
interaction on PKR activity was tested by knocking down TRBP expression in cells 
transfected with PACT. PACT overexpression, which normally results in PKR activation 
(as detected by phospho-PKR in western blot analysis) was absent in cells expressing 
TRBP, whereas stable knockdown of TRBP restored this activity, indicating that TRBP 
primarily served to inhibit PKR activity by heterodimerizing with PACT97. 
 Since it had been previously established that PACT interacts with and activates 
PKR in response to stress signals, it was predicted that PACT would dissociate from TRBP 
in response to stress signals to allow for PACT’s association with PKR. This idea was 
supported by results from co-immunoprecipitation experiments to assay for changes in 
PACT-TRBP interaction in response to hydrogen peroxide and sodium arsenite induced 
oxidative stress which showed that PACT-TRBP interaction is disrupted in response to 
stress98,67.  
 Stress-induced PACT phosphorylation at S287 dramatically increases PACT-PACT 
homomeric interactions as well as PKR-PACT heteromeric interaction, so experiments 
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were performed to test if this phosphorylation event was the trigger for the decrease in 
PACT-TRBP heteromeric interaction in response to stress67. As such, yeast two-hybrid 
experiments were performed with TRBP and phosphorylation mimetic PACT (S246D 
S287D) yeast expression constructs and followed by in vitro and in vivo co-
immunoprecipitation assays with S246D S287D PACT and TRBP. In all three experiments, 
researchers observed a dramatic reduction in 246D 287D PACT interaction with TRBP as 
compared to wt PACT, showing conclusively that stress-induced PACT phosphorylation 
increased PACT-PACT and ultimately PACT-PKR interaction and PKR activation by 
weakening PACT-TRBP interaction67. The functional importance of a weakened PACT-
TRBP interaction on PKR mediated apoptosis was demonstrated by analysis of induction 
of cell death after PACT (S246D S287D, wt) and TRBP co-transfection into HeLa cells67. 
While co-expression of TRBP and wt PACT was sufficient to rescue apoptosis induced by 
PACT transfection, TRBP was completely unable to rescue apoptosis induced by 
transfection of the S246D S287D phosphorylation mimetic mutant67. 
 Taken together, the results from these studies showed that TRBP prevents 
aberrant PKR activation by forming heterodimers with PACT and upon the receipt of 
stress signals due to PACT’s phosphorylation, dissociates from PACT to allow for PACT’s 
timely activation of PKR’s kinase activity. 
 
TRBP PHOSPHORYLATION REGULATES PKR ACTIVITY 
 In addition to its role as a PKR inhibitor during HIV infection and cellular stress, a 
recent study indicated that TRBP may also regulate PKR activity during the cell cycle92. In 
27 
one study, investigators noted that mitotic cells showed increased PKR phosphorylation 
levels that correlated with increased phosphorylated JNK and eIF2α levels92,99. eIF2α, of 
course, is a well characterized substrate of PKR, and JNK is a Mitogen Activated Protein 
Kinase (MAPK) whose efficient activation has been shown in several studies to depend 
on PKR activation32. This increased PKR phosphorylation during mitosis was shown to be 
independent of PACT92, and raised questions about TRBP’s role, if any, in modulating 
PKR’s activity during mitosis. 
 These questions were answered by the cell cycle analysis of TRBP knockout 
(TRBP KO) and wildtype cells92; evaluation of both sets of cells showed that the levels of 
phosphorylated PKR and eIF2α were significantly elevated and the duration of the G2/M 
phase was longer in TRBP KO cells as compared to the wildtype cells. These results, in 
addition to a previous finding that PKR overexpression in Chinese Hamster ovary (CHO) 
cells induces a similar delay in transition to the G1 phase99, suggested that TRBP could 
modulate PKR’s activity during the cell cycle, and consequently affect the cell cycle 
transition from the M to the G1 phase.  
 The western blot analysis of cellular extracts from cells arrested in the G1, S, and 
M phases did not show changes in TRBP expression during the cell-cycle, but showed 
changes in TRBP phosphorylation92. TRBP was hyperphosphorylated during M phase and 
the hyperphosphorylated TRBP isoform was subsequently shown to interact more 
strongly with PKR compared to the unphosphorylated S phase TRBP isoform. The 
phosphorylated TRBP inhibited PKR’s activation and eIF2α phosphorylation much 
strongly than the unphosphorylated isoform. In an intriguing turn, the kinase 
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responsible for TRBP’s phosphorylation during mitosis was revealed to be JNK, which is 
itself phosphorylated by PKR activated by nuclear dsRNAs during mitosis as the nuclear 
membrane disappears. Thus, PKR is involved in a negative feedback loop that promotes 
its own inhibition during the cell cycle by facilitating TRBP hyperphosphorylation 
through JNK activation92. 
 Another study also suggested that JNK-mediated TRBP phosphorylation plays a 
role in activating PKR during obesity and propagating inflammation in obese animals100, 
thereby implicating sustained PKR activation in metabolic disease. These results are 
controversial, as another report showed that PKR has no functional role in regulation of 
obesity-induced metabolic regulation101. The observed effects in the first study were 
deemed to be specific only to the animals used in that study.  
 Since TRBP phosphorylation has been shown to inhibit PKR’s activity during 
mitosis, it is interesting to investigate if, like PACT, TRBP is also phosphorylated in 
response to cellular stress and if this phosphorylation event alters the heteromeric 
interactions between TRBP and PACT/ PKR to dampen the negative effects of sustained 
PKR activation during cellular stress. These aspects were explored in chapter 3 of my 
dissertation.
 
1.4 STRUCTURE OF DISSERTATION 
 In Chapter 2 of this dissertation, we report the findings of our investigation into 
the mechanisms underlying PACT’s inability to activate PKR efficiently despite an 
increase in PACT protein levels during active HIV infection. Using a HIV LTR β-
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galactosidase reporter cell line, we found that PACT, like TRBP, enhances the expression 
of the LTR-driven reporter in a virally encoded transcription factor (Tat)-dependent 
manner at a translational level. Our results establish that PACT, in synergy with Tat, 
enhances the translation of HIV TAR-RNA containing transcripts by directly inhibiting 
PKR activation. We also demonstrate that the dsRNA binding protein ADAR1 as well as 
HIV TAR-RNA are required factors that inactivate PACT-mediated PKR activation. A 
complex of PACT-Tat-ADAR1 (and possibly TRBP) formed on TAR-RNA keeps PACT 
inactive for PKR activation and facilitates translation of HIV encoded transcripts79.  
 In Chapter 3, we examine the roles that stress-induced TRBP phosphorylation 
plays in regulating PKR activation in response to oxidative stress.  Using a tetracycline-
inducible TRBP overexpressing HeLa cell line, we demonstrate that TRBP is 
phosphorylated in response to sodium arsenite-induced oxidative stress by the MAPKs, 
ERK and JNK, and the time-course of this phosphorylation event directly coincides with a 
steady decline in PKR and eIF2α phosphorylation and results in a reduction of PKR-
mediated cellular apoptosis. We also show that the observed decrease in PKR activation 
is due to enhanced ability of the phosphorylated TRBP to inhibit PKR. This was further 
confirmed by assaying the effect of phosphorylation-mimetic TRBP mutants on the 
growth inhibition of yeast cells expressing catalytically active PKR. Finally, protein 
interaction studies lead us to conclude that TRBP phosphorylation during oxidative 
stress significantly weakens TRBP-TRBP homomeric interactions, which in turn results in 
increased TRBP-PKR heteromeric interactions and diminished PKR activity. These 
findings provide us with a model for the attenuation of sustained PKR activation and 
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induction of cellular apoptosis through increased inhibitory interactions between PKR 
and phosphorylated TRBP. 
 In Chapter 4, we further assess the effects of mutations of conserved 
hydrophobic residues in PACT’s M1 and M2 motifs on PACT’s dsRNA binding and 
interactions with PACT, TRBP, and PKR. By generating a dsRNA-binding and 
homodimerization- defective phosphorylation mimetic point mutant (L99E DD), we 
gained insight into how defective homodimerization affects stress-induced PACT-PACT 
interaction and PACT-mediated apoptotic induction. These findings together elucidate 
the contributions of each of PACT’s dsRNA binding motifs to efficient PACT-PACT, PACT-
TRBP, and PACT-PKR interaction and highlight the importance of PACT-PACT homodimer 
formation to efficient PKR activation in response to cellular stress.  
 In Chapter 5, we provide general conclusions about the studies presented. 
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Figure 1.1: Regulation of eukaryotic translation initiation by the eIF2α 
kinases. 
 The eukaryotic factor eIF2 (made up of α, β, and γ subunits) associates with 
GTP and the methionyl-charged initiator tRNA to form a ternary complex. 
This complex then associates with the 40S small ribosomal subunit to form a 
40S pre-initiation complex, which in turn binds the mRNA transcript as well 
as other initiation factors. The onset of translation due to the binding of the 
60S large ribosomal subunit is accompanied by the hydrolysis of GTP to GDP. 
Another initiation factor, eIF2B which is the dedicated eIF2 GTP exchange 
factor (GEF), exchanges the hydrolyzed GDP for GTP so another round of 
translation initiation can begin. However, the phosphorylation of eIF2’s α 
subunit on Serine 51 by one of the four eIF2α kinases during cellular stress 
prevents the exchange factor activity of eIF2B without preventing its 
association with eIF2α via eIF2β. This results in the blockage of active eIF2B 
as it stays complexed with eIF2α effectively shutting off protein synthesis, as 
eIF2B is present in limited quantities within the cell. The resulting decline in 
ternary complex formation leads to the cessation of general protein 
synthesis1. 
  
3
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Figure 1.2: Domain structure and activating stimuli of the four eIF2α kinases. Each of the four eIF2α kinases is activated by a 
diverse range of cellular stress signals and contain, in addition to a kinase domain, distinct regulatory domains. HRI possesses two 
heme binding domain s (HB; depicted in red) one of which is inserted within HRI’s kinase domain (KD I & II; depicted in light blue). 
GCN2 has an N-terminal RING finger and WD repeat domain (RWD; depicted in green), a pseudokinase domain (PKD; depicted in 
orange), a kinase domain (KD; depicted in light blue), a histidyl tRNA synthetase-like (HisRS-like) domain (His/RS; depicted in grey), 
and a C-terminal ribosome binding and dimerization domain (RB; depicted in purple). PERK, the ER resident eIF2α kinase, contains an 
N-terminal signal peptide (SP; depicted in green), and ER luminal domain (LD; depicted in orange), a transmembrane domain (TM; 
depicted in blue), and a cytoplasmic domain which envelopes its kinase domain (KD; depicted in light blue). PKR, the interferon 
induced eIF2α kinase, contains two N-terminal double-stranded RNA binding motifs (dsRBM1 and dsRBM2; depicted in navy blue) in 
addition to its C-terminal kinase domain (KD; depicted in light blue).
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Figure 1.3: Domain structure of the dsRNA binding proteins, PKR, PACT, and TRBP: All 
three dsRNA binding proteins contains multiple copies of the conserved dsRNA binding 
motifs. PKR possesses two dsRBMs (M1 and M2; depicted in grey) which mediate PKR’s 
interactions with dsRNA as well as with other dsRBM containing proteins. PKR also has a 
C-terminal kinase catalytic domain containing a region important for PACT interaction 
(denoted by PBM). Two threonine residues (T446, and T451) are the sites of PKR trans-
autophosphorylation required for PKR activation and phosphorylation of eIF2α on 
Serine 51. PACT, PKR’s cellular activator contains three dsRNA binding motifs (M1, M2, 
M3; depicted here in grey and light blue). Blue arrows depict the serine residues (S246, 
S287) identified as stress-induced phosphorylation sites necessary for increased PACT 
interaction with PKR and PKR activation. TRBP, an inhibitor of PKR’s activator during 
cellular stress and HIV infection, contains three dsRNA binding motifs like those of PACT 
(M1, M2, and M3 depicted here in grey and red). Red arrows depict serine residues 
(S121, S131, S262, S265) identified as MAPK (JNK/ERK) phosphorylation sites. PACT and 
TRBP’s respective M3 motifs confer each protein with their activities as pertains to PKR 
activity.
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CHAPTER 2 
 
ADAR1 AND PACT CONTRIBUTE TO EFFICIENT TRANSLATION OF 
TRANSCRIPTS CONTAINING HIV-1 TRANS-ACTIVATING RESPONSE (TAR) 
ELEMENT2
                                                          
2 Chukwurah, E., Handy, I., and Patel R.C. 2017 Biochemical Journal 474: 1241-1257 
Reprinted here with permission of publisher. 
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2.1. ABSTRACT 
 Human immunodeficiency virus type 1 (HIV-1) has evolved various measures to 
counter the host cell’s innate antiviral response during the course of infection. 
Interferon (IFN) stimulated gene products are produced following HIV-1 infection to 
limit viral replication, but viral proteins and RNA counteract their effect. One such 
mechanism is specifically directed against the IFN-induced Protein Kinase PKR, which is 
centrally important to the cellular antiviral response. In the presence of viral RNAs, PKR 
is activated and phosphorylates the translation initiation factor eIF2α. This shuts down 
the synthesis of both host and viral proteins, allowing the cell to mount an effective 
antiviral response. PACT (protein activator of PKR) is a cellular protein activator of PKR, 
primarily functioning to activate PKR in response to cellular stress. 
 Recent studies have indicated that during HIV -1 infection, PACT’s normal cellular 
function is compromised and that PACT is unable to activate PKR. Using various reporter 
systems and in vitro kinase assays, we establish in this report that interactions between 
PACT, ADAR1 and HIV-1-encoded Tat protein diminish the activation of PKR in response 
to HIV-1 infection. Our results highlight an important pathway by which HIV-1 
transcripts subvert the host cell’s antiviral activities to enhance their translation. 
 
2.2: INTRODUCTION 
 Cells infected with a virus employ a variety of mechanisms to counteract the 
negative impact of viral replication and promote cell survival102. The innate immune 
response to a viral infection is mediated by external and internal sensor molecules, 
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which recognize the viral components as “non-self” and trigger mechanisms leading to 
the production of interferons (IFNs)103. IFNs are secreted anti-viral cytokines that bind to 
receptors in a paracrine and autocrine manner on cells to trigger signaling cascades 
culminating in the expression of IFN-stimulated genes (ISGs)77. Most ISGs have antiviral 
functions, although some ISGs with both antiviral and proviral functions have been 
recently described78,104,105. Viral and cellular factors regulate ISGs to promote or limit 
viral replication respectively and this regulatory interplay between the virus and the 
host cell is crucial in determining the outcome of a viral infection. Retroviruses such as 
the Human Immunodeficiency Virus type 1 (HIV-1) produce viral factors that interact 
with various cellular proteins, including ISGs. As a result, the virus subverts their anti-
viral properties or co-opts them from their regular cellular activities to facilitate efficient 
viral replication within the infected host cell106,107.  
 One of the ISG products is PKR (protein kinase, RNA-activated), a protein kinase 
that plays a central role in regulating the outcome of a viral infection108–110. In virally 
infected cells PKR is activated by binding to dsRNA, a product of several viral infections, 
including HIV-134,83. The interaction between PKR and dsRNA induces a conformational 
change that is essential for PKR’s catalytic activation111. PKR then phosphorylates the 
translation initiation factor eIF2α on Serine 51, resulting in a decline of general protein 
synthesis, and consequent cessation of viral protein synthesis112,113. In order to 
counteract PKR’s antiviral actions, viruses have developed measures that include dsRNA 
sequestration, decoy substrates and direct interaction of virally encoded inhibitory 
proteins with PKR114,115. One of the host proteins that inhibits PKR activation during HIV-
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1 replication is the TAR RNA Binding Protein (TRBP), which was first identified due to its 
strong binding affinity for the Trans-activation response element (TAR) RNA found in the 
5’ end of all HIV-1 mRNA transcripts87,116. In eukaryotic mRNAs, the 5’ untranslated 
region (UTR) is critical for ribosome recruitment to the mRNA, start codon choice, and 
control of translation efficiency. This dual inhibitory effect of TAR on translation has 
promoted development of viral countermeasures in order to achieve efficient viral 
replication. During HIV-1 infection, TRBP inhibits PKR activation by sequestration of the 
activating TAR RNA and by direct interaction with PKR’s two dsRBMs95,117,118. Although 
TRBP is an effective inhibitor of PKR, HIV-1 has evolved additional mechanisms to more 
effectively block PKR activity and successfully replicate in infected cells109,119. 
 In the absence of viral infections, basal levels of PKR are present in all cells108. In 
uninfected cells PKR regulates responses to oxidative stress, endoplasmic reticulum (ER) 
stress and serum starvation97,120. Under these conditions, a cellular Protein Activator of 
PKR (PACT) regulates PKR activation121,122. PACT is constitutively phosphorylated on 
Serine 246, and is phosphorylated on Serine 287 in response to stress, resulting in 
increased homodimerization and PACT-PKR heterodimerization58,60,67. PACT activates 
PKR and general protein synthesis is halted, allowing the cell to mount an effective 
response to the stressor, or undergo apoptosis if the stressful conditions cannot be 
overcome. This stress response pathway is negatively regulated by TRBP, as TRBP 
interacts efficiently with PACT in the absence of stress. PACT’s phosphorylation at Serine 
287 in response to cellular stress decreases its interaction with TRBP and consequently 
PACT-PACT and PACT-PKR interactions increase to activate PKR66,67. Thus, TRBP 
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negatively regulates PKR activation during a virus infection, as well as during cellular 
stress68. 
Recent studies established that PACT’s function as a PKR activator is suppressed 
during HIV-1 infection and PACT is unable to activate PKR in HIV-1 infected cells98,109,119. 
During the course of HIV-1 infection, there is a transient increase in PKR activation 
followed by a gradual decrease, which indicates the presence of a viral mechanism to 
subvert sustained PKR activation. A significant increase in the interactions between 
PACT, PKR and ADAR1 (Adenosine Deaminase Acting on RNA 1) is observed, and it 
strongly correlates with decreased PKR activation and increased viral protein 
production98. ADAR1 p150 isoform is an ISG encoded, RNA editing enzyme that catalyzes 
the deamination of adenosine to inosine in viral and cellular dsRNA substrates76,123. This 
often results in the destabilization of RNA secondary structures or incorporation of 
amino acids detrimental to viral protein structure and function78,105,124. In this study, we 
further characterized the molecular mechanisms involved in mediating PACT’s proviral 
effects during HIV-1 replication. Our findings indicate that PACT increases HIV-1 gene 
expression at the translational level via inhibition of PKR activation by acting in concert 
with a HIV-1 encoded protein Tat and a cellular protein ADAR1 to bring about sustained 
PKR inhibition and efficient translation of TAR-containing mRNAs. This study 
underscores the essential role of Tat protein in this inhibitory complex and indicates 
that Tat enhances the translation of HIV-1 mRNAs in addition to its canonical 
transactivation function during transcription125 and its PKR inhibitory role by acting as a 
pseudosubstrate126. Our study also highlights the importance of ADAR1 in this 
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multiprotein complex as a key component that mediates PKR inhibition during HIV-1 
infection.  As all HIV-1 mRNAs contain the TAR structure at their 5’ end, these results 
shed light on how these mRNAs are efficiently translated in virally infected cells.
 
2.3 MATERIALS AND METHODS 
2.3.1 CELL LINES AND ANTIBODIES 
 HeLa MAGI-CCR5 cells127 were obtained through the NIH AIDS Reagent Program. 
HeLa-MAGI-CCR5 cells, PKR -/- murine embryonic fibroblasts (MEFs)80, HEK-293T (ATCC 
CRL-11268) and HeLa (ATCC CRM-CCL-2) cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% Fetal Bovine Serum and 
penicillin/streptomycin. The following antibodies were used: Anti-Flag monoclonal M2 
(Sigma), anti-PKR (human) monoclonal (71/10, R&D Systems), anti-V5 (Invitrogen), anti-
Myc (Santa Cruz). 
 
2.3.2 PLASMIDS 
 The CMV-TAR-Luciferase/pGL3 basic plasmid was constructed as follows: The 
TAR sequence was inserted as an oligonucleotide in the HindIII-BamHI sites of pcDNA3-
EGFP (Addgene). An 818 bp region containing the CMV promoter followed by TAR was 
excised from the TAR pcDNA3-EGFP plasmid described previously and inserted into the 
pGL3 basic vector (Promega) at the SmaI-XhoI site upstream of the luciferase coding 
sequence. The corresponding CMV-Luciferase pGL3 basic plasmid devoid of TAR was 
constructed as follows: A 753 bp region was excised from the pcDNA3-EGFP plasmid and 
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inserted into the SmaI-XhoI site upstream of the luciferase coding sequence. The mutant 
CMV-TAR-Luciferase/pGL3 basic was constructed by inserting the mutated TAR 
oligonucleotide into the HindIII-BamHI sites of pCDNA3-EGFP. The 818 bp region 
containing the CMV promoter and mutant TAR sequence was subsequently excised from 
the pcDNA3-EGFP expression construct and inserted into the pGL3 Basic vector at the 
Sma-XhoI site upstream of the luciferase coding sequence. PACT and TRBP expression 
constructs were as described previously60,62. The Tat/pcDNA3 expression construct was 
a gift from Dr. Ashok Chauhan128, while the pCMV-Rev and pcDNA3.1-ADAR1-p150-V5 
expression constructs were previously described128,129. To generate MycTat/pcDNA 3.1-, 
the Tat insert from Tat/pcDNA3 was subcloned into pcDNA 3.1- in order to put a Myc tag 
at its amino terminus. pCMV2-Flag-PACT was also previously described62. These 
constructs were a gift from Dr. Anne Gatignol (McGill University). 
 
2.3.3 β-GALACTOSIDASE ASSAY 
 HeLa-MAGI-CCR5 cells were transfected with indicated amounts of the 
Tat/pcDNA3, Flag PACT/pcMV2, Flag TRBP/pcDNA 3.1- or only pcDNA 3.1- expression 
constructs.  β-galactosidase activity was assayed 24 hours after transfection using the 
Galacto-Star Assay System (ThermoFisher Scientific). 
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2.3.4 SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE PCR 
 Total RNA was isolated from HeLa-MAGI-CCR5 cells transfected with indicated 
amounts of the Tat/pcDNA 3, Flag PACT/pcMV2, Flag TRBP/pcDNA 3.1- or pcDNA 3.1- 
expression constructs. After 2 washes with ice cold PBS, 250 µl of RNAZol B was added 
and total RNA was isolated as per the manufacturer’s instructions. cDNA was 
synthesized at 42oC for 1 hour using random hexamer primers, 1 µg total RNA, M-MuLV 
Reverse Transcriptase, 500 µM dNTPs, and RNase inhibitor RNAsin (Promega). For each 
PCR, 2 µl of cDNA and 50 pmoles of forward and reverse primers designed to amplify a 
166 bp region of the β-galactosidase transcript or a 500 bp region of the β-actin 
transcript were used with the Promega GoTaq Polymerase Kit. The following conditions 
were used for PCR: 95oC for 5 min (initial denaturation), denaturation at 95oC for 30 s, 
annealing at 45oC for 30 s, and extension at 72oC for 30 s for 20, 25, or 30 cycles. 
 
2.3.5 REAL-TIME PCR 
 RNA was isolated from PKR-/- MEFS transfected with either the CMV-TAR-
Luciferase pGL3 Basic or CMV Luciferase pGL3 Basic plasmids and the indicated 
combinations of Flag wt PKR/pcDNA 3.1-, Tat/pcDNA 3, and Flag PACT/pCMV2 
expression constructs using RNAzol B as per the manufacturer’s instructions. DNAse 
treatment was performed to remove plasmid DNA from isolated RNA using the DNA-
freeTM DNAse Removal Kit (Ambion).  
 cDNA was synthesized as described above using random hexamer primers. Real 
time PCR reactions were performed with serial dilutions of cDNA to ensure efficiency. 
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Reactions were performed in triplicate in a total reaction of 20 μl and included 4 μl 
cDNA, 250 nM firefly luciferase or β-actin primers, and SensiFAST™ SYBR® No-ROX Kit 
(Bioline). All reactions were run on a BioRad CFX96 Real Time System C1000 Thermal 
cycler machine with the following conditions: 95oC for 30 s, 95oC for 5 s, 53oC for 30 s 
(steps were repeated for 35 cycles), 60oC for 5 s, and then 95oC for 5 s. We used the 
BioRad CFX Manager software to generate standard curves to compare luciferase 
expression in each sample. 2 separate RNA isolations from transfected PKR-/- MEFs were 
used for analysis. 
 
2.3.6 TRANSFECTIONS FOR LUCIFERASE REPORTER ASSAYS AND REAL-TIME PCR 
ANALYSIS 
 All transfections were carried out in triplicate for each sample using indicated 
cell types cultured in six-well plates using Effectene (Qiagen) transfection reagent and 
500 ng of total DNA per well. One nanogram of pRL-null (Promega) plasmid was co-
transfected for normalization of the transfection efficiencies. Cell extracts were 
prepared at indicated time points and firefly and Renilla luciferase activities were 
measured with Dual Luciferase Reporter Assay system (Promega). 
 
2.3.7 PKR KINASE ACTIVITY ASSAY 
 PKR activity assays were performed using an anti-PKR monoclonal antibody 
(71/10, R&D systems). HeLaM cells were maintained in DMEM containing 10% fetal 
bovine serum. The cells were harvested when they were at 70% confluence. Cells were 
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washed in ice-cold PBS and collected by centrifugation at 600 g for 5 min. Cell extracts 
were prepared in lysis buffer [20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 50 mM KCl, 400mM 
NaCl, 2 mM dithiothreitol (DTT), 1% Triton-X 100, 100 U/ml aprotinin, 0.2 mM 
phenylmethylsulfonyl fluoride (PMSF) and 20% glycerol]. A 100 µg aliquot of total 
protein was immunoprecipitated using the anti-PKR monoclonal antibody (71/10) in 
high salt buffer [20 mM Tris-HCl pH 7.5, 50 mM KCl, 400 mM NaCl, 1mM EDTA, 1 mM 
DTT, 1% Triton-X 100, 100 U/ml aprotinin, 0.2 mM PMSF, 20% glycerol] at 4oC for 30 min 
on a rotating wheel. A 20 µl aliquot of Protein A-agarose beads was then added and 
incubated for 1h. The Protein-A agarose beads were washed four times in 500 µl of 
high-salt buffer and twice in activity buffer [20 mM Tris-HCl pH 7.5, 50 mM KCl, 2 mM 
MgCl2, 2 mM MnCl2, 0.1 mM PMSF, 5% glycerol]. The PKR assay was performed with 
PKR still attached to the beads in activity buffer containing 0.1 mM ATP and 1 µCi of 
[γ32P] ATP at 30oC for 10 min. PKR was activated using synthesized TAR RNA (IDT DNA 
Technologies) and the effect of PACT, Tat, ADAR1, and TRBP on TAR-activated PKR was 
assayed by the subsequent addition of increasing amounts of pure recombinant PACT or 
pure recombinant TRBP (4, 40, 400 pg and 4 ng) in the presence of recombinant Tat and 
increasing amounts of recombinant ADAR1 (1.5, 15, and 150 ng). Labeled proteins were 
analyzed by SDS-PAGE on a 12% gel followed by autoradiography. 
 
2.3.8 CO-IMMUNOPRECIPITATION ASSAY 
In vitro translated, 35S-labeled ADAR1 and flag epitope-tagged PACT and TRBP proteins 
were synthesized using the TNT T7 coupled reticulocyte system from Promega. A 5 µl of 
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35S-labeled proteins were mixed in indicated combinations and incubated with 20 µl of 
anti-flag mAb–agarose (Sigma) in 200 µl of immunoprecipitation (IP) buffer [20 mM 
Tris–HCl pH 7.5, 150 mM (or 300 mM) NaCl, 1 mM DTT, 100 U/ml aprotinin, 0.2 mM 
PMSF, 20% glycerol and 1% Triton X-100] at RT for 30 min on a rotating wheel. The 
beads were washed in 500 µl of IP buffer four times and the washed beads were then 
boiled in Laemmli buffer [150 mM Tris–HCl pH 6.8, 5% SDS, 5% β-mercaptoethanol and 
20% glycerol] for 2 min and eluted proteins were analyzed by SDS–PAGE on a 12% gel 
followed by phosphorimager analysis for quantification. 
 
2.3.9 YEAST TWO-HYBRID INTERACTION ASSAY 
 To compare the strength of TRBP-ADAR1 with PACT-ADAR1 interactions, ADAR1 
was expressed as a GAL4 DNA-activation domain fusion protein from the pGADT7 
vector, and TRBP and PACT were expressed as GAL4 DNA-binding domain fusion 
proteins from the pGBKT7 vector. ADAR1 pGADT7 /TRBP pGBKT7 and ADAR1 pGADT7/ 
PACT pGBKT7 were co-transformed into AH109 yeast cells (Clontech), and the 
transformed yeast cells were plated on double dropout SD (synthetic defined) minimal 
medium lacking tryptophan and leucine. In order to check for the transformants’ ability 
to grow on triple dropout media, transformed yeast cells were grown to an OD600 of 2 in 
liquid growth medium. A 500 μl aliquot of each culture was pelleted and resuspended in 
an appropriate amount of distilled water to yield an OD600 of 10. Serial dilutions were 
then made to yield OD600 values of 1, 0.1, and 0.01. A 10 μl aliquot of each dilution was 
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then spotted onto triple dropout SD minimal media lacking histidine, tryptophan, and 
leucine in. Plates were incubated at 30oC for 3 days. 
 
2.3.10 QUANTIFICATION AND STATISTICS 
 Radioactive bands were scanned for the TRBP-ADAR1 and PACT-ADAR1 co-
immunoprecipitation assays (Typhoon FLA7000) and were quantified using the GE Life 
Sciences ImageQuant TL software. To determine the statistical significance of the results 
of the co-immunoprecipitation assay and the β-galactosidase and luciferase assays, a 
two-tailed Student’s t-test was performed, assuming equal variance. Each figure legend 
indicates P-values as denoted by brackets and special characters. Note that our α-level 
was P = 0.05. 
 
2.4 RESULTS 
2.4.1 PACT ENHANCES HIV-1 GENE EXPRESSION FROM A TAT-INDUCED INTEGRATED 
LONG TERMINAL REPEAT 
 Our previous work indicated that PACT enhances expression from a HIV-1 
promoter in transfected HeLa cells as well as viral replication in HIV-1 infected cells62,98. 
Thus, in this context, PACT exhibited a proviral function similar to the PKR inhibitor 
TRBP. To determine if PACT can enhance HIV-1 long terminal repeat (LTR)- driven gene 
expression in the context of latently infected cells, we first compared the effects of TRBP 
and PACT when HIV-1 LTR is integrated into the host chromosome.  HeLa-MAGI-CCR5 
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cells contain a stably integrated β-galactosidase coding region expressed under the 
control of the HIV-1 LTR, whose transcription is dependent on HIV-1 Tat protein86,130–133. 
 We first verified that increasing amounts of Tat expression vector (blue bars) 
resulted in a dose-dependent increase in β-galactosidase activity (Figure 2.1 A) 
compared to the absence of Tat (black bar). Having confirmed that the cells are 
responsive to Tat, we next evaluated the effect of PACT in comparison to TRBP. The 
addition of PACT (green bars) or TRBP (red bars) expression constructs further 
stimulated Tat-trans-activated HIV-1 LTR-driven β-galactosidase activity (Figure 2.1B).  
 Furthermore, the addition of increasing amounts of Tat expression plasmid (blue 
bars) in the presence of a constant amount of PACT (green bars) or TRBP (red bars) led 
to increased β-galactosidase activity in a dose-dependent manner (Figure 2.1C). In 
contrast, in the absence of Tat, neither PACT (green bars) nor TRBP (red bars) had any 
effect on HIV-1 LTR driven expression (Figure 2.1D). These results indicate that similar to 
TRBP, PACT activates expression from HIV-1 LTR when integrated in the host 
chromosome and that this effect is dependent on the presence of the viral Tat protein. 
 
2.4.2 PACT DOES NOT AFFECT THE STEADY-STATE TRANSCRIPT LEVELS OF HIV-1 LTR-
DRIVEN GENES 
 To characterize PACT’s activating effect on HIV-1 LTR-driven gene expression as 
either transcriptional or post-transcriptional, we performed semi-quantitative RT-PCR 
analysis to assess changes in β-galactosidase mRNA levels in HeLa-MAGI-CCR5 cells 
transfected with Tat and PACT or TRBP expression plasmids relative to β-actin mRNA 
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levels (Figure 2.2). As expected, we observed that the expression of Tat increased β-
galactosidase mRNA levels (lanes 4-6) when compared with empty vector transfected 
HeLa-MAGI-CCR5 cells (lanes 1-3). As seen in lanes 7-9, there was no increase in β-
galactosidase mRNA levels between HeLa-MAGI-CCR5 cells transfected with Tat alone 
(lanes 4-6) and HeLa-MAGI-CCR5 cells transfected with Tat alone (lanes 4 -6) and HeLa-
MAGI-CCR5 cells transfected with Tat and TRBP (lanes 7-9) or Tat and PACT (lanes 10-
12).  
 These results show that the enhancing effect of PACT on β-galactosidase activity 
in HeLa-MAGI-CCR5 cells was not a result of increased levels of β-galactosidase mRNA, 
but resulted from a post-transcriptional mechanism. As all mRNAs produced from HIV-1 
LTR promoter driven reporters contain a TAR structure in their 5’-UTRs, these results 
indicate that PACT acts at a post-transcriptional level on TAR-containing mRNAs. 
 
2.4.3 TAT AND PACT INHIBIT PKR ACTIVATION INDUCED BY TAR CONTAINING MRNAS 
 The translation of HIV-1 mRNAs is diminished by the TAR RNA secondary 
structure in their 5’-UTRs and also by TAR- mediated PKR activation106,134,135. This effect 
is partially compensated for by the cellular proteins TRBP and ADAR186,118,129,136,137 as 
well as by the viral protein Tat126.  
 However, Tat also acts as a potent transcriptional trans-activator for HIV-1 LTR-
driven genes, and in order to specifically study Tat’s post-transcriptional effects, we 
used a system that is not affected at the transcriptional level by Tat. For this purpose, 
we designed an expression construct CMV-TAR-LUC, in which the TAR RNA was placed 
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directly upstream of the firefly luciferase open reading frame expressed from a CMV 
promoter. A CMV-Luciferase expression construct (CMV-LUC) was designed as a control 
without TAR. By producing TAR-containing transcripts from the CMV promoter which is 
nonresponsive to Tat’s transcriptional transactivation, we could specifically assess Tat’s 
post-transcriptional effects mediated by PKR activation. 
 To examine the activity of PACT and Tat on PKR-induced inhibition of translation, 
PKR-/- MEFs were co-transfected with either CMV-TAR-LUC/pGL3 Basic or CMV-
Luciferase/pGL3 Basic along with PACT and Tat expression plasmids, and luciferase 
activity was assessed. As seen in Figure 2.3A, co-transfection of PKR with CMV-TAR-LUC 
(white bars) or CMV-LUC (black bars) reduced luciferase activity as previously reported 
and in agreement with PKR’s effect on translation of plasmid-encoded 
transcripts62,98,118,129. Furthermore, co-transfection of Tat with PKR rescued the PKR-
mediated reduction of luciferase activity only when TAR was present, indicating that Tat 
can relieve the translational block imposed by PKR on TAR-containing mRNAs. 
Surprisingly, PACT also counteracted TAR-induced PKR translational inhibition, whereas 
it maintained PKR-mediated translational inhibition of plasmid-derived luciferase mRNA 
in the absence of TAR, suggesting that the presence of TAR is required for both PACT 
and Tat’s inhibitory effect on PKR. In addition, when expressed together, PACT and Tat 
showed a further significant increase of luciferase expression with CMV-TAR-LUC, but 
not with CMV-LUC.  
These results indicate that PACT inhibits PKR activation on TAR-containing mRNAs, in 
contrast with its well-characterized PKR-activating function61,121,122,138,139. Furthermore, 
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this PKR-inhibitory activity of PACT can only occur in the presence of TAR- containing 
mRNA transcripts (compare black bars with white bars) and is significantly enhanced in 
the presence of Tat. These results suggest that during active production of HIV-1 viral 
proteins, PACT acts in concert with Tat and TAR RNA to counteract PKR- mediated 
inhibition of viral mRNA translation. 
 To ensure that the Tat-dependent, PACT-mediated inhibition of PKR was not a 
result of changes in TAR-firefly luciferase mRNA or firefly luciferase mRNA transcript 
levels, we performed qRT-PCR analysis to quantify firefly luciferase mRNA levels in total 
RNA isolated from the PKR -/- MEFs transfected with the constructs indicated in Figure 
2.3A. There were no significant differences in firefly luciferase mRNA levels in the 
various samples (Figure 2.3B), demonstrating that PACT’s Tat-dependent effect on 
luciferase expression is at translational level, most probably by counteracting PKR 
activation. 
 
2.4.4 TAT-TAR INTERACTION IS ESSENTIAL FOR PACT’S PKR INHIBITORY ACTIVITY 
 As we observed that Tat and PACT work synergistically to increase translation of 
TAR containing mRNAs, we wanted to determine if Tat’s ability to bind to the TAR RNA 
was essential for this function. To test this, we generated a CMV-TARm-LUC construct in 
which the TARm RNA will not bind Tat but would still activate PKR59. PKR co-transfection 
with this construct dramatically reduced the firefly luciferase activity (Figure 2.4A). 
However, co-transfection of Tat or PACT had no effect on PKR-mediated inhibition of the 
luciferase activity. These results show that Tat’s ability to interact with TAR-containing 
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mRNAs is essential for the concerted PKR inhibitory effect of Tat and PACT on TAR-
containing mRNAs. 
 To test that the PKR inhibitory effect was specific to Tat-PACT combination, we 
performed the same transfection experiments with CMV-TAR-Luc and Rev, which is an 
HIV-1 viral protein that binds to a different RNA structured element in viral mRNAs 
known as the Rev response element211-213. Co-transfection of PKR reduced the luciferase 
activity as shown in Figure 2.3A, but that of PACT or/and Rev had no effect on luciferase 
activity (figure 2.4B). These results confirm that PACT’s PKR inhibitory activity on TAR-
containing mRNAs specifically required Tat and its TAR RNA-binding activity is essential 
for this function. 
 
2.4.5 ADDITIONAL CELLULAR FACTORS ARE ESSENTIAL TO INHIBIT TAR RNA-MEDIATED 
PKR ACTIVATION 
 Based on the above results, the combination of the TAR RNA. PACT, and Tat 
seems to induce strong inhibition of PKR activation in cell culture. To determine if these 
components are sufficient to provide complete PKR inactivation, we performed in vitro 
kinase activity assays using PKR immunoprecipitated from HeLa cells to recapitulate the 
mechanism in vitro. We first confirmed that PKR is activated robustly by TAR RNA similar 
to the synthetic dsRNA polyI:C, with a bell-shaped activation curve with no activation at 
low and high concentrations of TAR RNA (Figure 2.5A), as previously observed 214,94,215. 
We then assessed PACT’s ability to inhibit or activate PKR activation caused by TAR RNA 
in the absence (Figure 2.5B, lanes 3-6) or presence (Figure 2.5B, Lanes 7-10) of Tat. PACT 
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remained a PKR activator in the presence of TAR-RNA (Figure 2.5B, lanes 3-6). In the 
presence of Tat, a very modest inhibition of PKR activity with the highest amount of 
PACT was observed (Figure 2.5B, Lane 10), indicating that PACT and Tat cannot 
recapitulate PKR inhibition in vitro and that additional components present in the 
mammalian cells are required for the observed inhibition of PKR activation on TAR-
containing mRNAs. 
 
2.4.6 THE RNA-EDITING PROTEIN ADAR1 IS ESSENTIAL FOR THE COMPLETE INHIBITION 
OF TAR-ACTIVATED PKR BY TAT AND PACT 
 We previously reported that another double stranded RNA binding protein, 
ADAR1, directly interacts with PKR and PACT during HIV-1 infection to form a PKR-
inhibitory complex98,119,129. Thus, we investigated if ADAR1 can inhibit TAR-activated PKR 
when present together with Tat and PACT. Using an in vitro kinase assay, we observed 
that ADAR1 can inhibit PKR activation efficiently in a dose-dependent manner (Figure 
2.6, lanes 2-4).  
Under these conditions, 150 ng of ADAR1 was required for complete inhibition of PKR 
activity (lane 2), whereas 15 ng and 1.5 ng of ADAR1 showed partial (lane 3) and no 
inhibition (lane 4), respectively. The addition of PACT did not improve or compromise 
the PKR inhibitory function of ADAR1 (lanes 6-8). We then tested the effect of HIV-1 Tat 
protein on PKR activity as our results in Figure 3 suggested that Tat is required for PKR 
inhibition. When Tat was present, we observed a complete inhibition of PKR activity at 
all concentrations of ADAR1 (lanes 9-12). Thus, the Tat protein seems to significantly 
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enhance the PKR inhibitory actions of ADAR1; 100-fold less ADAR1 (lane 12, 1.5 ng 
ADAR1) was sufficient to inhibit PKR activity in the presence of Tat, when compared 
with the conditions where Tat was absent (lane 6, 150 ng ADAR1). Also, Tat when 
present with ADAR1 does not enhance ADAR1’s PKR inhibitory actions when compared 
with the inhibition observed with ADAR1 alone (lanes 14-16) when PACT is absent. 
 These results show that Tat, PACT, and ADAR1 act in concert to inhibit PKR and 
suggest that an inhibitory complex formed with Tat, PACT, and ADAR1 is essential for 
efficient PKR inhibition on TAR containing HIV-1 mRNAs. Tat by itself (data not shown) 
or with PACT (Figure 2.5) does not inhibit PKR activity. To further confirm that Tat 
enhances the PKR inhibitory activity of ADAR1 and PACT, we compared the effect of 
lower concentrations of ADAR1 in the presence and absence of Tat. As seen in Figure 
2.6B, in the absence of Tat, 1.5 ng of ADAR1 showed complete inhibition of PKR activity 
(lane 2), and 150 and 15 pg ADAR1 showed no PKR inhibition (lanes 3 and 4, 
respectively). In the presence of Tat, 1.5 ng ADAR1 showed complete inhibition (lane 6) 
and 150 pg of ADAR1 showed partial inhibition of PKR activity (lane 7). These results 
demonstrate that Tat enhances the PKR inhibitory actions of ADAR1 in the presence of 
PACT, and that Tat may function to recruit PACT and ADAR1 to the complex after 
binding to TAR in HIV-1 encoded transcripts. 
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2.4.7 A COMPARISON OF PKR INHIBITORY ACTIVITY OF ADAR1 IN THE PRESENCE OF 
PACT OR TRBP 
 As TRBP is known to inhibit PKR under various conditions including HIV infection, 
we wished to compare the relative efficiency of PACT and TRBP to inhibit TAR RNA-
activated PKR in the presence of Tat and ADAR1. As seen in Figure 2.7A, we observed 
that similar to PACT, ADAR1 can inhibit PKR activation efficiently in a dose-dependent 
manner in the presence of TRBP and Tat (lanes 4-6). Under these conditions, 150 ng 
ADAR1 was required for a complete inhibition of PKR activity (lane 4). Unlike PACT 
(which activates PKR in the absence of ADAR1), TRBP shows significant inhibition of PKR 
even in the absence of ADAR1 (lane 3), and this inhibition is further enhanced by the 
addition of ADAR1 (lanes 4-6).  
 Comparing the relative efficiency of TRBP and PACT to inhibit PKR, 100-fold less 
ADAR1 is required in the presence of PACT (lanes 9-11) when compared to conditions 
where TRBP was used (lanes 4-6) instead of PACT. Thus, PACT significantly enhances the 
PKR inhibitory actions of ADAR1 when compared with TRBP (lanes 4-6 and 9-11). These 
results show that Tat, PACT, and ADAR1 act in concert to inhibit PKR more efficiently 
than Tat, TRBP, and ADAR1. One possible mechanism for PACT’s enhanced ability to 
increase ADAR1’s effective inhibition of PKR could result from its higher affinity for 
ADAR1. Therefore, we compared the relative strengths of PACT-ADAR1 and TRBP-
ADAR1 interactions using a co-immunoprecipitation assay. We used an in vitro rabbit 
reticulocyte translation system to generate 35S-methionine labeled ADAR1, PACT, and 
TRBP proteins. As seen in Figure 2.7B, both PACT and TRBP can co-immunoprecipitate 
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ADAR1 at 150 mM (lanes 4-6) and 300 mM (lanes 7-9) salt concentrations. However, at 
both salt concentrations, PACT interacts significantly more efficiently with ADAR1 when 
compared with TRBP (Figure 2.7C). At 150 mM salt concentration, PACT pulled down 
12.3% of ADAR1, whereas TRBP could only pull down 3.2% of ADAR1. At 300 mM salt 
concentration, PACT pulled down 7.3% of ADAR1 and TRBP pulled down only 1.1% of 
ADAR1.  
 To compare the PACT-ADAR1 and TRBP-ADAR1 interactions further, we utilized a 
yeast two-hybrid assay (Figure 2.7D). We have used this system extensively to 
demonstrate that stress-induced phosphorylation of PACT results in changes in the 
affinity of its interaction with TRBP and PKR60,67,140. Thus, the yeast two-hybrid system is 
sensitive enough to detect changes in relative affinities between these proteins and 
measures direct interaction between two proteins. As seen in Figure 2.7D, in 
comparison with TRBP, PACT shows significantly stronger interaction with ADAR1. These 
results further suggest that ADAR1 functions as a more efficient inhibitor of TAR RNA-
activated PKR in the presence of PACT than in presence of TRBP, either because PACT 
recruits ADAR1 with higher efficiency to TAR containing mRNAs or because ADAR1 
forms a more stable PKR inhibitory complex with PACT. In HIV-infected cells, it is 
possible that both TRBP and PACT serve redundant roles to form complexes with Tat, 
ADAR1 and TAR RNA but PACT functions more efficiently to bring about PKR inhibition.
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2.5 DISCUSSION 
 In HIV-1 infected patients type I IFNs are produced by plasmacytoid dendritic 
cells and exert both antiviral and immunomodulatory activities141. However, this IFN 
response is insufficient to clear the virus from infected cells142,143. The inability of IFNs to 
clear the virus is not due to a lack of cellular response to IFN since the ISGs are induced 
in infected peripheral blood mononuclear cells (PBMCs) when in culture and show 
inhibition of HIV-1 replication98. Thus, the absence of a robust IFN antiviral response in 
patients is due to a block in the antiviral actions of ISGs. PKR is one of the ISGs whose 
regulation has been studied extensively in the context of many viral infections including 
HIV-1. PKR overexpression results in its activation that effectively restricts HIV-1 
replication117,129,144–146. In addition, a knockdown of PKR using siRNAs or overexpression 
of a trans-dominant negative PKR mutant results in increased HIV-1 replication in cell 
culture137. In spite of this, the virus replicates efficiently in patient cells, suggesting that 
PKR activity is heavily limited during the course of a natural infection129. 
  Our previous work showed that PKR activation takes place only transiently after 
HIV-1 infection of PBMCs or of lymphocytic cell lines with either X4 or R5 HIV-1 strains, 
suggesting that PKR activation is rapidly inhibited by the presence of HIV-1, which 
removes a barrier to replication129. During the course of HIV-1 infection, PKR is activated 
by the TAR RNA and inhibited by TRBP, ADAR1 and the viral Tat proteins. Of these 
inhibitors, the HIV-1 protein Tat inhibits PKR by acting as a substrate competitor81,82,126 
whereas TRBP and ADAR1 inhibit PKR activity by direct interaction. TRBP also sequesters 
the activator dsRNA and PACT molecules by a direct interaction with them95,117. ADAR1 
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was previously identified as an important contributor for effective PKR inhibition and 
has emerged as exhibiting both antiviral and proviral functions78,109. ADAR1 catalyzes 
the deamination of adenosine in RNAs with dsRNA regions, thereby causing a 
destabilization of RNA duplexes and genetic recoding123. Thus, ADAR1 functions as a 
suppressor of dsRNA-mediated antiviral responses, which include activation of PKR and 
IFN regulatory factor IRF3, the transcription factor for IFN genes78. The p150 isoform of 
ADAR1 is an ISG, present both in the cytoplasm and nucleus, as while the p110 isoform 
is constitutively expressed and is predominantly present in the nucleus147.  
 The results presented here demonstrate that TAR-mediated PKR activation is 
also suppressed by a complex of PACT, ADAR1, and the viral protein Tat. Thus, in 
addition to its well-established functions in the nucleus and in transcription of HIV-1 
proviral genome, Tat plays an important function in enhancing HIV-1 mRNA translation 
in the cytoplasm. Furthermore, in this complex, PACT is unable to activate PKR and that 
ADAR1 and Tat are essential for repressing PACT’s canonical PKR activating role. Neither 
Rev nor a mutated TAR can inhibit PKR activation, thus suggesting that TAR RNA serves 
as a scaffold to recruit and stabilize many RNA-binding proteins, and PACT’s PKR-
activating ability is inactivated by the recruitment of ADAR1 to this complex. It is 
possible that Tat binds to TAR first to recruit PACT, which in turn is able to efficiently 
bring ADAR1 to the complex. Our previous data established that PACT and ADAR1 
interact directly98 and our current results show that Tat has an essential function in this 
complex. Overall, our results suggest that during HIV-1 infection, cytoplasmic Tat may 
bind to the TAR RNA to simultaneously recruit PACT and ADAR1 to serve a PKR 
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inhibitory role. This complex serves a crucial role in enhancing translation of viral 
proteins needed for efficient viral replication as PKR is known to bind to the stem region 
of TAR RNA148. 
 In addition to its classical transcriptional trans-activation role in the nucleus, 
Tat’s cytoplasmic functions during HIV-1 replication have been reported before in other 
studies149,150. Tat protein counteracts the effect of TAR to stimulate translation of the 
viral mRNAs by enhancing the activity of RNA helicase DDX3151–154. Tat also showed a 
stimulatory effect on global protein synthesis by competing with eIF2α for 
phosphorylation by PKR or by inhibiting PKR activity, independently of the presence of 
TAR [reviewed in reference119]. Our work introduces one more regulatory layer for Tat’s 
central role in HIV-1 replication. As represented in Figure 2.8, our results establish that 
for efficient translation of TAR-containing mRNAs, the interaction between TAR and Tat 
is essential to promote the formation of a PKR inhibitory complex that contains PACT 
and ADAR1. Using a mutated TAR region that does not bind Tat but can activate PKR 
efficiently, we demonstrate that PKR-mediated translational downregulation was not 
overcome in the absence of TAR-Tat interaction (Figure 2.4). 
 As a part of this multiprotein complex, PACT is unable to activate PKR and ADAR1 
strongly represses PKR activity (Figure 2.6).  ADAR1 has been shown to inhibit PKR 
activity and reduce eIF2α phosphorylation efficiently to play a proviral role during the 
replication of several DNA and RNA viruses78,105. Overexpression of either the full-length 
ADAR1 p150 protein or the region with the RNA- and Z-DNA binding domains alone 
inhibited PKR autophosphorylation and eIF2α phosphorylation129,155. A stable 
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knockdown of ADAR1 expression causes enhanced PKR autophosphorylation and eIF2α 
phosphorylation following infection with measles virus or vesicular stomatitis virus156,157. 
In ADAR1 containing cells, PKR autophosphorylation is suppressed following a viral 
infection, but in ADAR1-deficient cells it is enhanced because of the lack of editing-
mediated destabilization of dsRNA, lack of sequestration of dsRNA by ADAR1 and also 
due to a lack of formation of inactive heterodimeric ADAR1:PKR complexes78.  
 Furthermore, a depletion of ADAR1 by RNAi in human cells or by genetic 
knockout in mouse MEFs leads to enhanced apoptosis and cytotoxicity following 
infection with RNA viruses from the Paramyxoviridae and the Rhabdoviridae families as 
well as the polyoma DNA virus156–159. Using an overexpression screening strategy in 
which more than 380 human ISGs were tested for their antiviral activity against many 
medically important viruses, ADAR1 emerged as the most potent proviral ISG, which 
enhanced the replication of HIV-1, West Nile virus, Chikungunya virus, Venezuelan 
equine encephalitis virus, and yellow fever virus160. In case of HIV-1 infection, our results 
demonstrate that ADAR1 is important to suppress PKR activation by TAR RNA to allow 
for efficient synthesis of viral proteins as only Tat, PACT, and TAR RNA cannot block PKR 
activation efficiently in the absence of ADAR1 (Fig. 2.6). 
 Several viruses have been shown to inactivate PACT function in the infected cells 
as PACT is involved both in activating PKR to suppress viral protein synthesis and in IFN 
production via RIG-I like receptors (RLRs)161. Middle East Respiratory Syndrome 
Coronavirus 4a protein162, Herpes Simplex Virus US 11 protein163,164, Ebola virus VP35 
protein165, Influenza virus NS1 protein166, and orf virus ov20.2 protein167 have been 
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shown to inactivate PACT. Overall, our results show that the suppression of PACT 
activity to effectively inactivate PKR in HIV-1 producing cells is the result of the 
combined activity of the recruited ADAR1 that mediates PKR kinase inhibition, and Tat 
most likely stabilizes the complex formed by PKR, PACT and ADAR1. Any effect that Tat 
may have on PACT’s function in the RLR mediated IFN production remains to be 
explored in future. 
 The results presented here shed light on how efficient translation of TAR-
containing HIV-1 encoded RNAs takes place by suppressing PKR activation. The present 
work also presents us with new paradigms for testing possible ways to suppress HIV-1 
viral protein synthesis. For example, if the formation of the inhibitory complex could be 
prevented by use of peptides that may block interaction between various components 
of this complex, we may be able to keep PKR activated in virally infected cells to prevent 
or at least partially block viral replication. 
.
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Figure 2.1: PACT activates Tat-enhanced HIV-1 gene expression from an integrated LTR  
(A). Requirement and dose response curve for Tat for HIV-1 LTR driven expression. 
HeLa-MAGI-CCR5 cells were transfected with 0 (black bar) or increasing amounts of 
Tat/pcDNA 3 (blue bars) as indicated. 
 β-Galactosidase activity was assayed 24 hours after transfection. Error bars indicate 
standard deviation calculated from three independent experiments. The P-value 
(0.0000038) calculated using statistical analyses indicated significant difference between 
the RLU values indicated by the bracket marked as ‘*’.  
(B and C) PACT and TRBP both enhance HIV-1 LTR driven expression. (B) HeLa-MAGI-
CCR5 cells were transfected with 0 (black bar), or 1ng Tat/pcDNA 3 (Blue bar) with 
increasing amounts of Flag TRBP/pcDNA 3.1- (Red bars) or Flag PACT/pCMV2 (Green 
bars) as indicated. The P-values (0.0045 and 0.0044) calculated using statistical analyses 
indicated significant difference between the RLU values indicated by the brackets 
marked as ‘*’ and ‘**’ respectively. (C) HeLa-MAGI-CCR5 cells were transfected with 0 
ng, (black bar), increasing amounts of Tat/pcDNA 3 (blue bars) and with 10ng of Flag 
TRBP/pcDNA 3.1- (red bars) or with Flag PACT/pCMV2 (green bars). β-Galactosidase 
activity was assayed 24 hours post-transfection. Error bars indicate standard deviation 
calculated from three independent experiments. The P-values (0.0011 and 0.0004) 
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Figure 2.1 (continued) calculated using statistical analyses indicated significant 
difference between the RLU values indicated by the brackets marked as ‘*’ and ‘**’ 
respectively.  
D. PACT and TRBP have no effect on HIV-1 LTR driven expression in the absence of Tat. 
HeLa-MAGI-CCR5 cells were transfected with 0 (black bar), or increasing amounts of Flag 
TRBP/pcDNA 3.1- (red bars), or Flag PACT/pCMV2 (green bars). β-Galactosidase activity 
was assayed 24 hours post-transfection. All transfections were compensated to the 
same amount of DNA with pcDNA 3.1. Error bars indicate standard deviation calculated 
from three independent experiments. The P-values (0.3863 and 0.9124) calculated using 
statistical analyses indicated no significant difference between the RLU values indicated 
by the brackets marked as ‘#’ and ‘##’ respectively. 
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Figure 2.2: PACT does not increase the steady –state mRNA levels of HIV-1 LTR-driven 
β-galactosidase. 
 
RNA was isolated from HeLa-MAGI-CCR5 cells transfected with pcDNA 3.1- only (-Tat, 
lanes 1-3), Tat/pcDNA 3 (+ Tat alone, lanes 4-6), Tat/pcDNA 3 and Flag TRBP/pcDNA 3.1- 
(Tat + TRBP, lanes 7-9), or Tat/pcDNA 3 and Flag PACT/pCMV2 (Tat + PACT, lanes 10-12).  
The RNA preparation was treated extensively with DNase to digest any DNA 
contamination. β-Galactosidase mRNA expression levels were analyzed by semi-
quantitative RT-PCR at the indicated number of reaction cycles. β-actin mRNA levels 
were also analyzed as a normalization control for each cycle number. No PCR products 
were obtained in the absence of reverse transcriptase.
  
6
3
 
 
Figure 2.3: PACT inhibits PKR activation induced by TAR-containing mRNAs. 
A. Tat enhances PACT mediated PKR inhibition on TAR containing mRNAs.  PKR -/- MEFs were co-transfected with CMV-TAR-
Luciferase or CMV-Luciferase (in pGL3 Basic plasmid backbone), and indicated combinations of Tat/pcDNA3, Flag PKR/pcDNA 3.1-, 
and Flag PACT/pCMV2. Firefly luciferase activity was assayed 24 h post-transfection and the error bars represent the standard 
deviation from three experiments. The P-values (0.0018 and 0.4601) calculated using statistical analyses indicated significant and 
non-significant differences between the RLU values indicated by the brackets marked as ‘*’ and ‘#’ respectively.  
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Figure 2.3 (continued) B. qRT-PCR analysis. qRT-PCR analysis was performed to analyze luciferase mRNA expression levels in 
samples from PKR-/- MEFs transfected as described in A. Data represents the average from six replicate experiments from two 
different RNA isolations. All results are normalized to β-actin. 
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Figure 2.4: Tat serves a specific function in mediating inhibition of PKR. 
A. Tat’s binding to the TAR is essential for PACT mediated PKR inhibition. PKR-/- MEFs were co-transfected with CMV mutant-TAR 
Luciferase (in pGL3-Basic plasmid backbone:EV) in which the mutant TAR element does not bind to Tat and the indicated 
combinations of Tat/pcDNA 3, Flag PKR/pcDNA 3.1-, and Flag PACT/pCMV2. Firefly Luciferase activity was assayed 24 h post-
transfection and the error bars represent the standard deviation from three experiments. The P-value (0.5852) calculated using 
statistical analyses indicated a non-significant difference between the RLU values indicated by the bracket marked as ‘#’. 
B. Rev, another HIV-1 encoded RNA-binding protein cannot substitute for Tat’s function. PKR-/- MEFs were co-transfected with the 
CMV TAR Luciferase expression construct and the indicated combinations of Rev/pcDNA 3, Flag PKR/pcDNA 3.1-, and Flag 
PACT/pCMV2. Luciferase activity was assayed 24 h after transfection and the error bars represent the standard deviation from three 
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Figure 2.4 (continued) experiments. The P-value (0.5852) calculated using statistical analyses indicates no significant difference 
between the RLU values indicated by the bracket marked as ‘##’.
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Figure 2.5: PACT and Tat are insufficient to inhibit TAR RNA dependent PKR activation. 
A. TAR RNA activates PKR: PKR immunoprecipitated from HeLaM cell extracts was 
activated by the addition of increasing amounts of TAR RNA as indicated (Lanes 3-8) or 
poly I:poly C (Lane 2, ds). Lane 1 indicates activity in the absence of any activator. The 
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis. 
B. Efficient inhibition of PKR requires components in addition to PACT and Tat. PKR 
immunoprecipitated from HeLaM cell extracts was activated with 67 pg TAR RNA [Lanes 
2-10]. Increasing amounts of pure recombinant PACT [Lanes 3-6 and Lanes 7-10] were 
added in absence of Tat [Lanes 3-6] or in combination with 4 ng of pure recombinant Tat 
[Lanes 7-10]. PACT amounts are as follows: 4 pg [Lanes 3 and 7], 40 pg [Lanes 4 and 8], 
400 pg [Lanes 5 and 9], and 4 ng [Lanes 6 and 10]. Lane 1 (C) shows the PKR activity 
without any added activator. The phosphorylated proteins were analyzed by SDS-PAGE 
and phosphorimager analysis.
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Figure 2.6. ADAR1 is essential for an efficient inhibition of PKR. 
(A) ADAR1, PACT, and Tat inhibit PKR efficiently. PKR immunoprecipitated from HeLaM cell extracts was activated with 67 pg of 
TAR RNA and varying amounts (150, 15, and 1.5 ng) of ADAR1 (Lanes 2-4, lanes 6-8, 10-12, and 14-16) were added as indicated to 
assess the inhibition of PKR. Lanes 2-4: PKR activity in presence of varying amounts of ADAR1; Lanes 6-8: PKR activity in the presence 
of 4 ng of PACT and varying amounts of ADAR1, lanes 10-12: PKR activity in the presence of 4 ng of PACT, 4 ng of Tat, and varying 
amounts of ADAR1; lanes 14-16: PKR activity in the presence of 4 ng of Tat and varying amounts of ADAR1. The phosphorylated 
proteins were analyzed by SDS-PAGE and phosphorimager analysis.  
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Figure 2.6 (continued) B. ADAR1 and PACT inhibit PKR more efficiently in the presence of Tat. PKR immunoprecipitated from 
HeLaM cell extracts was activated with 67 pg of TAR RNA and varying amounts (1.5 ng, 150 pg, and 15 pg) of ADAR1 (Lanes 2-4 and 
lanes 6-8) were added as indicated to assess the inhibition of PKR. Lanes 2-4: PKR activity in presence of varying amounts of ADAR1 
and 4 ng of PACT; Lanes 6-8: PKR activity in the presence of varying amounts of ADAR1, 4 ng of PACT, and 4 ng of Tat. The 
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis.  
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Figure 2.7. Comparison of TRBP and PACT’s PKR inhibitory activity on TAR RNA. 
(A) PACT is more efficient compared with TRBP in forming a PKR inhibitory complex. 
PKR immunoprecipitated from HeLaM cell extracts was activated with 67 pg of TAR RNA. 
Either 4 ng of PACT (lane 2) or TRBP (lane 8) or 4 ng of TRBP (lanes 4-6) or PACT (lanes 9-
11), 4 ng Tat, and varying amounts (150, 15, and 1.5 ng) of ADAR1 (Lanes 4-6 and 9-11) 
were added as indicated to assess the inhibition of PKR. Lanes 4-6 represent PKR activity 
in the presence of 4 ng of TRBP. Lanes 9-11 represent PKR activity in the presence of 4 
ng of PACT. Lane 1 (C) shows the PKR activity without any added activator. The 
phosphorylated proteins were analyzed by SDS-PAGE and phosphorimager analysis.  
(B) PACT interacts with ADAR1 with higher affinity when compared with TRBP. A 5 µl 
aliquot of in vitro translated, 35S-labeled Flag-tagged PACT and TRBP proteins was mixed 
with 5 µl of in vitro translated, 35S-labeled ADAR1. Flag-PACT proteins were 
immunoprecipitated using anti-Flag mAb-agarose, and ADAR1 co-immunoprecipitation 
was analyzed by SDS-PAGE. Total: input (20% of the IP samples); IP: 
immunoprecipitates. The bands seen at lower positions that the TRBP band in lanes 3, 6, 
and 9 are truncated TRBP proteins produced by translation initiation at internal 
methionines in the reticulocyte lysate system.  
(C) Quantification of data in B. The radioactivity present in the bands was measured by 
phosphorimager analysis and the % co-IP was calculated as follows: (radioactivity 
present in the co-immunoprecipitated ADAR1 band/the radioactivity present in the 
ADAR1 band in the total lane) X 100. This value was normalized to the amount of 
radioactivity present in the PACT or TRBP bands in IP lanes to correct for differences in 
translation/immunoprecipitation. Error bars: standard deviation from three 
independent experiments. The P-values (0.000029 and 0.000051) calculated using 
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Figure 2.7 (continued) statistical analyses indicate significant difference between % co-
IP of ADAR1 with PACT (white bars) and TRBP (black bars) at 150 mM (*) and 300 mM 
(**) salt concentrations respectively. 
(D) Yeast two-hybrid assay to compare TRBP-ADAR1 and PACT-ADAR1 interactions. 
TRBP or PACT in pGBKT7 and ADAR1 in PGADT7 or empty pGADT7 plasmids were co-
transformed into AH109 yeast cells and selected on SD double dropout media lacking 
tryptophan, and leucine. Aliquots (10 µl) of serial dilutions (OD600 = 10, 1.0, 0.1, 0.01) 
were spotted for each transformant on triple dropout SD medium plate that lacks 
tryptophan, leucine and histidine. Plates were incubated for three days at 30oC.  
Transformation of PACT or TRBP constructs in pGBKT7 and empty vector pGADT7 served 
as negative controls. 
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Figure 2.8: Schematic model. When TAR RNA present at the 5’ end of HIV-1 encoded 
transcripts binds PKR, activated PKR blocks translation of TAR-containing HIV-1 mRNAs. 
Efficient translation of HIV-1 viral proteins occurs by recruiting viral protein Tat and host 
factors PACT and ADAR1, to efficiently block PKR activation, thereby allowing synthesis 
of viral proteins. In this complex, the PKR activating role of PACT is suppressed by the 
presence of ADAR1. 
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CHAPTER 3
 
STRESS-INDUCED TRBP PHOSPHORYLATION ENHANCES ITS INTERACTION 
WITH PKR TO REGULATE CELLULAR SURVIVAL3
                                                          
3 Chukwurah, E. and Patel R.C. Submitted to Scientific Reports, 2017 
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3.1 ABSTRACT 
 Transactivation response element RNA-binding protein (TRBP or TARBP2) initially 
identified to play an important role in human immunodeficiency virus (HIV) replication 
has also emerged as a regulator of microRNA biogenesis. In addition, TRBP functions in 
signaling pathways by negatively regulating the interferon-induced double-stranded 
RNA (dsRNA)-activated protein kinase (PKR) during viral infections and cell stress. 
 During cellular stress, PKR is activated and phosphorylates the α subunit of the 
eukaryotic translation factor eIF2, leading to the cessation of general protein synthesis. 
TRBP inhibits PKR activity by direct interaction as well as by binding to PKR’s two known 
activators, dsRNA and PACT, thus preventing their interaction with PKR. 
 In this study, we demonstrate for the first time that TRBP is phosphorylated in response 
to oxidative stress and upon phosphorylation, inhibits PKR more efficiently promoting 
cell survival. These results establish that PKR regulation through stress-induced TRBP 
phosphorylation is an important mechanism ensuring cellular recovery and preventing 
apoptosis due to sustained PKR activation. 
 
3.2 INTRODUCTION 
The double-stranded RNA (dsRNA)-activated protein kinase (PKR) is an interferon 
(IFN)-induced serine/threonine protein kinase expressed ubiquitously in mammalian 
cells108,121,168. Although IFNs induce expression of PKR at a transcriptional level, PKR’s 
kinase activity stays latent until it binds to one of its activators leading to its 
autophosphorylation and catalytic activation169. The best-characterized cellular 
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substrate of PKR is the translation initiation factor, eIF2α, the phosphorylation of which 
on serine 51 (S51) results in an inhibition of protein synthesis115,170. An immediate 
response of cells exposed to various forms of stress is a general inhibition of protein 
synthesis, which is mainly caused by the increased S51 phosphorylation of eIF2α2. The 
eIF2α phosphorylation thus serves an important function to block the general protein 
synthesis and allow cells to either recover from stress or undergo apoptosis when the 
damage is beyond repair1. PKR plays an important role in regulating apoptosis after 
exposure to several diverse stress signals that include viral pathogens, oxidative stress, 
endoplasmic reticulum (ER) stress, and growth factor or serum deprivation34,171.  
 During viral infections, the double-stranded dsRNA, which is a replication 
intermediate for several viruses172, activates PKR by a direct interaction. The dsRNA 
binds to PKR via the two dsRNA-binding motifs (dsRBMs) present at the N terminus45,173–
175, changing the conformation of PKR to expose the ATP-binding site44,50 and 
consequent autophosphorylation48. The two dsRBMs also mediate dsRNA-independent 
protein-protein interactions with other proteins that carry similar domains176,177. Among 
these are proteins inhibitory for PKR activity such as TAR RNA-binding protein (TRBP)95, 
and also a PKR activating protein (PACT)58,60. PKR activation in response to stress signals 
is tightly regulated by PACT and TRBP, both acting to regulate its catalytic activity by a 
direct interaction with PKR as well as with each other67,98. As the dsRBMs in PKR, PACT, 
and TRBP mediate protein-protein interactions178, these three proteins form both 
heterodimers as well as homodimers and the stress-dependent phosphorylation of PACT 
changes the relative strengths of PKR-PACT, PACT-TRBP, and PACT-PACT interactions to 
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bring about timely and transient PKR activation with precise control67,68. This regulates 
the general kinetics as well as level of eIF2 phosphorylation thereby influencing the 
cellular response to stress either to recovery and survival or elimination by apoptosis179. 
 TRBP has three dsRBMs; the first two are true dsRBMs and interact with dsRNA, 
while the third carboxy-terminal dsRBM mediates TRBP’s interactions with other 
proteins such as Dicer, and Merlin91,123,178. TRBP inhibits PKR by interacting with dsRNA 
and sequestering it away from PKR as well as by forming PKR-TRBP heterodimers95,120. In 
the absence of viral infections and stress signals, TRBP forms heterodimers with both 
PKR and PACT, preventing their association and PACT-mediated PKR activation97,180. 
Importantly, the stress-induced serine 287 phosphorylation of PACT decreases its 
interaction with the PKR inhibitory protein TRBP thereby further aiding in rapid PKR 
activation following exposure to stress signals67,180. In contrast, not much is known 
about how similar post-translational modifications may affect TRBP’s interaction with 
PKR and consequently, its ability to inhibit PKR during cellular stress. Previous reports 
indicate that TRBP is phosphorylated by the two MAPKs; ERK 1/2 and JNK, with specific 
effects on RISC component stability and PKR activation by endogenous Alu transcripts 
during mitosis respectively92,181.  
 In this study, we used various biochemical assays to determine if TRBP 
undergoes stress-induced phosphorylation, and if this affects TRBP’s ability to inhibit 
PKR during oxidative stress. Our findings implicate MAPKs (ERK1/2 and JNK) in oxidative 
stress-induced TRBP phosphorylation, and show that TRBP phosphorylation significantly 
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enhances TRBP’s ability to interact with and inhibit PKR during oxidative stress to 
regulate apoptosis. 
 
3.3 MATERIALS AND METHODS 
3.3.1 REAGENTS, CELL LINES AND ANTIBODIES. 
HeLaM and HeLa Tet off cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% fetal bovine serum and penicillin/streptomycin. Transfections 
were performed with Effectene Transfection Reagent (Qiagen) according to the 
manufacturer’s protocol.  
Tetracycline inducible cell lines stably expressing Flag TRBP were generated by 
transfection of HeLa Tet off cells with 500 ng of Flag TRBP/pTRE2pur expression plasmid. 
Selection of puromycin-resistant colonies was carried out 24 hours after transfection by 
the addition of 700 ng/ml puromycin. Another cell line was also established using the 
pTRE2 puro plasmid as a control. Doxycycline inducibility was quantified in Flag 
TRBP/pTRE2pur cell clones after removal of doxycycline by western blot analysis. 
Sodium arsenite, phosphatase inhibitor cocktail (Phosphatase Inhibitor Cocktail 2 
– P5726), and the JNK inhibitor (SP600125, Catalog number S5567) were purchased 
from Sigma Aldrich. MEK1/MEK2 inhibitor (PD0325901) was purchased from 
Calbiochem (444968). 
Antibodies used are as follows: mouse monoclonal anti-FLAG M2 HRP (Sigma-
Aldrich A8592), mouse monoclonal anti-c-Myc HRP 9E10 (Santa Cruz Biotechnology SC-
40), mouse monoclonal anti-polyhistidine clone His-1 HRP (Sigma-Aldrich A7058), mouse 
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monoclonal anti-PKR (R&D systems MAB1980), rabbit polyclonal anti-phospho PKR Thr 
451 (Cell Signaling Technology 3075), rabbit monoclonal anti-Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® (Cell Signaling Technology 4370), rabbit 
monoclonal anti-p44/42 MAPK (Erk1/2) (137F5) (Cell Signaling Technology 4695), rabbit 
polyclonal anti-PARP (Cell Signaling Technology 9542), mouse monoclonal anti-β-Actin 
HRP (Sigma-Aldrich A3854), mouse monoclonal anti-GAPDH HRP (Sigma-Aldrich G9295), 
goat anti-mouse IgG HRP (Sigma-Aldrich A3682), and goat anti-rabbit IgG HRP (BioRad 
170-6515). 
 
3.3.2 PLASMIDS 
The Flag TRBP/BSIIKS+, TRBP/pGBKT7, K296R PKR/pGAD424 and PKR /pYES2 expression 
plasmids were prepared as previously56,67,182. Full length TRBP1 ORF with an N-terminal 
Flag tag from Flag TRBP/BSIIKS+ was inserted into the NotI and EcoRV restriction sites of 
the tetracycline-responsive vector, pTRE2pur (Clontech) to generate Flag TRBP/ 
pTRE2pur. The phospho-defective (TRBP AAAA) and phospho-mimic (TRBP DDDD) point 
mutants were generated at S121, S131, S262, and S265 by substituting each serine with 
alanine or aspartic acid using the following primers: 
TRBP sense: 
5’-GCTCTAGACATATGGAAATGCTGGCCGCCAACC-3’ 
S121D antisense: 
5’- GTTCCATGGCGGGGTCCCTGGTTAGGACTACAGATGGAACTGGGG-3’ 
S121A antisense: 
5’- GTTCCATGGCGGGGGCCCTGGTTAGGACTACAGATGGAACTGGGG-3’ 
S131D sense: 
5’-CGCCATGGAACTGCAGCCCCCTGTCGACCCTCAGC-3’ 
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S262D S265D antisense: 
5’CGGAGCTCACTGAGGACACGGCAGCAGGCAGGGCCCAGGGCACCCAGGTCGCCCAGGTCGC
AACTGC-3’ 
S131A sense: 
5’- CGCCATGGAACTGCAGCCCCCTGTCGCCCCTCAGC -3’ 
S262A S265A antisense: 
5’CGGAGCTCACTGAGGACACGGCAGCAGGCAGGGCCCAGGGCACCCAGGGCGCCCAGGGCG
CAACTGC-3’ 
 
 The PCR products were sub-cloned into the pGEMT-Easy vector (Promega) and 
each sequence was verified. Full length AAAA TRBP and DDDD TRBP point mutants were 
generated in the pGBKT7 yeast expression vector (Clontech) by three-piece ligation of 
NdeI-NcoI restriction fragment from S121A or S121D/pGEMT-Easy, NcoI-SacI restriction 
fragment from S131D S262D S265D or S131A S262A S265A/pGEMT Easy and NdeI-SacI 
cut TRBP/pGBKT7. Each point mutant was subsequently introduced into the pGADT7 
yeast expression vector (Clontech) by insertion of the NdeI-BamHI restriction fragment 
from AAAA TRBP or DDDD TRBP/pGBKT7 into the NdeI-BamHI restriction sites in 
pGADT7. 
 Flag-tagged full length AAAA and DDDD TRBP point mutants in pcDNA 3.1- 
(Invitrogen) were generated by first introducing the NdeI-BamHI restriction piece from 
AAAA TRBP/pGBKT7 or DDDD TRBP/pGBKT7 into NdeI-BamHI cut Flag/TRBP BSIIKS+, and 
then inserting the XbaI-BamHI restriction fragment from Flag/AAAA TRBP BSIIKS+ or 
Flag/DDDD TRBP BSIIKS+ into the XbaI-BamHI sites in pcDNA 3.1-. Myc-tagged full length 
AAAA and DDDD TRBP point mutants were generated by introducing HincII-BamHI 
restriction fragments from AAAA TRBP/pGBKT7 and DDDD TRBP/pGBKT7 into the 
EcoRV-BamHI restriction sites in pcDNA 3.1-. 
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3.3.3 DNA FRAGMENTATION ANALYSIS 
 5 X 106 Flag TRBP/pTRE2pur and pTRE2pur HeLa tet off cells described in 
“Reagents, Cell Lines and Antibodies” were treated with 10 μM sodium arsenite for the 
indicated time points. Cells were collected and washed with ice cold 1X PBS, and lysed in 
100 μl of lysis buffer [10mM Tris-HCl pH 7.5, 10mM EDTA, and 0.5% Triton-X 100] for 5 
minutes on ice. Lysates were centrifuged at 13200 rpm for 5 minutes, and were 
incubated with 100 μg Proteinase K at 37oC for 2 hours. 5 μl of 6M NaCl and 110 μl of 
isopropanol were subsequently added to the lysates which were then incubated at 20oC 
overnight. The precipitated DNA was then collected by centrifugation at 14,000 rpm for 
5 minutes. After the isopropanol was removed from each sample, the DNA was 
dissolved in 20 μl TE Buffer [10 mM Tris-HCl pH 7.5, 10 mM EDTA]. The DNA was 
incubated with 20 μg/ml RNase A at 37oC for 1 hour before analysis on a 1.5% agarose 
gel. 
 
3.3.4 WESTERN BLOT ANALYSIS 
 Cells were treated with sodium arsenite alone or in combination with 10 μM 
MEK1/MEK2 inhibitor PD0325901 (Calbiochem) or 10 μM JNK inhibitor SP600125 and 
harvested at indicated time points. Cells were washed twice with ice cold 1X PBS. 
Harvested cells were lysed in western lysis buffer [2% Triton X-100, 20 mM Tris–HCl pH 
7.5, 100 mM KCl, 200 mM NaCl, 4 mM MgCl2, 40% Glycerol, and phosphatase inhibitor 
cocktail 2 (Sigma) at 1:100 dilution] for 5 minutes on ice. Lysates were centrifuged at 
13,200 rpm for 2 minutes. Protein concentration in the supernatant was quantified 
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using Bradford reagent. Western blot was performed with the indicated antibodies and 
western blot images were analyzed using the Typhoon FLA 7000 and ImageQuant LAS 
4000 (GE Health). 
 
3.3.5 TRBP-PKR PULL-DOWN ASSAY 
 Flag TRBP/pTRE2pur HeLa Tet off cells grown to 50% confluency in 100-mm 
dishes were treated with 25 μM sodium arsenite for the indicated time points. Cell 
extracts were prepared in 100 μl co-immunoprecipitation buffer [20 mM Tris-HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% Triton-X 100, 2% Glycerol, and phosphatase 
inhibitor cocktail 2 (Sigma) at 1:100 dilution]. 25 μg of cell extract was bound to 500 μg 
of recombinant, hexahistidine-tagged PKR (His-PKR) protein immobilized on Ni2+-agarose 
resin (Novagen) in 100 μl co-immunoprecipitation buffer at 4oC for 1 hour.  
The beads were washed in 500 μl of co-immunoprecipitation buffer three times and 
bound Flag-TRBP was analyzed by western blot analysis using anti-Flag antibody. Blot 
was then stripped and re-probed with anti-His antibody to ascertain equal His-PKR pull 
down. 25 μg aliquots of whole cell-lysate were analyzed by western blot analysis with 
anti-Flag and anti-GAPDH antibodies to ensure that equal amounts of cell lysate were 
used for immunoprecipitation. 
 
3.3.6 TRBP-TRBP CO-IMMUNOPRECIPITATION ASSAY 
 HeLa cells were co-transfected in 6-well culture dishes with 250 ng each of (i) 
myc TRBP DDDD/ pcDNA 3.1- and Flag TRBP DDDD/ pcDNA 3.1-, (ii) myc TRBP DDDD/ 
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pcDNA 3.1- and pcDNA 3.1- (iii) myc TRBP AAAA/ pcDNA 3.1- and Flag TRBP AAAA/ 
pcDNA 3.1-, (iv) myc TRBP AAAA/ pcDNA 3.1- and pcDNA 3.1- using the Effectene reagent 
(Qiagen). 24 hours after transfection, cell extracts were prepared in co-IP buffer (150 
mM NaCl, 30 mM Tris-HCl pH 7.5, 1 mM MgCl2, 10% Glycerol, 0.4% Igepal). Flag TRBP 
AAAA and Flag TRBP DDDD were immunoprecipitated with anti-Flag mab-agarose 
(Sigma) in co- IP buffer. The agarose beads were washed 5 times in co-IP buffer. The 
bound proteins were then analyzed by western blot analysis with the anti-c-myc (Santa 
Cruz Biotechnology) and anti-Flag (Sigma) antibodies. 
 
3.3.7 YEAST GROWTH INHIBITION ASSAY 
 Wild-type and TRBP phospho-mimic and phospho-defective point mutants were 
subcloned into the pYES3CT yeast expression plasmid (Invitrogen). Wild-type PKR was 
subcloned into the pYES2 yeast expression vector (Invitrogen) as previously described 
for galactose inducible PKR expression. The constructs were introduced into InvSc1 
yeast cells (Invitrogen) using the Clontech Yeast Transformation Kit. Transformed yeast 
cells were grown to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose). 
500 μl of each culture was pelleted and resuspended in an appropriate amount of 
distilled water to yield an OD600 of 10. Serial dilutions were then made to yield OD600 
values of 1, 0.1, and 0.01. 10 μl of each dilution was then spotted onto synthetic 
medium lacking uracil and tryptophan and containing either glucose or galactose as a 
carbon source (Clontech). 
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3.3.8 YEAST TWO-HYBRID INTERACTION ASSAY 
 To test TRBP-PKR interaction, full length K296R PKR was expressed as a GAL4 
DNA-activation domain fusion protein from the pGAD424 vector and the AAAA and 
DDDD TRBP point mutants were expressed as GAL4 DNA-binding domain fusion proteins 
from the pGBKT7 vector.  Full length AAAA and DDDD TRBP point mutants were 
expressed as GAL4 DNA-activation domain fusion proteins from the pGADT7 vector and 
GAL4 DNA-binding domain fusion proteins from the pGBKT7 vector to test TRBP-TRBP 
interaction. The AAAA TRBP and DDDD TRBP pGBKT7 /pGADT7 construct pairs and 
PKR/pGAD424 and AAAA (DDDD) TRBP/pGBKT7 construct pairs were co-transformed 
into AH109 yeast cells (Clontech) and the transformed yeast cells were plated on double 
dropout SD minimal medium lacking tryptophan and leucine. In order to check for the 
transformants’ ability to grow on triple dropout media, transformed yeast cells were 
grown to an OD600 of 2 in YPD media (yeast extract, peptone, and dextrose). 500 μl of 
each culture was pelleted and resuspended in an appropriate amount of distilled water 
to yield an OD600 of 10. Serial dilutions were then made to yield OD600 values of 1, 0.1, 
and 0.01. 10 μl of each dilution was then spotted onto triple dropout SD minimal media 
lacking histidine, tryptophan, and leucine in the presence of 10 mM 3-amino-1,2,4-
triazole (3-AT). Plates were incubated at 30oC for 5 days. 
 
3.3.9 APOPTOSIS ASSAY 
 HeLa cells were grown to 50% confluency in six-well plates and co-transfected 
with 200 ng of Flag TRBP AAAA or TRBP DDDD/pcDNA 3.1- and 200 ng of pEGFPC1 
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(Clontech) using Effectene (Qiagen). Cells were also co-transfected with 200 ng BSIIKS+ 
(Agilent) and 200 ng pEGFPC1 as a control. The cells were observed for GFP fluorescence 
24 hours after transfection using an inverted fluorescence microscope (EVOS® FL 
Imaging System). Cells were treated with 25 μM sodium arsenite, and cellular 
morphology was monitored at 1 hour intervals. 12 hours after treatment, the cells were 
rinsed with ice-cold phosphate buffered saline (PBS) and fixed in 2% paraformaldehyde 
for 10 minutes. Cells were washed twice in ice-cold PBS and permeabilized with 0.1% 
Triton-X for 10 minutes, after which the cells were washed twice in ice-cold PBS. Cells 
were stained with the DAPI nuclear stain (4,6-diamidino-2-phenylindole) at 0.5 μg/ml in 
for 10 minutes at room temperature in the dark. The cells were rinsed once with PBS 
and viewed under the fluorescent microscope.  
 At least 300 GFP-positive cells were counted as apoptotic or live based on their 
morphology. Cells showing normal flat morphology were scored as live, while cells 
showing cell shrinkage, membrane blebbing, rounded morphology and nuclear 
condensation with intense fluorescence as apoptotic. The percentage of cells 
undergoing apoptosis (Percent apoptosis) was calculated using the formula: (EGFP- 
expressing cells with intense DAPI nuclear staining/Total EGFP-expressing cells) x 100. 
 
3.3.10 PKR-INHIBITION AND APOPTOSIS ASSAY 
 HeLa cells were grown on coverslips and transfected with 500 ng of wt PKR 
pEGFPC1 and 20 ng pcDNA 3.1-, Flag TRBP AAAA/ pcDNA 3.1-, or Flag TRBP DDDD/ 
pcDNA 3.1- using Effectene (Qiagen). 24 hours after transfection, the cells were rinsed 
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with ice-cold phosphate buffered saline (PBS) and fixed in 2% paraformaldehyde for 10 
minutes. Cells were washed twice in ice-cold PBS and permeabilized with 0.1% Triton-X 
for 10 minutes, after which the cells were washed twice in ice-cold PBS. The cover slips 
were mounted in Vectashield mounting medium containing DAPI (Vector Laboratories). 
Cells were then viewed under the fluorescence microscope (EVOS® FL Imaging System). 
At least 500 EGFP-positive cells were scored as live or apoptotic as described in 
‘Apoptosis Assay’. 
 
3.3.11 ESTIMATION OF MITOCHONDRIAL MEMBRANE POTENTIAL. 
 HeLa cells were grown to 50% confluency in six-well plates and transfected with 
500 ng of wt PKR pEGFPC1 and 20 ng pcDNA 3.1-, Flag TRBP AAAA/ pcDNA 3.1-, or Flag 
TRBP DDDD/ pcDNA 3.1-. MitoPT® TMRM assay was performed using the 
manufacturer’s instructions (ImmunoChemistry Technologies MitoPT® TMRM Assay Kit). 
Green fluorescence (EGFP-PKR) and changes in red fluorescence (changes in 
mitochondrial polarization) were observed under an inverted fluorescence microscope 
(EVOS® FL Imaging System). At least 500 PKR expressing cells (GFP positive cells) were 
scored as live or dead based on decreased or absent red fluorescence. The percentage 
of cells undergoing apoptosis (Percent apoptosis) was calculated using the formula: 
(EGFP- expressing cells with decreased or absent red fluorescence/Total EGFP-
expressing cells) x 100. 
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3.3.12 STATISTICAL ANALYSIS 
Statistical significance of western blot quantifications and percent apoptosis were 
determined by two-tailed Student’s T-test assuming equal variance or one-way ANOVA 
followed by post-Hoc Tukey test respectively. Figure legends indicate the statistical test 
used, and P-values are denoted by brackets and special characters. Alpha level was p = 
0.05. 
 
3.4 RESULTS 
3.4.1 TRBP OVEREXPRESSION INHIBITS OXIDATIVE STRESS-INDUCED APOPTOSIS. 
 To evaluate TRBP’s effect on the cellular response to oxidative stress, we 
established a stable HeLa-Tet off cell line that would conditionally overexpress Flag-
TRBP only when doxycycline was absent from the growth medium. A HeLa-Tet off cell 
line with stably transfected empty vector pTRE2pur was established as a control.  
We initially characterized 20 individual puromycin resistant clones and selected one 
clone that showed the least expression of Flag-TRBP in the presence of doxycycline and 
showed a good induction of Flag-TRBP expression in the absence of doxycycline. As seen 
in Figure 3.1A, the Flag-TRBP expression is induced to high levels in a time dependent 
manner after removal of doxycycline from the growth medium (lanes 2-5). We used 
these cells for assaying the effects of TRBP overexpression on apoptosis induced by 
oxidative stress. After the cells were grown in doxycycline-deficient growth medium for 
24h, they were exposed to sodium arsenite to induce oxidative stress. The cells were 
thus expressing high levels of Flag-TRBP when exposed to oxidative stress and this 
 87 
allowed us to assay the effect of TRBP overexpression on cellular apoptosis and PKR 
activation. 
 In order to compare the relative apoptosis in control and TRBP overexpressing 
cells we used DNA fragmentation analysis. DNA fragmentation is a late marker of 
apoptotic cells as the DNA is cleaved by caspase-activated DNases (CADs) into 
nucleosomal fragments of 180 bp183. As seen in Figure 3.1B, the control cells stably 
transfected with empty vector (EV-HeLa) showed high levels of DNA fragmentation in 
response to sodium arsenite (lanes 5-8). In comparison, the cells overexpressing Flag-
TRBP (TRBP-HeLa) have significantly less DNA fragmentation after exposure to sodium 
arsenite (lanes 1-4). These results indicate that TRBP overexpressing cells are 
significantly protected from oxidative stress-induced apoptosis. 
 In order to further assess the protection from cellular apoptosis by TRBP 
overexpression, we compared the cleavage of Poly-ADP Ribose Polymerase (PARP1) in 
response to arsenite treatment. The 116 kDa protein PARP1 is cleaved into an 89kDa 
fragment by Caspase-3 in response to apoptosis-inducing stimuli184. We measured and 
quantified PARP1 cleavage in both sets of cells after treatment with arsenite (Figure 
3.1C and 3.1D). As seen in Figure 3.1C, there is a steady increase in the levels of cleaved 
PARP1 in the control (EV-HeLa) and TRBP-overexpressing (TRBP-HeLa) cells in a time 
dependent manner. After 24 hours of arsenite exposure, there is significantly more 
cleaved PARP1 in the EV-HeLa cells (Lane 4) as compared to the TRBP-HeLa cells (Lane 
8). The percentage of cleaved PARP1 is about 90% in the HeLa cells (Figure 3.1D, 24 hr.), 
and only about 45% in the TRBP-HeLa cells (Figure 3.1D, 24 hr.). These results indicate 
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that caspase-3 activation and subsequent PARP1 cleavage is significantly impaired in 
cells overexpressing TRBP, and demonstrate that TRBP overexpression protects the cells 
from apoptosis in response to oxidative stress. 
 
3.4.2 BOTH ERK AND JNK PHOSPHORYLATE TRBP IN RESPONSE TO OXIDATIVE STRESS 
 In order to determine if TRBP undergoes post-translational modifications in 
response to stress signals with any functional implications on TRBP’s ability to inhibit 
PKR, we performed western blot analysis of extracts from TRBP-HeLa cells exposed for 
24 hours to sodium arsenite. The analysis revealed the presence of an additional Flag-
TRBP band with reduced electrophoretic mobility as indicated by an asterisk (Fig. 3.2A) 
that increased in intensity from 8 to 12 hours after arsenite treatment and declined at 
24 hours after treatment (Figure 3.2A, Flag-TRBP panel, Lanes 5 - 8). These results 
suggested that the slow migrating Flag-TRBP band may be indicative of TRBP 
phosphorylation at late time points after arsenite exposure. Interestingly, we also noted 
that the strengthening of the TRBP doublet banding pattern from 8 to 12 hours after 
treatment coincides with the gradual decrease in phosphorylated eIF2α levels at these 
time points after sodium arsenite treatment (Figure 3.2B: p-eIF2α panel, Lanes 6-8) and 
a decrease in phosphorylated PKR levels (Figure 3.2B: p-PKR panel, Lanes 5 -8). These 
results suggest that TRBP phosphorylation may regulate PKR activation and consequent 
eIF2α phosphorylation in response to arsenite.  
 To test this, we investigated if the slow migrating TRBP band resulted from 
phosphorylation by using phosphatase treatment in the presence and absence of 
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phosphatase inhibitors. Phosphatase treatment of cell extract prepared 8 and 12 hours 
after arsenite treatment completely removed the stress-induced slow-migrating band 
(Figure 3.2C, lanes 5 and 8), demonstrating that the slower mobility band (denoted ‘p-
TRBP’) did result from TRBP phosphorylation in response to oxidative stress. The p-TRBP 
band persisted when the phosphatase treatment was performed in the presence of 
phosphatase inhibitors, thereby confirming that the disappearance of the band in lanes 
5 and 8 was indeed due to phosphatase activity and not due to the presence of any 
contaminating proteolytic activity. These results indicate a possible link between the 
timing of PKR activation and its eventual inactivation during cell stress and the timing of 
TRBP phosphorylation in response to oxidative stress. 
 The Mitogen-activated protein kinase (MAPK) signaling pathways are activated in 
response to diverse stimuli185, and elicit either pro-apoptotic or pro-survival cellular 
responses. Previous studies have demonstrated that MAPKs such as the Extracellular-
signal regulated Kinase (ERK 1/2) and c-Jun N-terminal kinase (JNK) play important roles 
in mediating the cellular response to oxidative stress186. To test if ERK 1/2 
phosphorylates TRBP in response to oxidative stress, we pretreated the Flag TRBP 
overexpressing cells with the MEK inhibitor PD0325901, and exposed the cells to sodium 
arsenite. In the samples not pretreated with PD0325901, we observed the p-TRBP band 
at 8 and 12 hrs. after treatment (Figure 3.2D: TRBP panel, Lanes 1 -4). 
 Furthermore, we also observed that the increase in TRBP phosphorylation 
closely mirrored the increase in phospho-ERK levels at 8, and 12 hours of treatment 
(Figure 3.2D, p-ERK panel, Lanes 1-4). With the inhibition of ERK phosphorylation, 
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(Figure 3.2D, p-ERK panel, Lanes 5-8) the p-TRBP band is significantly diminished (Figure 
3.2D, TRBP panel, Lanes 5-8). To test if JNK also phosphorylates TRBP in response to 
oxidative stress, we pretreated the Flag TRBP overexpressing cells with the JNK inhibitor 
SP600125, and exposed the cells to sodium arsenite. In the samples not pretreated with 
SP600125, we observed the p-TRBP band at 8 and 12 hrs after treatment (Figure 3.2E: 
TRBP panel, Lanes 1 -4). Furthermore, we also observed that the increase in TRBP 
phosphorylation closely mirrored the increase in phospho-JNK levels at 8, and 12 hours 
of treatment (Figure 3.2E, p-ERK panel, Lanes 1-4). With the inhibition of JNK 
phosphorylation, (Figure 3.2E, p-JNK panel, Lanes 5-8) the p-TRBP band is completely 
absent (Figure 3.2E, TRBP panel, Lanes 5-8). The results in Figures 3.2D and 3.2E suggest 
that both ERK and JNK phosphorylate TRBP in response to oxidative stress. 
 
3.4.3 EFFECT OF TRBP PHOSPHORYLATION ON CELLULAR RESPONSE TO STRESS 
 Having demonstrated that TRBP is phosphorylated by JNK and ERK 1/2 in 
response to oxidative stress, we wanted to determine how TRBP phosphorylation 
affects oxidative stress and PKR-mediated cellular apoptosis. To evaluate the 
involvement of phosphorylation, we generated a phospho-defective TRBP point mutant 
(TRBP AAAA) which contains alanine for serine substitution at 4 sites (S142, S152, S283, 
S286) previously identified as MAPK/ERK 1/2 substrate sites181. Of these sites, S142 and 
S152 have also been previously shown to be phosphorylated by JNK92. A phospho-mimic 
TRBP point mutant (TRBP DDDD) was also generated by substituting aspartic acid for 
serine at the same four sites (Figure 3.3A). 
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 To examine the effect of TRBP phosphorylation on oxidative stress-induced 
apoptosis, we transfected HeLa cells with each TRBP phospho-mutant and observed 
changes in the induction of apoptosis in response to oxidative stress. As seen in Figure 
3.3B, the cells transfected with the empty vector (EV) alone showed 5.6% apoptosis (Untreated, 
black bar) in the absence of stress which increased to 46.9% at 24 h after sodium arsenite 
treatment (24 hrs, black bar). The DDDD TRBP phospho-mimic mutant showed significantly 
reduced apoptosis in response to oxidative stress with only 29.1% cells undergoing apoptosis at 
24 h after treatment (24 hrs, red bar).  
Statistical analysis also showed a significant difference between the % apoptosis in the 
cells expressing the empty vector as compared to the cells expressing the TRBP 
phospho-mimic mutant, indicating that TRBP phosphorylation does have a protective 
effect on cells during oxidative stress. Analysis of the % apoptosis in the cells expressing 
the AAAA TRBP phospho-defective mutant to that of cells expressing EV showed no 
statistical difference, highlighting the importance of phosphorylation for TRBP’s anti-
apoptotic activity. 
 We next examined the effect of TRBP phosphorylation on PKR-induced 
apoptosis. An overexpression of active PKR in mammalian cells is sufficient to trigger 
cellular apoptosis in the absence of any stress signals187,188. It has been previously 
observed by us and others that PKR-EGFP fusion construct encodes a constitutively 
active PKR, which induces apoptosis when transfected in mammalian cells189.  
Thus, cells were transfected with a constitutively active PKR expression plasmid (wt-
PKR-EGFP+EV) or in combination with the TRBP AAAA phospho-defective or DDDD 
phospho-mimic mutant and assayed for changes in apoptosis induced by active PKR. We 
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used nuclear condensation as a hallmark sign of apoptosis as indicated by intense DAPI 
fluorescence190. There is a significant amount of apoptosis at 87.5% (Figure 3.3C, wt 
PKR, black bar) in transfected cells that express constitutively active PKR. The 
percentage cell death is significantly reduced with the co-expression of both AAAA 
phospho-defective (65.9 %) and DDDD phospho-mimic TRBP (49.5 %) mutants with PKR-
EGFP (Figure 3.3C, wt PKR + AAAA and wt PKR + DDDD, blue and red bars). Consistent 
with our previous results in Figure 3.3A, we also observe greater reduction in apoptosis 
with expression of the TRBP phospho-mimic mutant, indicating that although AAAA 
phospho-defective mutant can still inhibit PKR, the DDDD phospho-mimic mutant 
inhibits PKR much more efficiently. 
 We further assayed apoptosis by using the mitochondrial membrane 
depolarization as an early marker for apoptotic cells191. The effect of TRBP phospho-
mutants (TRBP AAAA or TRBP DDDD) on apoptosis induced by constitutively active PKR-
EGFP was measured. Similar to our result in Figure 3.3C, we observed apoptosis (~75 %) 
in cells expressing constitutively active PKR. Cells co-expressing the AAAA TRBP 
phospho-defective mutant had a 16 % decrease in cell death compared to the cells 
expressing PKR-EGFP alone, while the cells co-expressing the DDDD TRBP phospho-
mimic mutant had a 63% decrease in cell apoptosis compared to the cells expressing 
PKR-EGFP alone. Taken together, these results clearly demonstrate that TRBP 
phosphorylation is protective during oxidative stress, and this protection is mediated via 
inhibition of PKR.  
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3.4.4 TRBP PHOSPHORYLATION INHIBITS PKR’S KINASE ACTIVITY MORE EFFICIENTLY 
 To determine if protection from apoptosis was a direct result of enhanced PKR 
inhibition by the phosphorylated TRBP isoform, we performed a yeast growth inhibition 
assay using the INVSc1 S. cerevisiae yeast strain (Figure 3.4). The expression of active 
PKR in S. cerevisiae suppresses yeast growth, and this growth inhibition can be reversed 
by co-expression of PKR inhibitors such as the dominant negative PKR mutant, 
K296R58,173,192. We introduced a galactose-inducible wt PKR yeast expression plasmid (wt 
PKR/pYES2) in combination with K296R, wt TRBP, AAAA TRBP, or DDDD TRBP expression 
plasmids (pYES3CT) into INVSc1 yeast cells. As expected, induction of PKR expression on 
galactose-containing media inhibited yeast cell growth (+ GAL panel, wt PKR alone). We 
also observed that co-expression of K296R or wt TRBP reversed the PKR-mediated 
growth phenotype (+ GAL panel, K296R, wt TRBP) in accordance with previous reports 
that have shown that K296R and TRBP inhibit PKR activity96,97. Interestingly, when we 
co-expressed the phospho-deficient TRBP mutant (AAAA TRBP), it was unable to reverse 
the growth phenotype (compare wt PKR alone to AAAA TRBP, + GAL panel) suggesting 
that TRBP phosphorylation is crucial for TRBP’s ability to inhibit PKR.  
On the other hand, co-expression of the phospho-mimic TRBP mutant (DDDD TRBP 
reversed the PKR-mediated growth inhibition more efficiently as compared to wt TRBP. 
These results indicate that phosphorylated TRBP inhibits PKR’s kinase activity in a more 
efficient manner. 
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3.4.5 STRESS-INDUCED TRBP PHOSPHORYLATION ENHANCES TRBP-PKR INTERACTIONS, 
WHILE WEAKENING TRBP-TRBP INTERACTIONS. 
 To understand how stress-induced phosphorylation of TRBP affects its 
interaction with PKR, we used the yeast-two hybrid system to test the strength of 
interaction between PKR and TRBP phospho-mimic and phospho-defective point 
mutants. The TRBP DDDD and TRBP AAAA point mutants were expressed in yeast as 
GAL4 DNA binding domain fusion proteins (pGBKT7) with PKR was expressed as a GAL4 
activation domain fusion protein. In this system, a stronger interaction between TRBP 
and PKR is indicated by increased yeast growth in media lacking tryptophan, leucine, 
and histidine in the presence of the imidazole glycerol-phosphate dehydratase 
competitive inhibitor, 3-Amino-1,2,4-triazole (3-AT). As seen in Figure 3.5A, the TRBP 
DDDD point mutant shows significantly stronger interaction with PKR as compared to 
the TRBP AAAA point mutant, suggesting that the stronger PKR inhibition by DDDD TRBP 
we observed in Figures 3.3 and 3.4 results from an enhanced TRBP-PKR interaction. 
 Since we showed enhanced interaction with PKR resulting in more efficient PKR 
inhibition with the phospho-mimic DDDD TRBP mutant, we tested if we would also 
observe significantly increased TRBP-PKR interaction in response to arsenite at 8 and 12 
hours post-treatment when we observe the strongest TRBP phosphorylation (Figure 
3.2A). We tested this by assaying if TRBP from treated cells interacts better with PKR in a 
pull-down assay. As seen in Figure 3.5B, in the absence of stress signals there is weak 
interaction between PKR and TRBP (Bound panels, Lane 2) which substantially decreases 
at 2 and 4 hours (Bound panels, Lanes 3 and 4) due to PKR’s disassociation from TRBP in 
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response to stress. We observed much stronger re-association between PKR and TRBP 
at 8 hours and 12 hours after treatment (Bound panels, Lanes 5 and 6). A quantification 
of the pull-down assay shown as a bar graph shows that both the reduction in TRBP-PKR 
interaction after stress and the reassociation of TRBP with PKR at later time points after 
stress is statistically significant. Thus, our results strongly support that TRBP’s 
interaction with PKR and consequently its ability to inhibit PKR effectively during cell 
stress is closely linked to its phosphorylation status.  
 Since stress-induced phosphorylation is essential for efficient PACT-PACT 
interactions68, we investigated how phosphorylation affects TRBP-TRBP interactions. We 
expressed both TRBP phospho-mutants in yeast as GAL4 DNA-binding domain fusion 
proteins (pGBKT7) and GAL4 activation domain fusion proteins (pGADT7) and assayed 
for the strength of TRBP AAAA and TRBP DDDD homomeric interactions by the amount 
of yeast growth on nutrient deficient media in the presence of 3-AT. As seen in Figure 
3.5C, yeast cells expressing both AAAA TRBP expression vectors show growth at all 
dilutions, indicating strong homodimer interaction between unphosphorylated TRBP 
proteins. In contrast to this, there was a complete absence of growth even at the most 
concentrated dilution of yeast cells (10 OD) expressing both DDDD TRBP yeast 
expression vectors, which indicates that TRBP phosphorylation is highly unfavorable to 
the formation of TRBP homodimers.  
 We also examined TRBP AAAA and TRBP DDDD homomeric interactions in 
mammalian cells using a co-immunoprecipitation assay. As seen in Figure 3.5D, we 
observed that significantly less myc-DDDD TRBP was co-immunoprecipitated with Flag-
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DDDD TRBP (IP Myc panel, Lane 1) compared to the myc-AAAA TRBP co-
immunoprecipitated with Flag-AAAA TRBP (IP Myc panel, Lane 3). The Flag panels 
demonstrate that comparable amounts of Flag-DDDD TRBP (IP panel, Lane 1) and Flag-
AAAA TRBP (IP panel, Lane 3) were immunoprecipitated, thereby confirming that the 
significant difference seen in co-immunoprecipitated bands reflects difference in TRBP 
homomeric interactions. The absence of co-immunoprecipitated myc-DDDD or myc-
AAAA TRBP without co-expression of Flag-DDDD TRBP (IP, Lane 2) or Flag-AAAA TRBP 
(IP, Lane 4) rules out any nonspecific immunoprecipitation. 
  Taken together, these results strongly demonstrate that stress-induced TRBP 
phosphorylation significantly weakens homomeric interactions between TRBP molecules 
while simultaneously enhancing TRBP-PKR interactions, which plays an important role in 
attenuating sustained PKR activation during cell stress and inhibits excessive apoptosis. 
The results presented here contribute to our understanding of how PKR activity is 
regulated negatively at later time points after oxidative stress to prevent excessive 
apoptosis. 
 
3.5 DISCUSSION 
 Activation of PKR during cellular stress is regulated by PACT and TRBP, PACT 
acting positively to activate PKR and TRBP acting negatively to suppress excessive PKR 
activity60,67,180. Initially at early time points after stress, PACT activates PKR to aid 
inhibition of protein synthesis via phosphorylation of eIF260,62,67. Our results presented 
here, for the first time demonstrate that TRBP is phosphorylated by ERK 1/2 and JNK in 
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response to oxidative stress at late time points and the phosphorylated TRBP inhibits 
PKR’s kinase activity more efficiently to protect cells from apoptosis. In addition, the 
enhanced PKR inhibition and protection from apoptosis by phospho-TRBP is brought 
about by an increased interaction between phospho-TRBP and PKR as well as decreased 
phospho-TRBP homomeric interactions. The timely downregulation of PKR activity and 
eIF2 phosphorylation is achieved in part by induction of GADD34, a regulatory subunit 
of protein phosphatase 1 (PP1)193,194. 
 Our data indicates that TRBP also plays an important role in the downregulation 
of PKR activity. Thus, PKR activity during cell stress is dictated not only by stress-induced 
changes in interactions between PACT and PKR, but also by interactions between PKR 
and TRBP. TRBP interacts with both PACT and PKR and although TRBP phosphorylation 
enhances its affinity for PKR while reducing the TRBP-TRBP interactions, we observed no 
effect of TRBP phosphorylation on TRBP-PACT interactions (data not shown). On the 
contrary, stress-induced PACT phosphorylation reduces the PACT-TRBP interactions 
while increasing PACT-PACT interactions and PACT-PKR interactions, thereby leading to 
PKR activation62,195. Strikingly, although TRBP and PACT are very homologous, the stress-
induced phosphorylation affects the protein-protein interaction properties of PACT and 
TRBP quite differently.  
 Based on our data, we present a schematic model for TRBP-mediated 
downregulation of PKR activity at late time points after cellular stress. As depicted in 
Figure 3.6, PKR and unphosphorylated TRBP interact under unstressed conditions in the 
cell, preventing PKR activation, and eIF2α phosphorylation. Unphosphorylated TRBP also 
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forms homodimers efficiently. In response to oxidative stress, PKR is activated by 
phosphorylated PACT homodimers (not depicted) and eIF2 is phosphorylated to bring 
about a transient protein synthesis inhibition. TRBP at this point remains 
unphosphorylated, and efficiently forms TRBP-TRBP homodimers. Late after the onset of 
the stressful event, ERK1/2 and JNK phosphorylate TRBP, leading to significantly 
decreased TRBP-TRBP interactions, and increased TRBP-PKR interactions. Phospho-TRBP 
interacts with PKR at significantly higher affinity to bring about efficient PKR 
inactivation, and eIF2α is dephosphorylated. Phospho-TRBP does not form homodimers 
efficiently and this could partly explain efficient PKR inhibition as it is established that 
PKR is activated mainly by trans-autophosphorylation and PKR-PKR interactions. Thus, 
monomeric phospho-TRBP could potentially function to inhibit PKR by preventing PKR-
PKR interactions. 
The dsRBM motifs present in PKR, TRBP, and PACT possess the characteristic 
alpha-beta-beta-beta-alpha fold that has two well-characterized functions to bind 
structured RNA molecules and to mediate protein-protein interactions176,196. This motif 
is widely distributed in eukaryotic proteins, as well as in proteins from bacteria and 
viruses and the dsRBM-containing proteins are involved in a variety of cellular processes 
ranging from RNA editing, nucleocytoplasmic transport, RNA localization, protein 
phosphorylation in translational control, and contain a variable number 
of dsRBM domains197. In addition, dsRBMs can also recognize non-RNA targets (proteins 
and DNA), and act in combination with other dsRBMs and non-dsRBM motifs to play a 
regulatory role in catalytic processes198. Our work presented here adds one more layer 
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of complexity to the versatility of the dsRBM as it demonstrates that phosphorylation 
sites residing outside the dsRBM influence the strength of protein-protein interactions 
mediated via the dsRBMs. This also underscores the importance of optimal juxtaposition 
of the multiple dsRBM motifs relative to each other in regulating protein interactions as 
the phosphorylation of specific serines outside the motif can possibly bring about 
significant changes in overall protein conformations. In other members of the diverse 
family of dsRBM-containing proteins, the role of phosphorylation and post-translational 
modifications in regulating interactions with RNA or proteins remains to be investigated 
in future. 
 Our results on the effect of TRBP phosphorylation on PKR activity are in 
agreement with Kim et al. who reported that phospho-TRBP efficiently inhibits PKR 
during M-G1 transition to regulate cell cycle99. In this study, the phosphorylation of 
TRBP during M-G1 transition was shown to be mediated by JNK. Of the four sites we 
studied, S142 and S152 were also identified by Kim et al. to be phosphorylated by JNK 
during M phase. ERK mediated phosphorylation of TRBP on S142, S152, S283, and S286 
was reported in response to mitogenic signaling and was accompanied by a coordinated 
increase in the levels of growth-promoting miRNAs and a reduction in the levels of 
tumor suppressor let-7 miRNA181. TRBP phosphorylation has been reported to occur in 
response to metabolic stress and inhibition of TRBP phosphorylation during metabolic 
stress reduced inflammation and improved systemic insulin resistance and glucose 
metabolism100,199. However, the exact functions of TRBP and PKR in high-fat diet-
induced obesity and associated metabolic and inflammatory complications remains 
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unclear and controversial101. TRBP plays an important pro-viral function in HIV infected 
cells by regulating PKR activity and promoting HIV replication109,118. Any effect of TRBP 
phosphorylation in HIV-infected cells also remains unexplored at present. Our work on 
the impact of TRBP phosphorylation on the stress signaling pathway and cellular survival 
thus presents an additional paradigm for exploring the existence and importance of 
such TRBP-mediated regulatory mechanisms in virus infected cells as well as miRNA 
expression and function in response to cellular stress. 
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Figure 3.1: TRBP overexpression protects cells from arsenite-induced apoptosis. 
(A) Establishment of a stable doxycycline-inducible HeLa cell line overexpressing Flag-
TRBP. HeLa-Tet off (Clontech) cells were transfected with either FlagTRBP/pTRE2pur 
expression construct or pTRE2pur (Clontech) empty vector (EV). Puromycin resistant 
clones were isolated, characterized, and one clone (TRBP-HeLa) that showed inducible 
expression of FlagTRBP was selected for further studies. Induction of FlagTRBP 
expression after removal of doxycycline from the growth medium at indicated time 
points is shown. Western blot analysis of cell lysates using 50 μg of total protein was 
performed using anti-Flag and anti-β-actin antibodies. The black line between lanes 3 
and 4 represents where different lanes from the same western blot were joined. 
(B) DNA Fragmentation Analysis. TRBP-HeLa cells overexpressing FlagTRBP (Lanes 1 -4) 
or EV-HeLa control cells (Lanes 5 -8) were treated with 10 μM sodium arsenite for 48, 
72, and 96 hours, fragmented DNA was isolated and analyzed. M: 100-bp ladder, Lanes 
1 & 5: 48 hr treatment. Lanes 2 & 6: 72 hr treatment, Lanes 3 & 7: 96 hr treatment, and 
Lanes 4 & 8: untreated cells. 
(C) Analysis of PARP cleavage in response to arsenite treatment. TRBP-HeLa and EV-
HeLa cells were treated with 25 μM sodium arsenite for the indicated time points, and 
western blot analysis using anti-PARP antibody was performed on cell lysates containing 
50 μg of total protein to assess increases in poly ADP-ribose polymerase (PARP1) 
cleavage. Western blot was also performed with anti-GAPDH antibody to ensure equal 
protein in all samples. 
(D) Quantification of PARP cleavage. PARP1 and cleaved PARP1 bands were quantified 
using ImageQuant TL Software. The percentage of cleaved PARP1 was calculated as 
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Figure 3.1 (continued) (cleaved PARP1 band intensity/cleaved + uncleaved bands 
intensities) X 100. Bars represent percentages of cleaved PARP1 from 3 independent 
experiments. Error bars represent standard deviation (S.D.) from three experiments. 
Student’s t tests were performed to determine statistical significance – ns: not 
significant, asterisk: P value of 0.000352
  
1
0
3
 
 
Figure 3.2: TRBP is phosphorylated by ERK and JNK in response to arsenite-induced oxidative stress. 
(A) TRBP’s electrophoretic mobility shifts in response to sodium arsenite treatment. Western blot analysis of 50 μg protein per 
lane from HeLa-TRBP cells treated with 10 μM sodium arsenite at the indicated time points is shown. Western blot analysis was 
performed with anti-Flag and anti-β actin antibodies. The slower migrating TRBP band at 8h, and 12h is indicated by an asterisk. The 
line between lanes 1 and 2 as well as between lanes 3 and 4 represents where lanes from the same western blot were joined.  
(B) PKR phosphorylation and eIF2α phosphorylation kinetics in response to sodium arsenite treatment. HeLa cells were treated 
with 10 µM sodium arsenite and cell extracts were prepared at the indicated time points. PKR and eIF2α phosphorylation status at 
each time point was determined by a western blot analysis using anti-phospho-PKR and anti-phospho-eIF2α specific antibodies using 
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Figure 3.2 (continued) 100 µg and 10µg of total protein respectively. Each blot was subsequently stripped and re-probed with anti- 
eIF2α or anti-PKR antibody to ensure equal loading in all lanes.  
(C) TRBP is phosphorylated in response to oxidative stress. Extracts from untreated, and 8h, or 12h arsenite-treated TRBP-HeLa 
cells were prepared in the presence or absence of phosphatase inhibitor (PPi) as indicated above the lanes and subsequently treated 
with phosphatase (Ptase) or left untreated as indicated. Western blot was performed with anti-Flag antibody followed by anti- β-
actin antibody.  
(D) ERK is phosphorylated in response to oxidative stress and phosphorylates TRBP. TRBP overexpressing TRBP-HeLa cells were 
treated with 10 μM arsenite alone or in combination with the MEK inhibitor PD0325901 for 24 hours. Cell extracts were made at the 
indicated time points, and western blot analysis was performed using anti-Flag, anti-phospho-ERK, anti-total ERK, and anti-GAPDH 
antibodies.  
(E) JNK is phosphorylated in response to oxidative stress and phosphorylates TRBP. TRBP overexpressing TRBP-HeLa cells were 
treated with 10 μM arsenite alone or in combination with the MEK inhibitor SP600125 for 24 hours. Cell extracts were made at the 
indicated time points, and western blot analysis was performed using anti-Flag, anti-phospho-JNK, anti-total JNK, and anti-GAPDH 
antibodies. 
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Figure 3.3: TRBP phosphorylation inhibits PKR-mediated apoptosis during cell stress. 
(A) Schematic representation of TRBP phosphorylation sites. Blue boxes represent the 
three double-stranded RNA binding motifs (dsRBMs), M1, M2, and M3. Red vertical lines 
represent previously identified ERK 1/2 phosphorylation sites at S142, S152, S283, and 
S286.  
(B) Expression of phospho-mimic TRBP protects cells during oxidative stress. HeLa cells 
were transfected with 200ng pEGFPC1 (EV) alone (black bars) or with 200ng each of 
pEGFPC1 and FlagTRBP AAAA/pcDNA 3.1- (blue bars) or with 200ng each of pEGFPC1 
and FlagTRBP DDDD/pcDNA 3.1- (red bars). 24 hours after transfection, the cells were 
treated with 25 μM sodium arsenite, fixed and stained with DAPI nuclear stain.  At least 
300 EGFP-positive cells were scored apoptotic or live based on nuclear condensation 
indicated by intense DAPI nuclear staining and cell morphology. The percentage of cells 
undergoing apoptosis (% apoptosis) was calculated using the formula: (EGFP- expressing 
cells with intense DAPI nuclear staining/Total EGFP-expressing cells) x 100. Bars 
represent averages ± S.D. from three independent experiments. One-way ANOVA 
followed by post-hoc Tukey test was performed, ns: not significant, asterisk: P-value of 
0.016.  
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Figure 3.3 (continued) (C) and (D) Phospho-mimic TRBP inhibits PKR mediated 
apoptosis more efficiently than phospho-defective TRBP (C) HeLa cells were plated on 
coverslips and transfected with 500ng of wt PKR/pEGFPC1 and 20ng of empty vector 
pCDNA3.1- (wt PKR; black bar) or with 500ng of wt PKR/pEGFPC1 + 20 ng of Flag TRBP 
AAAA/ pcDNA 3.1- (blue bar) or 500ng of wt PKR/pEGFPC1 + 20ng of Flag TRBP DDDD/ 
pcDNA 3.1- (red bar). 24 hours after transfection, the cells were fixed and mounted in 
Vectashield mounting media with DAPI nuclear stain. Representative fluorescent 
micrographs of HeLa cells transfected with wt PKR pEGFPC1 alone (Panel A), or in 
combination with Flag TRBP AAAA/ pcDNA 3.1- (Panel B) or Flag TRBP DDDD/ pcDNA 3.1- 
(Panel C) are shown. At least 500 EGFP-PKR expressing cells were scored as apoptotic 
Figure 3.3 (continued) (white arrows) or live (white arrowheads) based on nuclear 
condensation indicated by intense DAPI staining and cellular morphology. The 
percentage of cells undergoing apoptosis was determined as described in (A).  Bars 
represent averages ± S.D. from three independent experiments. One-way ANOVA 
followed by post-hoc Tukey test was performed, asterisk *: P-value 0.0034, double 
asterisk **: P-value 0.0002, #: P-value 0.0134. (D) Phospho-mimic TRBP expression 
abrogates mitochondrial depolarization during PKR-mediated apoptosis.  HeLa cells 
were plated on coverslips and transfected with 500ng of wt PKR/pEGFPC1 and 20ng of 
empty vector pCDNA3.1- (wt PKR; black bar) or with 500ng of wt PKR/pEGFPC1 + 20 ng 
of Flag TRBP AAAA/ pcDNA 3.1- (blue bar) or 500ng of wt PKR/pEGFPC1 + 20ng of Flag 
TRBP DDDD/ pcDNA 3.1- (red bar).  24 hours after transfection, changes in the 
mitochondrial potential of transfected cells were assessed using the MitoPT TMRM 
Assay kit and observed by fluorescence microscopy.  Representative fluorescent 
micrographs of the cells transfected with wt-PKR pEGFPC1 alone (wt-PKR-EGFP + EV, 
Panel A), and AAAA TRBP (wt-PKR-EGFP + AAAA, Panel B) or DDDD TRBP (wt-PKR-EGFP + 
DDDD, Panel C) are represented. At least 500 PKR expressing cells (GFP positive cells) 
were scored as live (white arrowheads) or dead (white arrows) based on decreased or 
absent red fluorescence. The percentage of cells undergoing apoptosis (% apoptosis) 
was calculated using the formula: (EGFP- expressing cells with decreased or absent red 
fluorescence/Total EGFP-expressing cells) x 100. Bars represent averages ± S.D. from 
three independent experiments. One-way ANOVA followed by post-hoc Tukey test was 
performed, asterisk *: P-value 0.0108, double asterisk **: P-value 0.0003, #: P-value 
0.0002.
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Figure 3.4: The phosphorylated TRBP isoform efficiently reverses PKR’s growth 
inhibition phenotype in yeast. (A) Yeast growth inhibition assay. Yeast INVSc1 cells 
were co-transformed with wt PKR/pYES2 and empty vector pYES3CT (PKR alone), wt 
PKR/pYES2 and K296R PKR/pYES3CT (PKR+K296R), wt PKR/pYES2 and wt TRBP/pYES3CT 
(PKR+wtTRBP), wt PKR/pYES2 and AAAA TRBP/pYES3CT (PKR+AAAA), or wt PKR/pYES2 
and DDDD TRBP/pYES3CT (PKR+DDDD). Ten microliters of transformed yeast cells (OD600 
= 10, 1, 0.1, 0.01) were spotted on double dropout media (-uracil, - tryptophan) with 
either glucose (+GLU) or galactose (+GAL) as sole carbon source. Plates were incubated 
for three days at 30oC. Transformation of INVSc1 with wt PKR/pYES2 and empty vector 
pYES3CT served as a control showing growth inhibition on galactose plates, while 
transformation with wtPKR/pYES2 and K296R PKR/pYES3CT served as a positive control 
for inhibition of PKR and a reversal of growth inhibition phenotype. 
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Figure 3.5: TRBP phosphorylation strengthens PKR-TRBP interaction and weakens TRBP-TRBP interaction.  
(A) Phosphomimic TRBP mutant interacts stronger with PKR compared to the phosphodefective TRBP mutant in yeast two-hybrid 
assay. PKR/ pGAD424 and either AAAA TRBP/pGBKT7, or DDDD TRBP/pGBKT7 were co-transformed into AH109 yeast cells and 
selected on SD double dropout media (-tryptophan, - leucine). Ten microliters of transformed yeast cells (OD600 = 10, 1, 0.1, 0.01) 
were spotted on SD triple dropout media (-tryptophan, - leucine, - histidine) containing 10 mM 3-amino-1,2,4-triazole (3-AT). 
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Figure 3.5 (continued) Plates were incubated for 5 days at 30oC. Transformation of PKR in pGAD424 and pGBKT7 empty vector 
served as a negative control.  
(B) Changes in TRBP association with PKR. Flag TRBP overexpressing cells were treated with 25 μM sodium arsenite for the 
indicated time points. Cell extracts were prepared in the presence of a phosphatase inhibitor and 25 μg of cell extract was incubated 
with 500 ng of pure recombinant hexahistidine (His)-tagged PKR immobilized on Ni2+-agarose beads. After washing the beads, PKR-
associated Flag TRBP was analyzed by SDS polyacrylamide gel electrophoresis followed by western blot analysis with anti-Flag 
antibody. Western blot analysis was also performed with anti-His antibody to ensure equal His- PKR in each sample. 25 μg of cell 
extract was also analyzed by western blot analysis with anti-Flag and anti-GAPDH antibodies to ensure equal addition of cell lysate 
for each pull down (Input). Quantification of TRBP-PKR pull down: Band intensities were quantified using ImageQuant TL Software, 
and the ratios of bound TRBP to bound PKR across all samples were calculated and normalized to the band intensities of Flag-TRBP 
input for each sample. Bound TRBP/his-PKR ratios for all samples were all expressed relative to the control sample (Lane 2). 
Averages from three independent experiments are plotted as bar graphs ± S.D. One-way ANOVA followed by post-hoc Tukey test 
was performed, asterisk *: p value 0.0000012 and double asterisk **: p value 0.0066374. 
(C) Phosphomimic TRBP mutant shows stronger homomeric interaction compared to the phosphodefective TRBP mutant in yeast 
two-hybrid assay. AAAA TRBP or DDDD TRBP point mutants in pGADT7 and pGBKT7 were co-transformed into AH109 yeast cells and 
selected on SD double dropout media (-tryptophan, -leucine). Ten microliters of transformed yeast cells (OD600 = 10, 1, 0.1, 0.01) 
were spotted on SD triple dropout media plate (tryptophan, -leucine, -histidine) containing 10 mM 3-amino-1,2,4-triazole (3-AT). 
Plates were incubated for 5 days at 30oC. Transformation of pGADT7 and pGBKT7 empty vectors served as a negative control.  
(D) Phosphomimic TRBP mutant shows stronger homomeric interaction compared to the phosphodefective TRBP mutant in 
mammalian cells. HeLa cells were transfected with either myc TRBP DDDD/ pcDNA 3.1- and Flag TRBP DDDD/ pcDNA 3.1- or Flag 
TRBP AAAA/ pcDNA 3.1- and myc TRBP AAAA/ pcDNA 3.1-. The cells were harvested 24 hours after transfection, and Flag TRBP AAAA 
or DDDD was immunoprecipitated using anti-Flag monoclonal antibody conjugated agarose beads. The co-immunoprecipitation of 
myc-TRBP was analyzed by western blot analysis with an anti-myc antibody (IP: x Myc panel). Blot was subsequently stripped and re-
probed with anti-Flag antibody to ensure equal Flag-TRBP immunoprecipitation from each sample (IP: x Flag panel). Equal AAAA 
TRBP and DDDD TRBP expression in all samples was tested by western blot analysis of equal amounts of total cell lysate with anti-
myc, and anti-Flag antibodies (Input: x Myc and x Flag panels). 
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Figure 3.6: A schematic model of PKR-TRBP interaction in response to oxidative stress. 
As previously established60,95,176, in the absence of stress, TRBP heterodimerizes with 
PKR, PKR is catalytically inactive and eIF2α is not phosphorylated. At early time points 
after ER stress, TRBP dissociates from PKR and PKR is activated leading to its 
autophosphorylation and eIF2α phosphorylation. At late time points after stress, TRBP is 
phosphorylated by ERK and JNK and interacts with PKR with higher affinity. The cells 
recover by forming TRBP-PKR heterodimers and turning off PKR and eIF2α 
phosphorylation. Phosphorylated TRBP largely remains monomeric as TRBP-TRBP 
interactions are weakened by phosphorylation of TRBP.  
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CHAPTER 4 
 
CONTRIBUTION OF THE TWO DSRBM MOTIFS TO THE DOUBLE-STRANDED 
RNA BINDING AND PROTEIN INTERACTIONS OF PACT4
                                                          
4 Chukwurah E., Willingham V., Singh M., Castillo D., and Patel RC Submitted to Journal of 
Cellular Biochemistry 2017. 
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4.1. ABSTRACT 
 PACT is a stress-modulated activator of protein kinase PKR (protein kinase, 
RNA activated), which is involved in antiviral innate immune responses and stress-
induced apoptosis. Stress-induced phosphorylation of PACT is essential for PACT's 
increased association with PKR leading to PKR activation, phosphorylation of 
translation initiation factor eIF2α, inhibition of protein synthesis, and apoptosis. 
PACT-induced PKR activation is negatively regulated by TRBP (Transactivation 
response element RNA-binding protein), which dissociates from PACT after PACT 
phosphorylation in response to stress signals. The conserved double-stranded RNA 
binding motifs (dsRBMs) in PKR, PACT, and TRBP mediate protein-protein 
interactions, and the stress-dependent phosphorylation of PACT changes the relative 
strengths of PKR-PACT, PACT-TRBP, and PACT-PACT interactions to bring about a 
timely and transient PKR activation. This regulates the general kinetics as well as level 
of eIF2 phosphorylation, thereby influencing the cellular response to stress either 
as recovery and survival or elimination by apoptosis. In the present study, we 
evaluated the effect of specific mutations within PACT’s two evolutionarily conserved 
dsRBMs on dsRNA-binding, and protein-protein interactions between PKR, PACT, and 
TRBP. Our data shows that the two motifs contribute to varying extents in dsRNA 
binding, and protein interactions. These findings indicate that although the dsRBM 
motifs have high sequence conservation, their functional contribution in the context 
of the whole protein needs to be determined by mutational analysis. Furthermore, 
using a PACT mutant that is deficient in PACT-PACT interaction but competent for 
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PACT-PKR interaction, we demonstrate that PACT-PACT interaction is essential for 
efficient PKR activation. 
 
4.2 INTRODUCTION 
 PACT is a double-stranded RNA binding protein that was identified originally as a 
Protein Activator of PKR (protein kinase, RNA activated: encoded by the Eif2ak2 gene) in 
human cells and later as PKR associated protein (RAX) in mouse. The gene that encodes 
PACT is designated as Prkra and recently several mutations that lead to the movement 
disorder dystonia have been described in the Prkra gene. PACT and RAX proteins are 
mostly identical with only 6 out of 313 residues being different with 4 of these 
substitutions being conservative. Initial studies on PACT focused on its ability to induce 
the autophosphorylation and activation of the interferon (IFN)-inducible, double-
stranded (ds) RNA dependent serine/threonine protein kinase (PKR) in response to 
various stress signals. Activation of PKR results in phosphorylation of eukaryotic protein 
synthesis initiation factor 2α (eIF2α) leading to an inhibition of protein synthesis. 
 PKR is expressed ubiquitously and mediates IFN’s antiviral actions in virally 
infected cells as well as regulates cellular survival and apoptosis in response to stress in 
uninfected cells. PKR's kinase activity remains latent until one of its activators bring 
about a conformational change by direct binding to cause its enzymatic activation108. 
During the replication of several viruses dsRNA is produced, which binds to PKR’s two 
dsRNA-binding motifs (dsRBMs)45,175,200 to activate PKR and unmask the ATP-binding 
site50 to promote autophosphorylation48. The two dsRBMs also mediate dsRNA-
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independent protein-protein interactions with other proteins that carry similar 
domains176,177. Among these proteins, PACT functions to activate PKR in response to 
stress signals and in the absence of dsRNA58,60 and TAR RNA-binding protein (TRBP) 
serves as an inhibitor.  
 PACT contains three copies of dsRBM (Figure 1.3), of which the two amino-
terminal motifs (M1 and M2) bind to dsRNA and also to dsRBMs of PKR. The third 
carboxy-terminal motif 3 (M3) lacks the conserved lysines required for dsRNA-binding 
and thus does not bind dsRNA. M3 is also dispensable for interaction with PKR’s dsRBM 
motifs but is essential for PKR activation and interacts with a specific region in its kinase 
domain63,64. Although purified, recombinant PACT can activate PKR by direct interaction 
in vitro58, PACT-dependent PKR activation in cells occurs in response to stress signals59–62 
such as arsenite, peroxide, growth factor withdrawal, thapsigargin, and tunicamycin, 
and leads to phosphorylation of the translation initiation factor eIF2 and cellular 
apoptosis59–61. PACT (and its murine homolog RAX) are phosphorylated in response to 
stress leading to its increased association with PKR59–61. The stress-induced 
phosphorylation site in PACT is at serine 287 (S287) and a constitutive phosphorylation 
at serine 246 (S246) is required for S287 phosphorylation in response to oxidative stress. 
The phosphorylation of S287 in response to oxidative stress increases the PACT-PKR and 
PACT-PACT interactions but decreases PACT-TRBP interactions promoting PKR 
activation. TRBP also has three dsRBMs; the first two are true dsRBMs and interact with 
dsRNA, while the third carboxy-terminal dsRBM does not bind dsRNA but mediates 
TRBP’s interactions with other proteins such as Dicer, and Merlin91,123,178. TRBP inhibits 
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PKR by interacting with dsRNA and sequestering it away from PKR as well as by forming 
PKR-TRBP heterodimers95,120. In the absence of viral infections and stress signals, TRBP 
forms heterodimers with both PKR and PACT, preventing their association and PACT-
mediated PKR activation97,180. PKR activation in response to stress signals is thus tightly 
regulated by PACT and TRBP, both regulating its catalytic activity by a direct 
interaction180,195. As the dsRBMs in PKR, PACT, and TRBP mediate protein-protein 
interactions201, these three proteins form both heterodimers as well as homodimers and 
the stress-dependent phosphorylation of PACT changes the relative strengths of PKR-
PACT, PACT-TRBP, and PACT-PACT interactions to bring about a timely and transient PKR 
activation with precise control68,195. This regulates the general kinetics as well as level of 
eIF2 phosphorylation thereby influencing the cellular response to stress either as 
recovery and survival or elimination by apoptosis179. 
 In this report, we examined the contribution of specific conserved amino acids 
within the two amino-terminal dsRBM domains in PACT to its dsRNA-binding and 
protein-protein interaction activities. Our results identify the conserved lysines and 
specific hydrophobic amino acids within the two dsRBMs that are important for dsRNA-
binding and protein-protein interactions respectively. In addition, the work underscores 
the importance of PACT-PACT interactions in PKR activation following oxidative stress as 
a phosphomimetic PACT mutant that is incapable of facilitating PACT-PACT interactions 
fails to activate PKR and induce apoptosis. The results shed light on the mechanism of 
PKR activation by PACT.
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4.3 MATERIALS AND METHODS 
4.3.1 REAGENTS AND CELL LINES 
 HeLaM and COS-1 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% Fetal Bovine Serum and penicillin/streptomycin. Transfections 
were performed with the Effectene Transfection Reagent (Qiagen) per the 
manufacturer’s instructions. 
 
4.3.2 PLASMIDS 
 The TRBP/pGBKT7, K296R PKR/pGBT9, Flag PACT S246D S287D (DD PACT)/ 
pcDNA 3.1-, wt PACT/BSIIKS+, Flag PACT/pCMV2, wt PACT/VP16 and wt PACT/GAL4 
expression plasmids were prepared as previously described. The M1 (K84E, K88E, 
A91E, A92D, L99E), and M2 (K177A, K181E, A184E, A185E, and F192E) point 
mutations were introduced into wt PACT using the Gene Editor Site Directed 
Mutagenesis Kit (Promega). After the sequence of each point mutant was verified, 
the point mutants in BSIIKS+ were subcloned into the pGBKT7 and pGADT7 (Takara 
Bio USA, Inc) yeast expression vectors at the NdeI and BamHI restriction sites.  
The Flag-tagged L99E S246D S287D (DD-L99E) PACT triple point mutant in BSIIKS+ 
(Agilent Technologies) was generated by a three-piece ligation of the NdeI – EcoRI 
restriction fragment from L99E BSIIKS+, EcoRI – EcoRI restriction fragment from DD 
PACT pcDNA 3.1-, and the NdeI – EcoRI cut Flag BSIIKS+ fragment. The Flag tagged 
triple mutant from BSIIKS+ was then introduced into the XbaI – EcoRI sites of the 
pcDNA 3.1- expression vector (Invitrogen). 
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4.3.3 DSRNA BINDING ASSAY 
 In vitro translated, 35S-labeled PACT proteins (wt, PACT M1 and M2 mutants) 
were synthesized using the TNT® T7 Coupled Reticulocyte Lysate System (Promega). 
The dsRNA-binding activity of each mutant was measured by the previously 
described poly(I)·poly(C)–agarose binding assay [Patel and Sen, 1992]. 4 μl of the 
translation products were diluted with 25 μl of binding buffer [20 mM Tris–HCl, pH 
7.5, 0.3 M NaCl, 5 mM MgCl2, 1 mM DTT, 0.1 mM PMSF, 0.5% Igepal, 10% glycerol], 
mixed with 25 μl of poly(I)·poly(C) – agarose beads and incubated at 30°C for 30 
minutes. The beads were subsequently washed four times with 500 μl of binding 
buffer and the proteins bound to the beads after the washes were analyzed by SDS–
PAGE and autoradiography. The T (Total) lanes represent the total synthesized 35S-
labeled proteins from the rabbit reticulocyte lysate, and the B (Bound) lanes 
represent the proteins that remained bound to the poly(I).poly(C) – agarose beads 
after washes. The interaction of each PACT protein with dsRNA was quantified using 
ImageQuant (GE Healthcare) by analyzing the band intensities of the total and bound 
PACT proteins. The percentage of the PACT protein bound to poly(I)·poly(C) – agarose 
beads was calculated from the band intensity values using this formula: 
% Binding = (100 * band intensity of protein in the Bound lane)/(band intensity of 
protein in the Total Lane). The calculated percentages were then plotted on bar 
graphs. The poly(I)·poly(C)–agarose binding assay was also performed with in vitro 
translated 35S-labelled firefly luciferase protein to demonstrate specific interaction 
between the PACT proteins and the poly(I).poly(C) synthetic dsRNA. 
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4.3.4 YEAST TWO-HYBRID INTERACTION ASSAYS 
 To test the interaction between the various indicated PACT point mutants and 
PKR, full length K296R PKR was expressed as a GAL4 DNA binding domain fusion protein 
from the pGBT9 vector while the PACT M1 and M2 mutants were expressed as GAL4 
DNA activation domain fusion proteins from the pGADT7 vector.  
 The PKR/PACT mutant construct pairs were co-transformed into AH109 yeast 
cells (Takara Bio USA) using the lithium acetate method192, which were plated on double 
dropout synthetic defined (SD) minimal media plates lacking tryptophan and leucine. 
The transformants were grown to an OD600 of 2 in YPD (yeast extract, peptone and 
dextrose) media, and 500 μl of each culture was pelleted and resuspended in an 
appropriate amount of distilled water to yield an OD600 of 10. Serial dilutions were then 
made to yield OD600 values of 1, 0.1, 0.01. 10 μl of each serial dilution was spotted on 
triple dropout SD media plates lacking histidine, tryptophan and leucine and incubated 
at 30oC for 4 days. AH109 cells were also co-transformed with wt PACT/pGADT7 and 
K296R/pGBT9 as a positive control, and with either A91E PACT/pGADT7, A92D 
PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and 
pGBKT7 as negative controls. 
 The relative strengths of the homomeric interactions of the PACT M1 and M2 
point mutants were assayed by co-transforming AH109 yeast cells with the PACT 
mutants expressed as both GAL4 DNA binding and activation domain fusion proteins 
from the pGBKT7 and pGADT7 vectors. Similarly, the strengths of the PACT mutants’ 
heteromeric interaction with TRBP were tested by co-transforming the yeast cells with 
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the PACT mutants expressed as GAL4 activation domain fusion proteins from the 
pGADT7 vector and TRBP expressed as a GAL4 DNA binding domain fusion protein from 
the pGBKT7 vector. 
 Selection of double transformant yeast cells and preparation of serial dilutions 
was carried out as previously described, and the serial dilutions were spotted on triple 
dropout media lacking histidine, tryptophan, and leucine in the presence of 10 mM 3-
amino-1,2,4-triazole (3-AT), a competitive inhibitor of histidine synthesis. The plates 
were incubated at 30oC for 4 days. As positive controls, AH109 cells were transformed 
with wt PACT/pGADT7 and wt PACT/pGBKT7 and wt PACT/pGADT7 and TRBP/pGBKT7 
for the PACT homodimer interaction and PACT-TRBP heterodimer interaction 
respectively.  
 For negative controls for the PACT-PACT homodimer yeast two-hybrid 
experiments, AH109 cells were co-transformed with either A91E PACT/pGBKT7, A92D 
PACT/pGBKT7, A184E PACT/pGBKT7, A185E PACT/pGBKT7, or F192E PACT/pGBKT7 and 
pGADT7 vectors. Negative controls for the PACT-TRBP heterodimer yeast two-hybrid 
experiments were AH109 yeast cells co-transformed with either the A91E 
PACT/pGADT7, A92D PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or 
F192E PACT/pGADT7 and pGBKT7 expression vectors. 
 
4.3.5 MAMMALIAN TWO HYBRID INTERACTION ASSAY 
 Sequences encoding the L99E, S246D S287D (DD), or L99E S246D S287D (DD-
L99E) PACT point mutants were introduced into the pSG424 expression construct to 
 120 
generate an in-frame fusion of each protein to the GAL4 transcription DNA binding 
domain (GAL4 DBD). In frame fusions of each protein to the activation domain of the 
herpes simplex virus protein VP16 were also generated by introducing the sequences 
into the pVP16AASV19N vector (VP16 AD).  
 COS-1 cells were transfected with 200 ng of each GAL4 DBD and VP16 AD 
construct pair and 200 ng of the pG5Luc (Firefly luciferase) reporter construct using the 
Effectene transfection reagent (Qiagen). The cells were also transfected with 1 ng of the 
pRL Null vector (Renilla luciferase) (Promega) to normalize for transfection efficiency. 
The cells were harvested 24 hours after transfection and assayed for firefly and Renilla 
luciferase activity using the Dual-Luciferase® Reporter Assay System (Promega). 
 
4.3.6 APOPTOSIS ASSAY 
 HeLaM cells were grown to 30% confluency in six-well plates and transfected 
with 300 ng of Flag wt PACT/pCMV2, Flag DD PACT/pcDNA 3.1-, or Flag L99E DD 
PACT/pcDNA 3.1- and 200 ng of pEGFPC1 (Takara Bio USA) using the Effectene 
Transfection reagent (Qiagen). As a control, cells were transfected with 300 ng BSIIKS+ 
(Agilent Technologies) and 200 ng pEGFPC1.  
 The cells were observed for EGFP fluorescence 24 hours after transfection using 
an inverted fluorescent microscope (EVOS®FL Imaging System, Thermo Fisher Scientific), 
at which time they were washed twice with PBS and fixed in 4% paraformaldehyde for 5 
minutes. The cells were subsequently washed with PBS and incubated with DAPI at 0.5 
μg/ml in PBS for 10 minutes at room temperature. The cells were washed again in PBS 
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and viewed under the fluorescent microscope. At least 300 GFP positive cells were 
scored as apoptotic or non-apoptotic based on their morphology. Cells showing normal 
flat morphology were scored as non-apoptotic, while cells showing cell shrinkage, 
membrane blebbing, round morphology and nuclear condensation with intense DAPI 
fluorescence were scored as apoptotic. The percentage of cells that underwent 
apoptosis (% Apoptosis) was calculated using the formula: (EGFP-positive cells with 
intense DAPI nuclear fluorescence/Total EGFP-positive cells) * 100.  
 
4.3.7 STATISTICAL ANALYSES 
Statistical significance of the dsRNA-binding quantifications, percent apoptosis, and 
results from the mammalian two-hybrid interaction assay were determined by Student’s 
T test or one-way ANOVA followed by post-hoc Tukey test as indicated in the figure 
legends. P-values are denoted by brackets and special characters. Alpha level was p = 
0.05.
 
4.4 RESULTS 
 The high-affinity interaction between PKR and PACT is mainly mediated by 
PACT’s M1 and M2 motifs and M3 motif is dispensable for PKR-PACT interaction but is 
essential for PKR activation63,64. The M1 and M2 motifs are also involved in dsRNA 
binding via the conserved dsRBMs, which possess the characteristic amphipathic helix 
also present in PKR49,202. Specific lysines on the charged side of this amphipathic helix 
are important for dsRNA-binding, whereas hydrophobic amino acids on the opposite 
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side are important for the protein-protein interactions. In order to characterize the 
contribution of specific amino acids within the M1 and M2 motifs to dsRNA-binding and 
PKR-PACT, TRBP-PACT, and PACT-PACT interactions, we created point mutations using 
site-directed mutagenesis. As shown in Fig. 4.1 A, five residues were mutated 
individually in M1 and M2. The selected residues are conserved in the M1 and M2 
motifs of both PACT and TRBP (Fig. 4.1 B). We tested the effect of these mutations on 
PACT’s dsRNA-binding (Fig. 4.1 C and D). Mutations in both M1 and M2 affected dsRNA 
binding, but the M1 mutations showed a more drastic reduction in dsRNA binding 
where all five mutations reduced the dsRNA binding to less than 20% of the wild type 
PACT. The mutations in M2 showed a moderate effect with reduced dsRNA binding that 
ranged from 15% to 65% of the wild type PACT. These results indicate that the M1 motif 
contributes most to the dsRNA binding activity and M2 motif serves a supplementary 
role. 
 The dsRBMs are also involved in mediating protein-protein interactions in a 
dsRNA independent manner176. To understand the role of the hydrophobic residues 
within the M1 and M2 motifs in mediating protein-protein interactions, we tested the 
direct interactions of the point mutants with PKR, PACT, and TRBP using a yeast two 
hybrid assay. Specifically, the three hydrophobic residues have been previously shown 
to contribute towards PKR homodimer formation49,202. We have used the yeast two-
hybrid assay to understand the interactions between PKR, PACT, and TRBP successfully 
and the system is sensitive enough to allow for detecting moderate to subtle changes in 
protein interaction affinities68,179,195. As seen in Figure 4.2, the A91E and A92D mutants 
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showed a drastic reduction in interaction with PKR, but the L99E mutant showed strong 
interaction with PKR. Contrary to M1 mutants, none of the M2 mutations showed any 
effect on the PACT-PKR interaction. These results strongly suggest the important role of 
alanine 91 and alanine 92 in M1 motif for mediating the interaction between PACT and 
PKR. 
 PACT-PACT interactions are important for PACT mediated PKR activation in 
response to stress68,179 and we next examined the effect of the point mutations on 
PACT-PACT interactions. The effect of M1 mutations on PACT-PACT interaction was 
quite drastic with A91E, A92D, and L99E mutants showing a complete lack of interaction 
(Figure 4.3). However, the M2 mutations showed no effect on PACT-PACT interaction 
indicating that the PACT-PACT interaction is mainly mediated by the M1 motif. TRBP 
interacts with both PACT and PKR to act as an inhibitor of PKR and the TRBP-PACT 
interaction regulates PACT’s ability to activate PKR in a negative manner during stress 
signaling. Our results shown in Figure 4.4 indicate that the TRBP-PACT interaction is 
mainly mediated by PACT’s M1 motif as the A91E, A92D, and L99E mutations resulted in 
a complete lack of TRBP-PACT interaction. The M2 motif mutations A184E, A185E, and 
F192E had no effect on the TRBP-PACT interaction. These results indicate that similar to 
PACT-PACT interaction shown in Figure 4.4, the TRBP-PACT interaction is also mediated 
mainly by the M1 motif in PACT.  
 Our previous results had indicated that the stress-induced PKR activation by 
PACT is dependent on efficient PACT-PACT interactions and the stress-induced 
phosphorylation at serine 287 of PACT enhances PACT-PACT and PACT-PKR interactions 
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while decreasing TRBP-PACT interactions195. Since the L99E mutant retains its ability to 
interact efficiently with PKR but loses its ability for PACT-PACT interactions, we wanted 
to create a triple mutant by combining the L99E mutation with phosphomimetic S246D 
and S287D mutations. The phosphomimetic S246D and S287D double mutant (DD 
mutant) activates PKR in the absence of stress signals, induces apoptosis, and shows 
enhanced PACT-PACT and PACT-PKR interactions60,62,91,195. Thus, we wanted to test if the 
DD mutation, when combined with the L99E mutation will promote PACT-PACT 
interactions. We used the mammalian two-hybrid assay to test this and the results are 
shown in Fig. 4.5 A. The wild type PACT shows good PACT-PACT interaction and the L99E 
mutant shows no PACT-PACT interaction above the EV control. The DD mutant shows 
enhanced PACT-PACT interaction as compared to wild type PACT and in contrast to this, 
the combined triple mutant DD-L99E shows a lack of PACT-PACT interaction. This 
allowed us to examine if the phosphomimetic DD mutant would promote apoptosis if it 
lacked the PACT-PACT interactions.  
 In order to understand the contribution of PACT-PACT interactions towards 
PACT mediated PKR activation, we performed the apoptosis assay using nuclear 
condensation as a marker of apoptotic cells. We overexpressed the wild type PACT, 
DD mutant, and DD-L99E mutant in HeLa cells and assayed for apoptosis induction. 
The overexpression of both wild type and DD mutant PACT proteins is known to 
induce apoptosis in the absence of any stress signals. As seen in Fig. 4.5 B, an 
overexpression of wtPACT induced apoptosis in about 25% of the cells as compared 
to the 5% apoptosis in empty vector transfected cell. The overexpression of the DD 
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mutant caused apoptosis in about 36% cells and in contrast to this, the 
overexpression of DD-L99E mutant showed apoptosis in only 8% of the transfected 
cells. These results indicate that the PACT-PACT interaction is crucial for induction of 
apoptosis and the lack of PACT-PACT interactions inactivate PACT’s ability to activate 
PKR. These results underscore the importance of enhanced PACT-PACT interactions 
in response to stress signals. 
 
4.5 DISCUSSION 
In this report, we investigated the role of conserved residues within the M1 and 
M2 motifs in PACT towards dsRNA-binding, and interaction with PKR, TRBP and PACT. 
Overall, M1 motif plays a more significant role in dsRNA-binding activity of PACT. Similar 
to the two lysines at positions 60 and 150 in PKR, the corresponding lysines at positions 
84 and 177 showed an essential role in dsRNA-binding. The lysine 88 mutation also 
showed a significant reduction in dsRNA-binding similar to the corresponding lysine 64 
mutation in PKR. However, the lysine 181 mutation in M2 motif of PACT showed a much 
smaller reduction in dsRNA-binding as compared to a drastic effect of corresponding 
lysine 154 mutation in PKR.  
 These results indicate that although the dsRBMs are well conserved in various 
members of this diverse family of proteins, the effect of individual analogous point 
mutations in various motifs in the context of whole proteins needs to be examined in a 
case by case manner. Certain hydrophobic residues in M1 motif (alanine 91, alanine 92, 
and leucine 99) as well as in motif 2 (alanine 184) play an important role in dsRNA-
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binding, similar to alanine 68 in M1 and alanine 158 in M2 of PKR202. When we tested 
the dsRNA-binding of individual M1 or M2 motifs previously, both M1 and M2 showed 
strong dsRNA-binding activity63. The data presented here underscores the importance of 
testing the effect of point mutations in the whole protein context instead of individual 
domains. The M2 motif, although fully capable of binding dsRNA on its own when 
existing as a separate domain, plays an auxiliary role towards dsRNA-binding in the PACT 
protein as a whole. Many members of the family of proteins have multiple dsRBMs 
present in tandem similar to PACT, TRBP, and PKR196. The dsRBM is known to be a 
versatile motif and the individual dsRBMs present in the same protein are known to 
have properties that differ in terms of dsRNA-binding and dimerization/multimerization 
contributing to their unique contribution to the functionality of the whole protein203. 
 An investigation of the relative contribution of the hydrophobic residues in M1 
and M2 motifs to the protein-protein interactions demonstrated that M1 motif 
contributes maximally for the PKR-PACT, PACT-PACT, and PACT-TRBP interactions. All 
three residues (alanine 91, alanine 92, and leucine 99) were indispensable for PACT-
PACT and PACT-TRBP interactions. In contrast to this, for the PKR-PACT interactions, the 
mutation of leucine 99 showed no effect and the alanine 91 and alanine 92 mutations 
showed a slight reduction in interaction. The M2 mutations showed no effect on any of 
the interactions. These results indicate that either of the M1 or M2 motifs can 
effectively mediate the interaction between PKR and PACT. In future, it may be 
interesting to test the effects of double mutants in M1 and M2 motifs on PKR-PACT 
interactions. The observation that M1 mutations had similar effect on PACT-PACT and 
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PACT-TRBP interactions indicates that the individual PACT molecules in cells would 
either be present as heteromeric complexes with TRBP or as homomeric PACT-PACT 
complexes. However, if the two proteins are capable of forming multimers, it remains to 
be determined if the stoichiometry of such complexes may change in response to stress 
signals to change the biological consequence and alter survival versus apoptosis 
equilibria.  
 Our previous results demonstrated that a phosphomimetic mutant of PACT 
with an aspartic acid substitution at both serines 246 and 287 (DD mutant) shows 
enhanced PACT-PACT interactions as compared to wild type PACT indicating that 
PACT-PACT interaction promotes PACT-PKR interaction and consequently PKR 
activation68. Thus, we further investigated if PACT-PACT interaction may be essential 
for PACT’s ability to activate PKR and induce apoptosis by generating a triple mutant 
where we combined the DD mutation with L99E mutation. L99E mutation disables 
PACT-PACT interactions but keeps the PKR-PACT interaction intact and we previously 
have demonstrated that the L99E mutant was unable to activate PKR68. Thus, the 
triple mutant (S246D, S287D, L99E) allowed us to test if the phosphomimetic mutant 
could activate PKR if it cannot form PACT-PACT interactions.  
 The inability of the triple mutant to show interaction in mammalian cells as 
well as its inability to induce apoptosis, underscores the importance of PACT-PACT 
interactions in PKR activation. These results are very significant for understanding the 
stress-induced signaling pathways leading to apoptosis since they add an additional 
layer of complexity brought about by phosphorylation-mediated changes in the 
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relative affinity of various binding partners within the dsRBM family. This is an aspect 
that has not been explored to date and can have a significant influence on the 
various biological processes regulated by the dsRBM containing proteins176,196. 
 The essential role of PKR dimerization in activating its kinase function has been 
established in many studies when dsRNA is the activating agent177,204,205. PKR activation 
is brought about mainly when two PKR molecules bind to a single dsRNA molecule140,206. 
PKR’s second dsRBM motif interacts with the catalytic domain to keep PKR in a closed 
conformation that prevents ATP binding50,207. Binding to dsRNA induces a 
conformational change that releases the dsRBM from the catalytic domain, thus 
allowing for ATP-binding. Structural and biophysical data also indicates that dsRNA 
principally functions to induce dimerization of PKR via the kinase domain208. Although 
PKR exists in an equilibrium between monomeric and dimeric states in the absence of its 
interaction with dsRNA, binding to dsRNA shifts this equilibrium towards the dimeric 
form and also induces a conformational change necessary to relieve the 
autoinhibition209.  
 In contrast to this, activated PKR phosphorylated on several serines and 
threonines exists in monomeric as well as dimeric forms and both forms are competent 
in kinase function and active in phosphorylating eIF2α210. Similar to dsRNA mechanisms, 
it is likely that two or more molecules of PKR are brought in close proximity by virtue of 
their interaction with PACT dimer or multimer. Thus, PACT may serve the same function 
that a dsRNA molecule of sufficient length serves, which is to allow for binding of two 
PKR molecules to promote trans-autophosphorylation. It is interesting to note that 
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PACT-PKR interaction is strongest when PKR is not catalytically active and PACT interacts 
much weakly with catalytically active PKR. PKR activation thus seems to dissociate PACT 
from PKR. In future, it will be interesting to study if protein-protein interactions play 
similar regulatory roles in RNAi69,70,72, and innate immunity73 pathways that are 
regulated by PACT. 
 
.
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Figure 4.1: Mutations in conserved amino acids in PACT’s M1 and M2 dsRNA 
binding motifs (dsRBMs) disrupt PACT’s interaction with dsRNA.  
(A) Schematic representation of PACT’s domain structure and conserved amino 
residues in PACT’s M1 and M2 dsRBMs. Gray boxes represent PACT’s dsRNA binding 
M1 and M2 motifs, while the blue box represents PACT’s M3 motif which does not 
interact with dsRNA, but is essential for PKR activation by PACT. Conserved residues 
in PACT’s M1 and M2 motifs are displayed; residues in red were mutated for this 
study. 
(B) Sequence alignment of PACT, TRBP, and PKR’s dsRNA binding motifs. The three 
conserved dsRBMs of PACT (PACT M1, PACT M2, PACT M3) are aligned to those of 
TRBP (TRBP M1, TRBP M2, TRBP M3) and PKR (PKR M1, PKR M2). Amino acid residues 
in bold are conserved residues present in all 8 dsRBMs or conservative changes from 
the consensus sequence below. Note the presence of several hydrophobic amino 
acid residues (AA---AL—L) in all 8 dsRBMs which are known to be important in 
mediating each protein’s homodimer and heterodimer interactions and with dsRNA. 
(C) dsRNA binding assay. The dsRNA binding activity of each M1 and M2 PACT point 
mutant was compared to that of wt PACT using a poly(I).poly(C)-agarose binding 
assay with in vitro translated 35S-labeled proteins. 35S-labeled in vitro translated 
firefly luciferase protein was used as a control to demonstrate specific PACT 
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interaction with poly(I).poly(C). T represents the total input, while B represents the 
proteins still bound to poly(I).poly(C)-agarose beads after washes. 
(D) Quantification of the dsRNA binding assay. Band intensities of the total and 
bound proteins were quantified by phosphorimager analysis, and % dsRNA binding 
was calculated for each PACT protein. % dsRNA-binding averages from four 
independent experiments are plotted as bar graphs ± S.D.  
One-way ANOVA followed by post-hoc Tukey test showed a statistically significant 
difference between wt PACT dsRNA binding and that of each of the PACT mutants. P 
value wt PACT vs. K84A, K88E, A91E, A92D, L99E, K177E, and K184E PACT mutants = 
0.000013, P-value wt PACT vs. K181E PACT mutant = 0.000198, P-value wt PACT vs. 
A185E PACT mutant = 0.000014, and P-value wt PACT vs. F192E PACT = 0.000078 
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Figure 4.2: Mutations of specific hydrophobic residues in PACT’s M1 dsRBM disrupt PACT’s interaction with PKR. The K296R 
PKR/pGBT9 yeast expression vector and PACT M1 and M2 mutants in the pGADT7 yeast expression vector were co-transformed into 
AH109 yeast cells. Co-transformants were selected on SD double dropout media (-Tryptophan, - Leucine). 10 microliters of the 
transformed yeast cells (OD600 = 10, 1, 0.1. 0.01) were spotted on SD triple dropout media agar plates (-Tryptophan, -Leucine, -
Histidine). Plates were incubated at 30oC for 4 days. AH109 cells were co-transformed with wt PACT/pGADT7 and K296R PKR/pGBT9 
expression vectors as a positive control, and with either the A91E PACT/pGADT7, A92D PACT/pGADT7, L99E PACT/pGADT7, A184E 
PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 expression vector as negative controls.
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Figure 4.3: Mutations of hydrophobic residues in PACT’s M1 dsRBM disrupt PACT-PACT homodimer interaction. Each M1 and 
M2 PACT point mutant in the pGBKT7 and pGADT7 yeast expression vectors were co-transformed into AH109 yeast cells, and 
successfully co-transformed yeast cells were selected on SD double dropout media (-Tryptophan, - Leucine). 10 microliters of the 
transformed yeast cells (OD600 = 10, 1, 0.1. 0.01) were spotted on SD triple dropout media agar plates (-Tryptophan, -Leucine, -
Histidine) containing 10mM 3-amino-1,2,4-triazole (3-AT). Plates were incubated at 30oC for 4 days. AH109 cells were also co-
transformed with wt PACT/PGBKT7 and wt PACT/pGADT7 as a positive control, and with either A91E PACT/pGADT7, A92D 
PACT/pGADT7, L99E PACT/pGADT7, A184E PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 as negative 
controls. 
  
1
3
4
 
 
Figure 4.4: Hydrophobic residue mutations in PACT’s M1 dsRBM disrupt PACT-TRBP heterodimer interaction. AH109 cells were 
co-transformed with the TRBP/pGBKT7 yeast expression vectors and each of the previously described PACT M1 and M2 point 
mutants in the pGADT7 yeast expression vector. Co-transformed yeast cells were selected on SD double dropout media (-
Tryptophan, - Leucine). 10 microliters of serial dilutions (OD600 = 10, 1, 0.1. 0.01) of the yeast cells were spotted on SD triple 
dropout media agar plates (-Tryptophan, -Leucine, -Histidine) containing 10mM 3-amino-1,2,4-triazole (3-AT). Plates were 
incubated at 30oC for 4 days. AH109 yeast cells co-transformed with TRBP/pGBKT7 and wt PACT/pGADT7 served as the positive 
control, while AH109 cells co-transformed with either A91E PACT/pGADT7, A92D PACT/pGADT7, L99E PACT/pGADT7, A184E 
PACT/pGADT7, A185E PACT/pGADT7, or F192E PACT/pGADT7 and pGBKT7 were negative controls.  
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Figure 4.5: PACT homodimer interaction is required for stress-
induced PACT-PACT interaction and PACT- mediated apoptotic 
induction.  
(A) The phosphomimetic point mutation is unable to rescue L99E 
PACT’s homodimerization defect. COS-1 cells were transfected 
with 200 ng each of the indicated GAL4 DBD and VP16 AD 
construct pairs, 200 ng of the pG5 Luc reporter construct, as well 
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Figure 4.5 (continued) as 1ng of the pRL-Null construct to 
normalize for different transfection efficiencies. Cells were 
harvested 24 hours after transfection, and lysates were assayed 
for Firefly and Renilla luciferase activity. Experiments were 
performed thrice in triplicate, and the bars represent the averages 
of the experiments ± S.D. Student’s t tests were performed to 
determine statistical significance – asterisk * P-value = 0.0027, 
double asterisk **P-value = 0.000764, triple asterisk *** P-value = 
0.015, # P-value = 0.001158. 
(B) Loss of PACT homodimer interaction significantly weakens the 
induction of apoptosis due to PACT phosphorylation. HeLaM cells 
were transfected with 200ng of pEFPC1 and 300ng of Flag wt 
PACT/pCMV2 (wtPACT), 300ng of the phosphomimetic PACT 
expression construct (Flag DD PACT/pcDNA 3.1- (DD)) or 300 ng of 
the PACT triple mutant construct (Flag L99E DD PACT/ pcDNA 3.1- 
(DD-L99E)). Cells were also transfected with 300 ng of BSIIKS+ and 
200 ng of pEGFPC1 (EV) as a control.  The cells were observed for 
GFP expression 24 hours after transfection, and at least 300 GFP 
positive cells were scored as non-apoptotic or apoptotic based on 
nuclear condensation indicated by intense DAPI staining. The 
percentage of apoptotic cells (% Apoptosis) was calculated using the 
formula: (EGFP- expressing cells with intense DAPI nuclear 
staining/Total EGFP-expressing cells) x 100. Bars represent averages 
± S.D. from three independent experiments. Student’s t tests were 
performed to determine statistical significance – ns: not significant, 
* asterisk: P-value of 0.0391, ** double asterisk: P-value of 0.00294.  
 137 
 
CHAPTER 5 
 
GENERAL DISCUSSION
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 This dissertation focused on the various mechanisms through which the 
interferon-induced eIF2α kinase, PKR, is regulated during viral infection and oxidative 
stress via its interactions with the dsRNA binding proteins, PACT and TRBP. This 
dissertation also underscored the importance of both of PACT’s M1 and M2 dsRBMs in 
mediating efficient PACT homodimerization, PACT-TRBP and PACT-PKR 
heterodimerization, and consequently PKR activation during cellular stress.  
 In Chapter 2, we demonstrated that PACT, which normally acts as a cellular 
activator of PKR during non-viral cellular stress, is co-opted by the HIV-1 virus to subvert 
PKR’s antiviral activity through the formation of a PKR-inhibitory complex that includes 
ADAR1, Tat, and dsRNA-containing HIV-1 transcripts. While we have established that 
ADAR1 suppresses PACT’s PKR activating function during HIV-1 infection, the effects of 
the observed increased ADAR - PACT interaction on potential viral infection-induced 
PACT phosphorylation have yet to be elucidated. In vivo 32P orthophosphate labelling of 
PACT over the course of infection in cells could establish if PACT is phosphorylated in 
virally infected cells, and if ADAR1 precludes this phosphorylation and consequent PACT-
mediated-PKR activation. As both ADAR1 and PACT contain dsRBMs which are known to 
mediate both dsRNA and protein-protein interactions, determination of the essential 
dsRBMs and residues in each protein responsible for their interaction can facilitate 
peptide-mediated disruption of PACT-ADAR1 interaction during HIV-infection and 
enhance PKR-mediated inhibition of viral replication in infected cells. This would be an 
exciting novel therapeutic approach in the combinatorial therapy options used currently 
for HIV patients.  
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 In Chapter 3, we examined the functional importance of TRBP phosphorylation 
on TRBP’s homomeric interactions as well as its heteromeric interactions with PKR, and 
consequently, on PKR inhibition and cell fate during oxidative stress. Our work 
established for the first time that TRBP is phosphorylated in response to oxidative stress 
and consequently exhibits increased interaction with PKR to limit the negative effects of 
sustained PKR activation and ensure cellular recovery. Since TRBP phosphorylation by 
ERK has been shown to stimulate the expression of pro-growth miRNAs and enhance 
the stability of the RNA induced silencing complex181, an investigation into any TRBP 
phosphorylation dependent alterations of miRNA profiles in response to stress signals 
may reveal an additional layer of TRBP mediated modulation of the cellular stress 
response independent of PKR and translational inhibition.  
 In Chapter 4, we determined the relative contributions of each of PACT’s dsRNA 
binding motifs to the entire protein’s interactions with dsRNA, with itself, as well as with 
PKR and TRBP. Our experiments established that while both dsRBMs mediate dsRNA 
interaction, PACT’s M1 motif is important for heterodimeric interactions with TRBP and 
PKR and PACT-PACT homodimer formation and highlight the critical role that stress-
induced PACT phosphorylation and PACT-PACT homodimerization plays in ensuring a 
timely PKR activation in response to various stress. Future experiments can be 
performed to determine the importance of PACT homodimerization in various cellular 
processes in which PACT has been shown or suggested to play an important role such as 
the innate immune response through ADAR1 and the cytoplasmic RNA sensor RIG-I and 
RNA interference through interactions with Dicer and TRBP. 
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 This work emphasizes the importance of stress-induced alterations in the 
interactions between these three dsRNA binding proteins in restoring cellular 
homeostasis after cellular stress, particularly in light of the fact that all three proteins 
are at the intersection of the cellular response to viral and non-viral stress, innate 
immunity and small RNA biogenesis. 
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